5bc844fc-e852-4270-bfaf-36ea9eface3d	All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these.
capecitabine	CHEBI:31348	59-71
lapatinib	CHEBI:49603	78-87
86b7cb3d-6186-4a04-9aa6-b174ab764eed	Patients with Platelet count over 100,000/mm¬¨‚â•, ANC < 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial.
platelet count	CMO:0000029	14-28
hemoglobin	CHEBI:35143	75-85
dbed5471-c2fc-45b5-b26f-430c9fa37a37	Heart-related adverse events were recorded in both the primary trial and the secondary trial.
20c35c89-8d23-4be3-b603-ac0ee0f3b4de	Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial.
adult	EFO:0001272	0-5
bilateral	HP:0012832	56-65
breast carcinoma	HP:0003002,DOID:3459	66-82
m1	CHEBI:34826	90-92
f17cb242-419d-4f5d-bfa4-41494ed5ac0e	Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy.
laser	BAO:0150033	0-5
fc5c4554-7ce9-4c16-b374-a3cd9d15b021	Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial.
96b77cdd-aa9f-4770-8447-8a04d9ca5da7	Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial.
carcinoma	HP:0030731,DOID:305	57-66
c73faed2-371b-4238-bf7d-293fae380203	the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention.
pain	HP:0012531	111-115
8765009d-ffc4-4395-ab7a-11ecdfd43a40	Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial
year	UO:0000036	15-19
breast cancer	DOID:1612	73-86
0ad7293d-df35-42e8-881d-f2afc3f7d3fd	Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever.
radiotherapy	OAE:0000235	112-124
2bc1e094-41a1-46d9-9b0c-b5a47f23323d	Certain drinks are banned for patients undertaking the primary trial.
83b83400-1439-462d-bba3-42817b5b1fa1	Most of the cases of CHF in the primary trial, were in cohort 1.
c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f	Candidates for the primary trial must have a life expectancy over 6 months.
17a821f8-5e68-4bf7-ac01-3f96ddfc5187	Patients eligible for the primary trial must live in the USA.
d76d6c7f-ba39-483c-a89e-152af5ae2878	Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT.
group	CHEBI:24433	12-17
65f3e755-3e23-4e84-a218-87922759094d	the primary trial administers letrozole for 28 days, whereas the secondary trial administers is intervention over 4 cycles of 21 days.
letrozole	CHEBI:6413	30-39
d3590771-806b-4754-a455-38113bfedfca	Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion.
colon	UBERON:0001155	52-57
liver	UBERON:0002107	62-67
function	BAO:0003117,BFO:0000034	68-76
function	BAO:0003117,BFO:0000034	179-187
amiodarone	CHEBI:2663	114-124
amiodarone	CHEBI:2663	142-152
day	UO:0000033	168-171
941b960f-8d57-4830-9d4c-8e96765ba76c	both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient.
patient	HADO:0000008,OAE:0001817	92-99
f79a9011-0a68-4255-a40f-5d73af412bf0	CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial.
part of	BAO:0090002,BFO:0000050	19-26
1b4f8828-cc7f-4831-a1c0-cc14e6ad23af	There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial.
57f3a264-9119-4931-9f9c-9cb20e945973	the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course.
589e2f5b-9286-465b-8162-bb1549cd5ece	At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). 
8275f846-59b6-404d-a6d8-e01335279f1a	Less than 1/4 patients in the primary trial experienced adverse events.
b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7	The both Cohorts of the primary trial receive their treatment via Subcutaneous administration.
18d9991c-ca96-4bab-93af-77654857a07f	the primary trial does not accept patients with grade 1 alopecia.
alopecia	HP:0001596,DOID:987	56-64
6fb9056d-277c-4dc2-9b45-d7661bb41831	Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography.
estradiol	CHEBI:23965	133-142
52b23601-2276-4634-96c7-8b6e55596085	A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat.
patient	HADO:0000008,OAE:0001817	9-16
throat	UBERON:0000341	107-113
95e05332-4926-4381-90a4-87941269e7bf	More than 5% of the primary trial participants achieved partial response (PR).
20d51467-b059-4f39-b636-d32f2dc692da	Both the primary trial and the secondary trial at least partly administer their interventions orally.
15c83d26-f9ba-44cc-a920-6941781cdd8b	Neutropenia affected the majority of patients in cohort 1 of the primary trial.
neutropenia	HP:0001875,DOID:1227	0-11
affected	HP:0032320	12-20
e100212f-5bef-4f84-a3c1-d18a6b3e8355	the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation.
time	PATO:0000165	32-36
56d2a387-49dd-49b9-93bb-bcb092bf2714	the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.
2485a3e1-7520-47d2-b941-32ebf91e5b65	Participants of the primary trial are assigned an intervention depending on their prior treatments.
b97d9465-db14-43af-9451-4b824e67abb8	the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other.
798c0983-5265-47ea-bfcd-735738793482	A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
tamoxifen	CHEBI:41774	38-47
breast cancer	DOID:1612	57-70
excluded	HP:0040285	81-89
127e9179-6781-4b9a-abe9-080d2ffad591	Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention.
radiotherapy	OAE:0000235	60-72
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d	Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial.
week	UO:0000034	34-38
adenocarcinoma	DOID:299	75-89
breast	UBERON:0000310	97-103
disease	DOID:4,BAO:0002927,OGMS:0000031	136-143
16dc5a77-5758-4d19-9801-6e9932d9fbc9	several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration.
drug administration	OAE:0000011	88-107
2ed770a0-fe98-4029-9511-ad04a94a1a69	In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia.
leukopenia	HP:0001882,DOID:615	53-63
leukopenia	HP:0001882,DOID:615	217-227
b4c97206-66fd-468b-8388-fac076222c10	There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.
disseminated intravascular coagulation	HP:0005521,DOID:11247	54-92
6e22d118-af77-41bd-bd47-9385779f33aa	There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial.
ccc5362a-33d0-4f1b-be46-d31729ba9194	The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.
group	CHEBI:24433	36-41
group	CHEBI:24433	117-122
month	UO:0000035	74-79
median	BAO:0002174	97-103
fa530b28-9142-49f2-aa80-4d04fa532910	Participants in group 2 of the primary trial receive taping to anastomosis regions., but no Complex Decongestive Physiotherapy.
group	CHEBI:24433	16-21
physiotherapy	OAE:0002476	113-126
7cbe445f-2df6-4a87-be6b-7ecc1e80b08b	None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia.
41cf791e-ed7a-48e5-af84-eefc9fa41ba7	The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event.
alcohol	CHEBI:16236	101-108
d417aa7b-6d2c-46f8-812c-426ea60e0328	There were only 3 adverse events in the primary trial which occurred more than twice.
2744cc0a-86e9-4764-ae1c-f10f635dc283	Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.
letrozole	CHEBI:6413	21-30
group	CHEBI:24433	31-36
bone mineral density	CMO:0001226	74-94
2e4717fd-b349-48a3-b751-88674dfaaa18	In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy.
b0c65cd7-8cad-404d-8704-ee074e480f57	the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18.
age	PATO:0000011	113-116
28e20650-e100-4e30-a319-5eceb69a979d	1 patient in the primary trial had toxic hepatitis.
patient	HADO:0000008,OAE:0001817	2-9
hepatitis	HP:0012115,DOID:2237	41-50
8cf0c320-9486-4531-9212-bb3284b734f1	the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP. 
efficacy	BAO:0000656	109-117
lymph	UBERON:0002391	121-126
34a75478-e7cc-495e-86c3-d0accdaf1ddd	Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.
breast cancer	DOID:1612	95-108
47780450-1202-4934-8e50-b29416b124f5	All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen.
letrozole	CHEBI:6413	60-69
tamoxifen	CHEBI:41774	145-154
27421e64-e9f0-42a9-8070-bdfb0ce4ce7c	There were 2 cases of severe back pain observed in the primary trial.
severe	HP:0012828	22-28
back pain	HP:0003418	29-38
c5e6497a-2e2f-4663-97fd-e73ba8904b0c	Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis.
myocarditis	HP:0012819,DOID:820	105-116
thrombosis	DOID:0060903	121-131
c4dd814d-f525-465f-abe1-a7975771d57e	Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolone 3 times per week for 6 doses.
week	UO:0000034	216-220
cfd93077-87c5-458b-8712-e1896929309d	One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets.
patient	HADO:0000008,OAE:0001817	4-11
blood	UBERON:0000178	56-61
blood	UBERON:0000178	75-80
a3faaf85-62c6-430f-acf2-9c5992ee5221	The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event.
disease	DOID:4,BAO:0002927,OGMS:0000031	116-123
65e3afbb-70f6-4e1a-89e6-d819f8b95ab6	Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar.
blood	UBERON:0000178	55-60
blood	UBERON:0000178	132-137
335936e4-9eaa-43b3-84fe-6f112c0d0226	Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial.
radiotherapy	OAE:0000235	0-12
19921113-538e-4fd2-81a6-6053f2dd6459	There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.
6a013bb4-0688-4f02-96c5-062f3ca67ae1	In total there were 5x more adverse events in cohort 1 of the primary trial, than in cohort 2.
c103a786-0b1d-4124-aa5d-4945ded2c384	the primary trial and the secondary trial are not studying PFS, PBR or DLTs.
2746a75c-7f01-4dc3-a05e-5c7499e75555	Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial.
cancer	DOID:162	30-36
df64a4c5-08f3-40c7-a4e7-2a6271bc9e53	Patients with a prior malignancy of skin cancer are excluded from the primary trial.
skin cancer	DOID:4159	36-47
excluded	HP:0040285	52-60
682f5e80-75c4-4a36-9bc1-b389a98ad160	None of the patients in Cohort 1 of the primary trial suffered from Hypotension.
hypotension	HP:0002615	68-79
7028841e-28e6-4fd3-a27c-2ae2e7dc7b52	Only White and Asian patients are eligible for both the primary trial and the secondary trial.
348c9273-6aa1-43a8-840d-3cf080874669	In total, across both cohorts of the primary trial, there were at least 2 patients with a fever.
fever	HP:0001945	90-95
dfe6228e-6bfb-49d3-b0b4-397aab177bea	We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1.
9f424ebb-63b8-4930-b2c1-cd46fff4d706	Only one patient cohort of the primary trial had a positive median Insulin change from baseline.
patient	HADO:0000008,OAE:0001817	9-16
median	BAO:0002174	60-66
insulin	CHEBI:145810	67-74
c1f8c7fb-22de-4501-af86-d9eb59542ae3	Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.
patient	HADO:0000008,OAE:0001817	43-50
stable	HP:0031915	56-62
disease	DOID:4,BAO:0002927,OGMS:0000031	63-70
6630047b-7ebc-4435-8203-cf6bbe6b6ee7	Left ventricular ejection fraction > 50% is required for participation in the primary trial.
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
039c3fc2-f798-4d97-b904-9aa7d363eeef	Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial.
cancer	DOID:162	14-20
50a2a4a9-2b30-4901-b7bc-9c77b8ca870f	the primary trial requires participants to have undergone PTR.
f8028143-35d1-4cc3-895a-acb577db4715	participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD.
anastrozole	CHEBI:2704	110-121
simvastatin	CHEBI:9150	143-154
907f7e56-b6ec-4a43-bf3a-14f93c644bc1	A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial.
female	PATO:0000383	2-8
patient	HADO:0000008,OAE:0001817	9-16
age	PATO:0000011	26-29
chronic	HP:0011010	51-58
viral hepatitis	HP:0006562,DOID:1884	59-74
3fa58451-21ba-4ad9-8d13-6a9eefa17a5b	Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial.
breast cancer	DOID:1612	44-57
a41bf7b0-9a09-4ce0-8832-f13758581f20	Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.
5f2d2015-eaf9-45a8-9583-fddbc9807287	Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.
609ddd08-ebd5-4661-be43-874b65dbfe52	Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial.
dementia	HP:0000726,DOID:1307	14-22
schizophrenia	HP:0100753,DOID:5419	26-39
b6ac985d-87ae-4e0f-83e1-38033c1db5cc	the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status.
43ff9425-5e6e-4a85-a8ca-0c0c67a96623	More than 5% of the primary trial participants achieved Objective Response (OR).
b3ccde30-cdfc-4e18-aee0-8b3a921dde39	Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection.
patient	HADO:0000008,OAE:0001817	6-13
tipifarnib	CHEBI:141969	44-54
paclitaxel	CHEBI:45863	70-80
doxorubicin hydrochloride	CHEBI:31522	82-107
lymph	UBERON:0002391	185-190
8697a59e-0f1c-452a-b15a-6d24e2df387f	None of the patients in the primary trial or the secondary trial committed suicide.
4ab74186-5f4e-4139-af05-d4a9871a251d	Stephanie has been living with her husband for 31 years, she is eligible for the primary trial.
082ee581-f420-4892-b098-ce82c6ad0210	All of the adverse events recorded in the primary trial were cardiac related.
7bf084eb-873a-4011-9b98-3a899ee582ee	Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.
hormone	CHEBI:24621	93-100
ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a	the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle.
day	UO:0000033	130-133
06bc9cff-e9fc-42c7-a2a3-c01a036e04c6	Patients with ERBB2 positive tumors are eligible for the primary trial.
f6c85ce8-e0fc-4186-a961-6207dd4cacd2	Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR).
eribulin mesylate	CHEBI:70710	48-65
5bdd61d9-aadf-4944-afe3-a04242d9c2b2	Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial.
breast cancer	DOID:1612	23-36
diameter	PATO:0001334	44-52
b8ce7d6a-d707-48e0-816c-de7ac3a63823	Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial.
carcinoma	HP:0030731,DOID:305	64-73
53d88010-e7d7-41c7-b20d-6328c8e507d1	For some adverse event types in the primary trial, there were no recorded cases.
adverse event	OAE:0000001	9-22
8257bf5c-fae6-44c0-a86d-293746fdc468	Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.
hepatic encephalopathy	HP:0002480,DOID:13413	48-70
pneumonia	HP:0002090,DOID:552	75-84
7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2	Patients with HER2 positive breast tumors are eligible for the primary trial, but excluded from the secondary trial.
breast	UBERON:0000310	28-34
excluded	HP:0040285	82-90
974225b7-9089-499c-9550-0a7207fd28b2	The intervention for the primary trial does not require patients to undergo any medical treatment during the study, whereas in the secondary trial, all patients receive Radiation Therapy.
6f533f52-c8e4-4983-8968-69af03a9e34a	Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial.
breast cancer	DOID:1612	38-51
recurrent	HP:0031796	67-76
disease	DOID:4,BAO:0002927,OGMS:0000031	77-84
690b8562-7d68-4642-bacb-601f227bb763	the primary trial does not have an intervention section.
75f94edd-dbde-4a19-be18-e67c767f6d8f	the primary trial's intervention section does not describe the intervention dosage, frequency or duration for cohort 2, however cohort 1 recieves placebo twice daily for two months.
frequency	HP:0040279	84-93
duration	PATO:0001309	97-105
e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4	the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial.
34ee4f66-e6f7-458c-964c-12fa730a9d56	Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study.
day	UO:0000033	102-105
week	UO:0000034	112-116
9b0451fe-f760-46d3-b555-0a9b83546e73	the primary trial recorded half as many patients vomiting as the secondary trial.
vomiting	HP:0002013	49-57
b9304415-073d-476e-a056-cb2a747d56fa	Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study.
doxorubicin	CHEBI:28748,BAO:0000639	39-50
doxorubicin	CHEBI:28748,BAO:0000639	84-95
cyclophosphamide	CHEBI:4026	97-113
6e365e33-16b8-43e1-99b5-49dfed6f7b13	Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial.
recurrent	HP:0031796	57-66
cancer	DOID:162	67-73
cancer	DOID:162	81-87
breast cancer	DOID:1612	74-87
7c2dd3c3-8e72-451e-9fe7-c442f659bfc3	Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.
paclitaxel	CHEBI:45863	74-84
27acc6d7-c12d-4a38-9133-a5c8429dd264	the primary trial recorded 23 adverse events.
5919a080-2f0d-4c3b-9b03-10df80b2e680	There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort.
adverse event	OAE:0000001	14-27
affected	HP:0032320	55-63
patient	HADO:0000008,OAE:0001817	94-101
91f6e62a-97e7-49fa-8509-7ff8c1f0155e	Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both the secondary trial and the primary trial, and are able to participate in these trials alongside other drug trials, up to a maximum of 3.
ductal carcinoma in situ	HP:0030075,DOID:0060074	19-43
melanoma	HP:0002861,DOID:1909	54-62
drug	CHEBI:23888	188-192
b351a091-d5fb-49f9-a864-5c89c6316b1b	 Patients must have histologically or cytologically confirmed PR+ invasive breast cancer, with Primary tumor > 2 cm in diameter TO PARTICIPATE in the primary trial.
breast cancer	DOID:1612	75-88
diameter	PATO:0001334	119-127
d5ca2086-8404-42d1-bf45-5370f3d4e8e8	There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial.
4c038972-20a9-4031-a1cd-ba00e9dd0908	In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in the secondary trial.
median	BAO:0002174	72-78
82d6275a-97e6-4d13-84eb-5f7c2585db8b	Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure.
patient	HADO:0000008,OAE:0001817	20-27
patient	HADO:0000008,OAE:0001817	105-112
heart	UBERON:0000948	126-131
286e74e5-74ed-4d42-b32d-f1398c514d37	At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.
afatinib	CHEBI:61390	89-97
vinorelbine	CHEBI:480999	203-214
634642da-db6d-49cc-a999-67f46e91dbca	the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria.
a529e364-2da7-4067-acb6-9fb2f0adf08b	A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
excluded	HP:0040285	77-85
317e00ae-9d17-4f85-8787-602cc2548fdb	Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial.
cancer	DOID:162	14-20
breast	UBERON:0000310	44-50
bone marrow	UBERON:0002371	66-77
excluded	HP:0040285	82-90
de955acc-ce0e-4416-9884-644a06971603	Cohort 2 of the primary trial and the secondary trial are test groups. 
4956f0d0-4df4-4de3-9a46-6073927485c3	the secondary trial has more patients cohorts than the primary trial.
9ca0cc75-58b3-451d-abcc-378526744ca4	Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.
brain	UBERON:0000955	167-172
6efb001b-5ed3-470b-a206-7768a1adf597	histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial, but not from the secondary trial.
breast cancer	DOID:1612	41-54
result	BAO:0000179	61-67
70dd1a42-6e40-4880-80a8-45dfd4941ce4	the primary trial uses a 3 week cycle for SB-715992 administration.
week	UO:0000034	27-31
85f43677-b680-4127-b1da-7e1cc966e4b2	Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi.
4cccea8a-22ae-4813-96df-b902850f4991	Women of any age can participate in the primary trial or the secondary trial.
age	PATO:0000011	13-16
8574ecd7-4da7-49b0-a273-de495bc1fee7	Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial
nausea	HP:0002018	0-6
death	OAE:0000632	11-16
01b82c51-dd3d-430b-9523-0e93a9eb9c1a	the primary trial recorded a multitude of patients with chest pain, whereas the secondary trial observed only one patient with abdominal pain.
chest pain	HP:0100749	56-66
patient	HADO:0000008,OAE:0001817	42-49
patient	HADO:0000008,OAE:0001817	114-121
abdominal pain	HP:0002027	127-141
93149dfc-667b-48d3-a46d-ad48b15e701f	Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events.
d080eec7-412f-4a44-8c56-91e0ec459acc	the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks.
fluocinonide	CHEBI:5109	85-97
fd18a599-f94a-478a-975f-854a4210ccad	the primary trial has a 5 year long intervention, the duration of the secondary trial is only a single day after removal of the drains.
year	UO:0000036	26-30
duration	PATO:0001309	54-62
day	UO:0000033	103-106
drains	RO:0002179	128-134
ac9ca070-80b2-4913-97d8-06d1b90fcfce	the secondary trial and the primary trial both have a placebo arm and a test arm.
19f5ff0d-3419-4f27-a7e5-6c7291c3cd21	Throughout the duration of the primary trial, pariticpants receive increasing doses of Fulvestrant.
duration	PATO:0001309	15-23
fulvestrant	CHEBI:31638	87-98
009d23bb-2179-4ce3-927d-4dedca6b32a8	Patients that have previously been trated with bevacizumab are not eligible for the primary trial.
5152d810-7669-4fb2-a66b-a0a1d6026af5	the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame.
month	UO:0000035	124-129
time	PATO:0000165	130-134
e8f4a600-0296-47d4-903b-2fa840ebcf28	Patients with stage 3 Cervical carcinoma are excluded from the primary trial.
carcinoma	HP:0030731,DOID:305	31-40
excluded	HP:0040285	45-53
3fa8b747-b48d-4fb4-995d-38a23c64ccb3	2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.
hydrate	CHEBI:35505	138-145
b9c294c3-93b7-4681-be02-285f9e5cd867	Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort.
9df90d78-d857-4e1d-a650-e47f7b6b68d6	Cohort 2 of the primary trial receive a higher dose of Ixabepilone, at a higher frequency, than cohort 1, 
ixabepilone	CHEBI:63605	55-66
frequency	HP:0040279	80-89
4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe	There results section indicates there were no patients in the primary trial with 0 adverse events.
92ac6e0c-8427-454d-9218-36eda1c580a7	The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them.
f0aff1fc-4a67-4b28-a974-a4a67a5c930f	There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.
2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6	Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.
96ab702d-cfe1-48fb-b348-a7c7b8db3f16	The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months.
median	BAO:0002174	4-10
length	PATO:0000122	11-17
time	PATO:0000165	21-25
patient	HADO:0000008,OAE:0001817	33-40
6224d2de-c62b-4b43-8517-475eaa565491	The majority of patients in the primary trial experienced at least one adverse event.
adverse event	OAE:0000001	71-84
95154c62-9f79-4d80-90fd-2f61612285b0	In total more than 5 patients in the primary trial and the secondary trial experienced Earache.
2f6243a9-af40-426d-9a6a-a5c5708cf1b4	the primary trial and the secondary trial recorded the exact same number of cases of nausea.
nausea	HP:0002018	85-91
837f0588-22fc-4069-b2bc-297b3f6aabf7	Candidates for the primary trial do not need to meet a specific life expectancy criteria.
01ef1af2-bac4-4ff9-9f0e-bb39276a9d78	Patients in the primary trial will not be made to take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously like those in the secondary trial.
paclitaxel	CHEBI:45863	86-96
e7b47e19-9cd0-4121-a79a-ee223e7f3ab7	Patients must have a life expectancy over half a year to participate in the primary trial.
year	UO:0000036	49-53
21cf4dfe-2cd7-4e60-943d-2f7e1266a80d	A 30% of patients in the primary trial suffered a life-threatening reaction to an infection.
d72ecaae-c132-480c-af5e-87c58dd26082	The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer.
adverse event	OAE:0000001	9-22
cancer	DOID:162	114-120
80245791-4a95-4682-bd5f-856694c9f52f	Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial
be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138	the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold.
f0da58e6-e937-41ac-b53a-d46ec8a28d11	Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily.
5a74a63a-3912-44f0-9e83-4e6b678cbe90	the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography.
43f03ba4-ef03-4f57-b059-3d9267f0dcf8	Patients under the age of 18, wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months.
age	PATO:0000011	19-22
6e106caf-2522-4022-898d-64b82093d77a	Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial.
age	PATO:0000011	17-20
cancer	DOID:162	90-96
7f8a918c-fab8-4129-8178-0cda7d0441e1	Cohort 2 of the primary trial recieves Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study.
doxorubicin	CHEBI:28748,BAO:0000639	39-50
cyclophosphamide	CHEBI:4026	52-68
84aa1194-c081-4acf-9ed6-8cf0d1a08f5d	At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.
afatinib	CHEBI:61390	90-98
vinorelbine	CHEBI:480999	204-215
2bd65df6-4f1d-461c-93f5-f2ddbfde57b6	Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial.
fever	HP:0001945	26-31
0290bc2d-9cd3-44ab-9b04-385f19527c42	Patients must have ductal carcinoma, that can be felt by touch to be eligible for the primary trial.
carcinoma	HP:0030731,DOID:305	26-35
505afbf8-b2b4-4b12-99c5-e0feef473248	the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.
rate	BAO:0080019	75-79
time	PATO:0000165	135-139
19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5	Patients with histologically confirmed, newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial, but may still be eligible for the secondary trial.
bilateral breast cancer	DOID:6741	64-87
2e540abd-06e3-483d-bd69-6eb5d2275e9e	Patients in the primary trial and the secondary trial are administered daily oral medication.
d905f4cb-32aa-41b8-8f61-40578d8ea9ae	No less than 2 patients from either cohorts of the primary trial felt nauseous.
45510043-7931-493b-8251-41b0be9aabbd	There were 2 instances of patients with Atrial tachycardia in the primary trial.
tachycardia	HP:0001649	47-58
e7037f34-bd2e-402e-a19c-48073781885a	10 of the patients in Cohort 1 of the primary trial suffered from Hypotension.
hypotension	HP:0002615	66-77
5275a332-46c1-4941-8850-26a8033012e3	Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20.
cancer	DOID:162	52-58
cancer	DOID:162	80-86
age	PATO:0000011	177-180
1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0	the secondary trial and the primary trial both used MRI and Letrozole for their interventions.
letrozole	CHEBI:6413	60-69
b02f43d7-44bb-4219-9a08-fd70e7cc9b87	Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial.
year	UO:0000036	93-97
1a6661e0-343f-4056-b568-611e7cc7750c	Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial.
breast cancer	DOID:1612	18-31
excluded	HP:0040285	101-109
ec97c90e-f904-4cf2-9567-8525edf747cf	the primary trial and the secondary trial are both evaluating patient assisted imaging interventions.
patient	HADO:0000008,OAE:0001817	62-69
7a129a1e-20d9-4f5a-a921-d30957460e27	the secondary trial and the primary trial do not test the same modalities of cancer treatments.
cancer	DOID:162	77-83
fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4	The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.
adverse event	OAE:0000001	61-74
a1c99d5b-d53a-4195-ad5f-5e1b48c22078	Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.
thrombocytopenia	HP:0001873,DOID:1588	60-76
0203435e-03a0-4c41-afdf-6c497d8908c1	Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial.
left	HP:0012835	9-13
ejection fraction	CMO:0000180	26-43
excluded	HP:0040285	54-62
e6388dc2-b096-467d-8b70-fd5346dd581a	The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.
adverse event	OAE:0000001	41-54
93511e52-1c12-4dee-858e-13b10793e2a6	the secondary trial exclusively uses radiotherapy in its intervention, whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study.
radiotherapy	OAE:0000235	37-49
patient	HADO:0000008,OAE:0001817	107-114
day	UO:0000033	158-161
cb932dbf-4c98-4488-b189-1286442968b6	Patients with Cervical carcinoma in situ are excluded from the primary trial.
carcinoma	HP:0030731,DOID:305	23-32
excluded	HP:0040285	45-53
0b9aa7e8-5912-44db-b9b0-6a84df769e19	There were no patients with paranasal sinus reactions in the primary trial.
570ab6bb-b23c-4955-b6b0-d756d1b69c0e	Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial.
breast cancer	DOID:1612	72-85
daf105f8-58e8-47d7-b0a2-5949620b0a2b	the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin.
acid	CHEBI:37527	58-62
frequency	HP:0040279	81-90
c4b671ae-4701-43a3-ada1-659c265d1f3a	In order to participate in the primary trial, participants must be aware of where they are, and what day it is.
day	UO:0000033	101-104
0a17a404-ed1d-4c31-a192-509b68198ea8	There was a dental adverse event in the primary trial.
adverse event	OAE:0000001	19-32
9661db11-0c91-48c6-a8e8-6cb7cc2b06fd	Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device.
e8b86ef4-3ce8-4d81-a632-f30672c80ff5	Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix.
lipid	CHEBI:18059,BAO:0000171	64-69
peritoneum	UBERON:0002358	170-180
879f2f14-38a8-419a-bae0-e62ed81eb9dd	Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006.
2ec46285-dd0c-4420-b9f6-e44a1ac74f20	There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial.
f8afffdc-649b-4921-942a-66b804a3717f	In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-4, N1 and M1 bilateral breast cancer.
anthracycline	CHEBI:48120	87-100
m1	CHEBI:34826	161-163
bilateral breast cancer	DOID:6741	164-187
65f22210-47dd-4865-99e2-ddd414dddb08	In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years.
patient	HADO:0000008,OAE:0001817	18-25
ff8a1e0d-d2ee-4687-b429-5b3b6081edc6	INR of 1.35 is enough for participation in the primary trial and the secondary trial.
b86f0f3c-7905-470d-ae5d-e1867eb8bd3b	One patient in cohort 2 of the primary trial crashed their motorbike.
patient	HADO:0000008,OAE:0001817	4-11
0aa3c085-b9c6-4918-a5d0-eabc55bdd177	There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.
333c2723-e2e8-4c68-9591-36b7f169ff26	A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.
fever	HP:0001945	69-74
1fa01b9a-1288-404c-ad58-8dcf3db3264c	59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.
stable	HP:0031915	134-140
disease	DOID:4,BAO:0002927,OGMS:0000031	141-148
ed272c3f-37a1-4db7-8990-bf226f8c9822	There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial.
diplopia	HP:0000651	37-45
anemia	HP:0001903,DOID:2355	70-76
b1497cf4-6b06-4227-b679-19e2ac5fb5c3	the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS), 9 weeks after the start of treatment.
epothilone	CHEBI:60831	56-66
central nervous system	UBERON:0001017	70-92
186d5a67-1309-4abc-b31a-de026c5b8bda	Patients diagnosed with intradural tumors are excluded from the primary trial.
excluded	HP:0040285	46-54
6b86f306-f989-4676-8f5e-c4c8a6aa4258	the primary trial participants will receive either Lapatinib, WBRT or Herceptin.
lapatinib	CHEBI:49603	51-60
0e8e4a92-b104-4192-ad36-33b683f94216	There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial.
group	CHEBI:24433	75-80
47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12	the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions.
03a8a787-2bf3-43e5-9c9e-7bd9c3278751	All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years.
letrozole	CHEBI:6413	20-29
group	CHEBI:24433	30-35
bone mineral density	CMO:0001226	73-93
7d7a9a69-533a-4480-b2e7-aa59eb8a738b	the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial, than in the ER+ and/or PR+ group.
group	CHEBI:24433	124-129
group	CHEBI:24433	179-184
c6fc8336-7c74-443e-9548-3bbafe21fc37	In total Less than 10% of patients in the primary trial either had a disease relapse or died.
disease	DOID:4,BAO:0002927,OGMS:0000031	69-76
9035000f-d87b-439f-882a-e6e30694e391	Patients currently prescribed Diuretics are excluded from the primary trial.
excluded	HP:0040285	44-52
522ca0ec-aeb0-4083-a274-ab58c2cddb8a	Unlike the primary trial, the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices.
hormone	CHEBI:24621	84-91
46d65581-7a0a-423b-907e-662c1f5843cc	There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial.
dyspnea	HP:0002094	42-49
dehydration	HP:0001944	55-66
f4ea6e98-75e1-43a0-8202-548bb7ceb66c	The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once.
c3a618d6-2c2e-4ed6-bfe7-88d28ec18240	The median TTP for patients in cohort one of the primary trial is NA.
median	BAO:0002174	4-10
ttp	CHEBI:63550	11-14
932728c5-2e7f-401f-be64-e90597ff2ce2	There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.
54ad9406-852c-40fc-bd0e-8e7e81eacc71	It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours
time	PATO:0000165	68-72
7021a4a9-b474-4568-a3b8-015a50c9d9cc	Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial.
breast carcinoma	HP:0003002,DOID:3459	50-66
24eced44-40b2-4365-abd3-42eb13220cf0	There is no radiotherapy or educational part of the intervention used in the primary trial.
radiotherapy	OAE:0000235	12-24
part of	BAO:0090002,BFO:0000050	40-47
3e2dda3a-815f-4681-a470-009d9f9b30d6	the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device 
radiotherapy	OAE:0000235	31-43
1a293e7c-691f-4f93-bab8-6bf5d9b3f904	The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication, however they are not using the same doses.
a87e6e20-c7d0-4941-9933-204fab99b299	Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment.
lapatinib	CHEBI:49603	61-70
rate	BAO:0080019	106-110
6c3427a8-27a1-459c-9fbc-175649210868	There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.
883bec6a-bce2-4e60-9304-49a056e66df7	A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin < 1.2 x ULN are eligilbe for the primary trial.
female	PATO:0000383	2-8
hemoglobin	CHEBI:35143	14-24
platelet count	CMO:0000029	75-89
x	LABO:0000148	132-133
8720143a-2611-4502-a5ee-da4e641df918	There were no cases of extravasation in either the primary trial or the secondary trial.
0fdda7a2-4119-40a7-84f3-6c5c6077df49	Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.
e7eae332-6b6a-41e0-aa31-86a781fd373f	There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial.
dyspnea	HP:0002094	59-66
9a52d5d4-ff71-42ee-8672-ec4ac3cfd591	In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.
magnesium oxide	CHEBI:31794	30-45
magnesium oxide	CHEBI:31794	80-95
c09b9f7c-2d22-4c44-a79d-32929530dd9e	the secondary trial and the primary trial are both testing Biodesign interventions.
6f143256-52e4-40b7-950c-5c892f8632b9	The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	98-105
patient	HADO:0000008,OAE:0001817	143-150
group	CHEBI:24433	12-17
percent	UO:0000187	35-42
disease	DOID:4,BAO:0002927,OGMS:0000031	135-142
d2718f05-1d35-4c84-a054-06a3fe4a0a9c	To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.
size	PATO:0000117	131-135
7f49cafd-3a27-4fc8-872d-914b9176442e	Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial.
neutropenia	HP:0001875,DOID:1227	0-11
adverse event	OAE:0000001	32-45
2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25	The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.
neutropenia	HP:0001875,DOID:1227	28-39
pancytopenia	HP:0001876,DOID:12450	44-56
3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8	Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial.
radiotherapy	OAE:0000235	20-32
cancer	DOID:162	62-68
4ab00376-83a4-467e-8a1e-6b8b1643a8f0	Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial
x	LABO:0000148	43-44
x	LABO:0000148	62-63
x	LABO:0000148	147-148
history	BFO:0000182	84-91
blood	UBERON:0000178	95-100
excluded	HP:0040285	146-154
e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1	None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues.
heart	UBERON:0000948	66-71
heart	UBERON:0000948	171-176
407369fa-92ba-4994-8a0f-d372995f3241	Neither the primary trial or the secondary trial require participants to practice yoga.
05e50a3d-d5b2-4fe6-9709-c884c89c5f71	the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments.
59fd53e4-b38c-4018-bafc-6fd7f7becebe	1 patient in the primary trial suffered from a blood clot blocking their blood vessels.
patient	HADO:0000008,OAE:0001817	2-9
blood	UBERON:0000178	47-52
blood	UBERON:0000178	73-78
c17eaeab-4e99-4cc4-8681-ae6ccddba572	There were no cases of Cellulitis, Nausea or Anaemia in the primary trial.
cellulitis	HP:0100658,DOID:3488	23-33
nausea	HP:0002018	35-41
621d06ac-12dd-42c2-a012-15c1d94a4f0b	Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months
function	BAO:0003117,BFO:0000034	70-78
amiodarone	CHEBI:2663	116-126
amiodarone	CHEBI:2663	144-154
021e79d2-ce70-43cf-aac9-fa8d4c8d3770	In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot.
patient	HADO:0000008,OAE:0001817	21-28
pneumonia	HP:0002090,DOID:552	93-102
06aa0fbc-fe49-4715-88cc-507646f6323f	The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga.
21947261-bbef-4d3a-adda-02bb4a91a3ca	the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast.
progesterone	CHEBI:17026	68-80
adenocarcinoma	DOID:299	97-111
breast	UBERON:0000310	119-125
71daae7c-3ee5-4451-91e2-273d8ff55aae	the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial.
4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37	Every single patient in the primary trial experienced at least 1 adverse event.
patient	HADO:0000008,OAE:0001817	13-20
adverse event	OAE:0000001	65-78
7d22937b-9823-45fa-a914-261f993e4d64	Throughout the primary trial, one patient developed issues with their vision.
patient	HADO:0000008,OAE:0001817	34-41
507a4189-4905-4752-8348-d715a5ce3962	There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.
24001e83-6a8c-4f67-9c24-55dc285c4cc2	the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo.
fatigue	HP:0012378	67-74
d179396d-94fe-465f-a4f1-e7c3291a0a9a	filgrastim is the only drug in the primary trial given by subcutaneous injection.
drug	CHEBI:23888	23-27
4b893eeb-80a4-4a83-8df5-b5c668ce55b1	More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial.
44cd16f5-6638-4d82-9121-1941eb8ce4b5	In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2.
50ac2c53-3b63-4507-8712-41f8c257b4da	Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.
cyclophosphamide	CHEBI:4026	30-46
14607d45-9aef-458d-89cc-d47c62c23322	A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
breast cancer	DOID:1612	56-69
brain	UBERON:0000955	85-90
history	BFO:0000182	115-122
autoimmune disease	DOID:417	133-151
d2961e96-bd3b-4994-aa7e-2b310eb6204e	At least 1 participant in the primary trial showed signs of poor liver function.
liver	UBERON:0002107	65-70
function	BAO:0003117,BFO:0000034	71-79
8a5d7285-f4be-4e50-9057-19f74bcc410b	Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks.
512990dd-45d2-4b31-b571-66735ff02308	There were 4 different adverse events, for which 0 cases were recorded in cohort 1.
383db144-4bcd-4ebc-989c-b6ae7d282026	Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial .
bfa07fb7-f8cb-4215-9bca-ddee8b3bea73	Most patients in cohort 1 of the primary trial died of unknown causes.
228e80ab-84d6-4b60-9960-dcdcbd78c03c	Patients with an FEV1 of 80% to 120% are ineligible for the primary trial.
b7caad28-5fb2-4eb6-845e-8315cff97318	prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial, neither is Adequate organ function or a particular racial or ethnic background.
adjuvant	CHEBI:60809	49-57
organ	UBERON:0000062	138-143
function	BAO:0003117,BFO:0000034	144-152
73c37b9c-e7ba-4c90-b26e-23b7a65509c4	T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial.
adenocarcinoma	DOID:299	9-23
breast	UBERON:0000310	31-37
d5b81f6c-821a-4db5-8810-9cc47a952913	Informed consent is obligatory for entry in the primary trial.
cdba382e-894b-4f79-a8e2-ff818746adc5	100% of patients in the primary trial suffered adverse events.
0093175a-38cb-4f63-b391-709ac48158b8	Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial.
19106207-4fa2-4cc4-8e22-6e5330bf05ce	None of the adverse events recorded for the primary trial occurred more than once.
a015685e-f744-4bb2-a6d3-893f081d6dcc	the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.
day	UO:0000033	54-57
b9578bae-6640-4ef1-ba2c-899b45c602ee	All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in.
water	CHEBI:15377	57-62
water	CHEBI:15377	80-85
405369ef-d216-4d81-a04f-46f36f466a19	Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.
e424c65e-7c6f-43a4-95e4-6beb705d9903	A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial.
percent	UO:0000187	9-16
stomatitis	HP:0010280,DOID:9637	76-86
f2bd0a9c-74c4-443e-b666-0a0b3aa125e1	The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group.
group	CHEBI:24433	30-35
group	CHEBI:24433	103-108
mean	BAO:0002173	49-53
donepezil hydrochloride	CHEBI:4696	73-96
0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a	Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial.
breast	UBERON:0000310	28-34
lymph	UBERON:0002391	66-71
6843daf8-8136-4973-9bf2-62a622d5a890	Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned.
2687b547-c225-4838-bbcd-99212a74d815	Patients in the primary trial and the secondary trial did not have any of the same adverse events.
fadf7710-6e4d-49d6-82fc-4f3137b5e26b	Only one adverse event is observed in patients from cohort 1 of the primary trial.
adverse event	OAE:0000001	9-22
8c4e6f36-37b4-4bde-b518-08a6dc55f7a5	All of the adverse event cases in the primary trial occurred in patients from cohort 2.
adverse event	OAE:0000001	11-24
6c0896ac-db42-45b4-a6e2-620a27fd321a	In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide.
magnesium oxide	CHEBI:31794	30-45
magnesium oxide	CHEBI:31794	72-87
3a80ba8a-265f-4931-a9a8-b7e00e372599	All of the adverse events recorded in the primary trial occurred in patients from cohort 1.
df4b98f2-7ca9-4855-8d94-d62407ff8535	the primary trial only has one test cohort whereas the secondary trial has both a test and control group.
group	CHEBI:24433	99-104
5d2542fa-5482-4aff-af29-80875a0a9dcc	the primary trial records instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages.
patient	HADO:0000008,OAE:0001817	68-75
5deb8ebd-fbd2-4d84-8ad2-a1248426908b	HIV+ Patients are excluded from both the secondary trial and the primary trial.
excluded	HP:0040285	18-26
5f4880ac-1ce2-4b89-841b-a9918720b6ea	 To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL.
phosphatase	GO:0016791,BAO:0000295	128-139
x	LABO:0000148	144-145
x	LABO:0000148	185-186
aspartate	CHEBI:29995	151-160
hemoglobin	CHEBI:35143	195-205
b3aabfaa-23cb-4a75-8416-761d8574f0a4	Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.
afatinib	CHEBI:61390	84-92
f697c2d8-e0dd-476e-8ff4-dffe053076f8	The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.
rate	BAO:0080019	56-60
rate	BAO:0080019	141-145
lapatinib	CHEBI:49603	106-115
f2c0f753-1775-42af-94f0-b87b20156e65	the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions 
radiotherapy	OAE:0000235	67-79
17b31c1d-db62-4628-b390-02da22512079	Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.
inhibitor	CHEBI:35222	24-33
pain	HP:0012531	112-116
sensory neuropathy	HP:0000763,DOID:2491	120-138
2e6e1044-8b4a-41f7-8319-85fc5bba4482	Radiotherapy is used in all cohorts of the primary trial and the secondary trial.
radiotherapy	OAE:0000235	0-12
456c6011-52bb-4c8b-9e82-e5a85cbbe0e3	There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.
0c0324d2-0672-45cb-b715-e51e48786afb	the primary trial's intervention section does not describe the intervention dosage, frequency or duration.
frequency	HP:0040279	84-93
duration	PATO:0001309	97-105
b3bd3522-8731-448a-bade-a5a350697a98	Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream.
blood	UBERON:0000178	104-109
blood	UBERON:0000178	131-136
present	PATO:0000467	116-123
8607e8c1-6e99-49be-a63e-e707856c805a	Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead.
patient	HADO:0000008,OAE:0001817	5-12
patient	HADO:0000008,OAE:0001817	93-100
group	CHEBI:24433	134-139
1c26e1a7-9d77-46ff-b1c6-179ece7c190f	On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time.
neutropenia	HP:0001875,DOID:1227	76-87
time	PATO:0000165	111-115
0a156ee2-eb90-40d2-9802-27b9b4a42ff3	In cohort 2 and 3 of the primary trial there was only case 1 of jaundice.
jaundice	HP:0000952	64-72
82895f11-37bf-4d03-8de2-84818d93cce0	the primary trial and the secondary trial have entirely different adverse event reports.
adverse event	OAE:0000001	66-79
f94643de-7122-4a58-972d-b0bb7e59d441	the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.
pancreatic cancer	DOID:1793	57-74
1485315b-3169-42a3-a672-6f7963d49a51	Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis.
biomarker	CHEBI:59163	84-93
b4ef27ca-52b4-4af3-9b60-e9e0285e0e86	Potential participants will be considered regardless of the hormone receptivity of their breast cancer.
hormone	CHEBI:24621	60-67
breast cancer	DOID:1612	89-102
769bb3b2-9d2d-4dad-bd59-0042c55ac1ee	patients with Karnofsky Index = 72 are eligible for the primary trial.
426196d8-44ab-4c5c-8f81-5cb12345ad69	the primary trial uses different inclusion criteria for its cohorts, the secondary trial only uses one set on inclusion criteria for all cohorts.
bcf433b6-4029-4d00-9ccf-d8d94f1722d8	the primary trial and the secondary trial only recorded one type of acute adverse event.
acute	HP:0011009,PATO:0000389	68-73
adverse event	OAE:0000001	74-87
1268edfc-cce2-4f07-9fbb-392341b7f399	The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.
ridaforolimus	CHEBI:82677	4-17
exemestane	CHEBI:4953	34-44
group	CHEBI:24433	45-50
median	BAO:0002174	78-84
58ccfd13-aa6d-4604-bf3d-c69270fe50d2	1 patient in the primary trial died in an event not associated with a specifc CTCAE term.
patient	HADO:0000008,OAE:0001817	2-9
a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249	The majority of patients in the primary trial and the secondary trial experienced an adverse event.
adverse event	OAE:0000001	85-98
8c84c96f-1635-40dc-839b-fc937ed566a2	Patients with measurable diseases are only eligible for phase 2 of the primary trial.
7b48355e-3b9c-4cca-b7fa-1cbd612d1523	There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients.
adverse event	OAE:0000001	13-26
3d188d93-13c6-48f3-b231-dcdeef81080e	Presence of Extracranial metastases is part of the exclusion critera for the primary trial.
part of	BAO:0090002,BFO:0000050	39-46
d7e81d80-5cbf-4969-be00-4fdf17aa4eb9	Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.
paclitaxel	CHEBI:45863	26-36
2206dc2a-93da-4c11-b110-81f9c39af807	A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin > 1.6 x ULN are eligilbe for the primary trial.
female	PATO:0000383	2-8
hemoglobin	CHEBI:35143	14-24
platelet count	CMO:0000029	75-89
x	LABO:0000148	132-133
6173faf3-f845-4cf1-94a9-756d1bff48bb	There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood.
patient	HADO:0000008,OAE:0001817	14-21
blood	UBERON:0000178	123-128
512c72ab-f1b3-450d-8167-6e0d8d2bf5dd	Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines.
lymph	UBERON:0002391	61-66
ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104	More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.
breast	UBERON:0000310	116-122
87987ebb-6799-4d1d-8529-d33c6b7799f8	64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks.
lapatinib	CHEBI:49603	60-69
week	UO:0000034	139-143
week	UO:0000034	220-224
bf94f208-a29b-4d8f-92a7-3cb8241ce344	Black women cannot take part in the secondary trial or the primary trial.
c68f6822-24fa-44b5-bf63-c272a8031fab	Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial.
54a459cf-f01a-4abc-a8cf-0efebc01c694	the primary trial and the secondary trial recorded none of the same types of adverse events
dd4b5a08-c033-4429-81d0-1ad59596edbd	sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial.
hyperthyroidism	HP:0000836,DOID:7998	13-28
diabetes mellitus	HP:0000819,DOID:9351	33-50
d97ebc59-ab4b-462a-9057-12f4fc46df56	Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.
vorinostat	CHEBI:45716	38-48
frequency	HP:0040279	61-70
2e4c7d0b-f1a2-4204-bac3-7445852fd916	the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry 
ct	BAO:0002125	92-94
fafac1e0-1eaa-4a99-8f3f-72b3f71c4691	All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of the secondary trial receive all of these.
capecitabine	CHEBI:31348	108-120
lapatinib	CHEBI:49603	127-136
4546c169-cc5c-4e03-bcce-31d491ed18e0	the primary trial only records cardiovasuclar adverse events.
1bb3badf-41c6-4741-90f0-367473ce254d	children and illiterate adults are not able to take part in the primary trial.
87953ba3-3e94-421c-b426-b716562b8b5d	A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
breast cancer	DOID:1612	63-76
847b4dbe-428f-431c-8916-2a9c0c80cce4	dosages are specified in the intervention section of the secondary trial and the primary trial
9c00b318-0a3a-43c9-a6cd-2983c07be393	There were no instances of patients with abnormal heart rates in the primary trial.
heart	UBERON:0000948	50-55
cbfe14a5-5169-4de3-b69f-13b489be949a	the primary trial and the secondary trial do not use cyclical interventions.
bd6bf811-e9a8-4e1e-ace1-703aa8f5374b	There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect.
increase	BAO:0001251	172-180
3c4d9ab0-5e16-48b3-96d4-ae9d337b2822	There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.
hypotension	HP:0002615	30-41
eae76b80-107c-4469-b06f-73d5f7a4c1d5	Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial.
day	UO:0000033	49-52
6cf7d10e-902e-4f78-85f6-e06d63e1cd0e	less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.
lapatinib	CHEBI:49603	57-66
progressive	HP:0003676	82-93
disease	DOID:4,BAO:0002927,OGMS:0000031	94-101
week	UO:0000034	105-109
91ad45ae-6714-4c27-ac1a-d8ff8e89684f	A Female patients with a bilateral mastectomy would be excluded from the primary trial.
female	PATO:0000383	2-8
bilateral	HP:0012832	25-34
excluded	HP:0040285	55-63
91cf53f9-7233-49ee-a619-c027f6db67ac	Only men can be eligible for the primary trial.
78894316-fc7d-4d61-a2d4-9ea369bfce20	Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea.
erysipelas	HP:0001055,DOID:11330	70-80
889e6622-1614-4f6c-a47c-e7caad6e154f	Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.
neutropenia	HP:0001875,DOID:1227	85-96
leukopenia	HP:0001882,DOID:615	130-140
4577d986-d7e5-4b5d-9852-b944a6f7f252	the secondary trial and the primary trial accept patients in the same age range.
age	PATO:0000011	70-73
range	LABO:0000114	74-79
e83b56ba-d129-4cde-976d-2865e67ef4a3	the primary trial studies tumours response, whereas the secondary trial investigates changes in Bone Mineral Density.
bone mineral density	CMO:0001226	96-116
eee75423-9a61-4a57-8baf-8f91b9562486	The majority of patients in the primary trial suffered from Kidney stones.
kidney	UBERON:0002113	60-66
9e046221-7d4b-4681-a374-96793350927d	Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort.
group	CHEBI:24433	0-5
everolimus	CHEBI:68478	62-72
letrozole	CHEBI:6413	75-84
5448c6b8-244c-4a42-bbef-e1a1a2e254e2	Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.
cyclophosphamide	CHEBI:4026	0-16
135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2	pre-menopausal patients are excluded from the secondary trial, but eligible for the primary trial.
excluded	HP:0040285	28-36
8d450d42-4eb1-4edb-be76-b2885964aa90	Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial, but are eligible for the primary trial.
breast cancer	DOID:1612	38-51
recurrent	HP:0031796	67-76
disease	DOID:4,BAO:0002927,OGMS:0000031	77-84
2674e194-3113-4a11-b2cc-f089d960d194	the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention.
tamoxifen	CHEBI:41774	44-53
exemestane	CHEBI:4953	57-67
a7232387-b266-4bfb-8df8-ca9789188500	Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.
2e317381-2704-4d06-a793-1d2b29139969	In total only one participant of the primary trial did not achieve Pathological Complete Response.
030316a2-fb48-469d-9c55-04cdc9a37fb6	the primary trial participants are given saracatinib PO every single day of the study duration.
saracatinib	CHEBI:47458	41-52
day	UO:0000033	69-72
duration	PATO:0001309	86-94
2c723e02-14d8-4a80-a95f-517e904bbbad	No participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month.
year	UO:0000036	76-80
month	UO:0000035	128-133
8befa03f-c3da-4950-8d27-491ea06b51ed	Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial.
affected	HP:0032320	29-37
affected	HP:0032320	81-89
32424458-a3e2-440a-9693-6a2f8d4aaddb	Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.
capecitabine	CHEBI:31348	11-23
group	CHEBI:24433	24-29
group	CHEBI:24433	267-272
target	BAO:0003064	128-134
target	BAO:0003064	228-234
diameter	PATO:0001334	216-224
a2b25229-c003-49c3-8b0b-94b68f756d3c	the primary trial did not record any skin infections in their patients.
728721c4-6376-4ab8-9e4a-af8596bd1ab3	Laser Therapy is only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this.
laser	BAO:0150033	0-5
c7151ad6-bcac-48e1-ba1e-e6f56a043804	the primary trial and the secondary trial both record cases of Cholecystitis.
cholecystitis	HP:0001082,DOID:1949	63-76
4f71e33c-4f0f-4952-bb03-52402be5f9f4	There is 1 case (1.45%) of thrombocytopenia in the primary trial.
thrombocytopenia	HP:0001873,DOID:1588	27-43
ef675459-a7d9-4ea1-8963-c95682c38d15	Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial.
breast carcinoma	HP:0003002,DOID:3459	27-43
f9df9e45-eb68-4257-801e-b086a89374b8	Female Patients with LVEF > 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial.
female	PATO:0000383	0-6
paclitaxel	CHEBI:45863	129-139
lapatinib	CHEBI:49603	153-162
excluded	HP:0040285	212-220
94fc10ff-65e1-4b0a-8ff3-1cc48db3433e	the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement.
rate	BAO:0080019	47-51
rate	BAO:0080019	69-73
rate	BAO:0080019	103-107
958721dc-e374-4fd1-abb9-071add70bde3	According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg.
mtd	BAO:0001248	50-53
paclitaxel	CHEBI:45863	57-67
19c0b2c7-e45c-4740-b25d-f6e738b59893	Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia.
thrombocytopenia	HP:0001873,DOID:1588	53-69
7bcfca9e-1b09-45d4-8165-cb6ac96b8815	the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial.
e3a8be03-20e4-460d-9ebc-f958a515ac45	Less than 5 patients in the primary trial experienced Earache.
f1096271-3160-4483-9246-ba0d96735efb	Less than 5% of the primary trial participants achieved CR or PR.
329b6871-2edc-4142-a4af-e7f8cef118ee	More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events.
67522762-9423-4e3d-bf75-247f84ba7f05	 To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2.5 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL.
phosphatase	GO:0016791,BAO:0000295	128-139
x	LABO:0000148	146-147
x	LABO:0000148	187-188
aspartate	CHEBI:29995	153-162
hemoglobin	CHEBI:35143	197-207
efd37946-54f3-4813-b63d-6d7df6123677	A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection.
dcf62f43-04b7-4acb-b444-2d805238a8b1	The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group.
group	CHEBI:24433	14-19
group	CHEBI:24433	139-144
83dc7b9a-b863-4f81-88fb-763afc3b79e8	None of the subjects in the primary trial are required to injest any pills, and half the subjects in the secondary trial must take a weekly tablet.
d446920a-2b8e-4452-b9f2-17d2771dbb07	The most common adverse event in cohort 1 of the primary trial is Neutropenia.
adverse event	OAE:0000001	16-29
neutropenia	HP:0001875,DOID:1227	66-77
aa710138-bf2a-4a7f-8014-4513fa1f448b	Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events.
aa38a1cc-35d6-4194-9e9e-3bcc0298a95c	Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.
week	UO:0000034	66-70
6a71c114-2e38-4d57-8f8b-8252d9c62cbe	There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure.
neutropenia	HP:0001875,DOID:1227	30-41
heart	UBERON:0000948	91-96
4333aaa3-dbe4-4275-a982-881fe25c96c0	Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.
day	UO:0000033	70-73
disease	DOID:4,BAO:0002927,OGMS:0000031	112-119
d605b820-2915-4b19-b9cd-ca7850645f83	Only 6 patients in cohort 1 of the primary trial had Varicose Veins.
varicose veins	HP:0002619,DOID:799	53-67
d6de70df-d113-4bc8-9d3b-b71f31937ebe	People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial.
breast cancer	DOID:1612	43-56
gene	BAO:0000582	57-61
9f897b29-7cfa-414c-8cf6-212a68ec2216	Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions, they are only testing effectiveness of consultations.
0d0deba5-c7bd-489b-a49d-c6af9a5cd92a	The the primary trial placebo group performed much better than the test group, as a lower PFS is ideal.
group	CHEBI:24433	30-35
group	CHEBI:24433	72-77
4606f64f-64cc-4d73-a8be-75701c97008d	A patient in cohort 2 of the primary trial received a Plasma transfusion.
patient	HADO:0000008,OAE:0001817	2-9
40bef815-18ed-4db5-8108-9a1cdbdd0a13	Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. However, being pregnant is required.
function	BAO:0003117,BFO:0000034	40-48
5c676007-9ea4-4f80-82dd-89293237cb07	the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement.
rate	BAO:0080019	47-51
rate	BAO:0080019	69-73
a6682883-ace7-4d83-a35c-956928fdc75a	the secondary trial and the primary trial do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language.
1a271e29-477b-4819-a472-5c7c7df99e70	2 cases of hematolysis were recorded in the primary trial, none in the secondary trial.
060e833e-384f-48f0-8e56-ebd95f55f221	There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial.
cellulitis	HP:0100658,DOID:3488	23-33
vertigo	HP:0002321	35-42
ac193d32-156e-48bf-bc6b-d613691f869c	the primary trial only recorded three types of adverse events.
d79173da-5e59-4150-99bd-f1c20118dddc	All participants of the primary trial must have recently undergone either an echocardiography.
50559f15-636d-4265-8f8c-4aad016c6c50	postmenopausal women are eligible for the primary trial, and Premenopausal women are eligible for the secondary trial.
a5af6d2b-4cea-40aa-acdc-59fab5362b3e	Patients with Breast cancers that have estrogen receptors are included in the primary trial.
breast	UBERON:0000310	14-20
estrogen	CHEBI:50114	39-47
7e89b190-b8f7-4281-b0f1-0e65dcebf402	Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan.
exemestane	CHEBI:4953	50-60
6036d341-9c6a-49fc-a2f4-19c0e2399f4c	There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial.
ventricular tachycardia	HP:0004756	39-62
ventricular tachycardia	HP:0004756	73-96
supraventricular tachycardia	HP:0004755	68-96
a84afa25-2741-4a08-9e6c-4049f5feca48	patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial, if this treatment ended over 5 years prior.
phosphoinositide	CHEBI:16749	14-30
inhibitor	CHEBI:35222	40-49
09e4c746-642a-4a5d-a267-25258a3f2ec0	the primary trial and the secondary trial do not have the same duration of intervention administration.
duration	PATO:0001309	63-71
99855d11-e2e4-4a0e-b40e-2264ff128ac5	the primary trial recorded the same number of occurences for every type of adverse event.
adverse event	OAE:0000001	75-88
54fe69c7-5a67-49b1-8bc5-c975133e2bb7	Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine.
76362fd3-3a07-4aa3-a072-b9075d2ea791	Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment).
patient	HADO:0000008,OAE:0001817	13-20
congestive heart failure	HP:0001635,DOID:6000	56-80
active	PATO:0002354	89-95
064b39e9-e9d8-4c51-a76a-ad150bb127f1	the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0.
pancreas	UBERON:0001264	57-65
67a628d7-d883-44b9-b351-901f20fd5d0a	the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study.
patient	HADO:0000008,OAE:0001817	53-60
day	UO:0000033	104-107
78c60212-28f7-4306-9f63-549be04687b2	Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial.
leukopenia	HP:0001882,DOID:615	34-44
patient	HADO:0000008,OAE:0001817	86-93
a72e1259-50be-48e5-bdf8-296040cbf7ce	Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial.
aspartate	CHEBI:29995	14-23
excluded	HP:0040285	89-97
19cfd511-8582-4116-8d51-7ec4a6221022	0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms.
breast cancer	DOID:1612	88-101
3f012bd3-bb89-414b-9dd9-35cef524a69a	According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.
mtd	BAO:0001248	50-53
paclitaxel	CHEBI:45863	94-104
5eafb3a1-473a-4270-848d-173e5dca9466	Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial.
leukemia	HP:0001909,DOID:1240	14-22
hepatitis	HP:0012115,DOID:2237	24-33
ed956644-5228-4915-b706-1cedb0462577	the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial.
02158762-9490-46a1-b494-0589885fd4ce	the primary trial does not record any cardiac related adverse events.
c0a8e1a0-cbe6-4240-b578-59afa4d6cf23	the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.
rate	BAO:0080019	42-46
7ec286e9-f519-41da-848d-a0bc5a50c0ee	dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear.
d0af59a9-04ae-4922-97eb-dc29f5bc44e3	the primary trial and the secondary trial use completely different drugs and techniques for their interventions, however they both require trained Radiologists on site for evaluation.
site	BFO:0000029	163-167
5d4cbb15-ea50-4394-b1b9-ab4553b5b275	 Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.
pazopanib	CHEBI:71219	44-53
day	UO:0000033	71-74
disease	DOID:4,BAO:0002927,OGMS:0000031	93-100
bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8	All 4 of the CHF cases in the primary trial, were in cohort 1.
78a5162d-140a-4631-b776-5c284446b5ec	the primary trial and the secondary trial have entirely different adverse event profiles.
adverse event	OAE:0000001	66-79
633ef768-9e9b-4336-9142-8d4ce7ee2342	There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.
left ventricular systolic dysfunction	HP:0025169	34-71
7c5b29bc-ac37-48bb-abb1-a102174f79ef	Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21 
day	UO:0000033	94-97
day	UO:0000033	103-106
b8881e2e-ca25-4c1b-bbd2-281ebdb7514a	All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.
afatinib	CHEBI:61390	97-105
letrozole	CHEBI:6413	117-126
group	CHEBI:24433	127-132
a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e	the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.
e852619c-312a-470f-8b77-149e79f69a3f	In both the secondary trial and the primary trial the test cohorts produced better results than the control groups.
27160f45-e4cb-48be-8cf2-c23ced4578c0	The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total.
adverse event	OAE:0000001	16-29
affected	HP:0032320	90-98
e4b65e9f-10f6-4424-95d2-837e29587a63	the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast.
adenocarcinoma	DOID:299	93-107
breast	UBERON:0000310	115-121
68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1	Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial.
7796fe1b-1952-4339-90f3-47b051ebe927	One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days.
neutropenia	HP:0001875,DOID:1227	65-76
c7df7b38-068b-48a8-b805-b8ebb3e854e6	the primary trial and the secondary trial do not record any of the same adverse events.
39227bbb-0e26-4ba0-94a7-762376541889	patients with Multi-focal breast cancer cannot be accepted for the primary trial.
breast cancer	DOID:1612	26-39
fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106	the primary trial and the secondary trial have a different number of cohorts.
fd15ddaf-1abc-4551-a5b3-08217b975e36	Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial.
breast cancer	DOID:1612	23-36
diameter	PATO:0001334	44-52
067f4671-0720-4980-a0fa-8d01d31daa9a	As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results.
026e7eb7-37fd-4aae-b74f-dacf905db262	the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial .
a79fc503-215f-40d4-9cc1-e101cec3a9c9	Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial.
active	PATO:0002354	24-30
excluded	HP:0040285	104-112
ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee	the primary trial measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions.
disease	DOID:4,BAO:0002927,OGMS:0000031	59-66
death	OAE:0000632	87-92
7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a	There were no cases of cardiac tamponade in the primary trial or the secondary trial.
cardiac tamponade	HP:0033415,DOID:115	23-40
ccb703ea-df18-451b-8db8-ed0e510a4c0f	Unlike the secondary trial, the primary trial does not specify a specific dosage or frequency for its intervention.
frequency	HP:0040279	84-93
56cd4492-3884-4b2a-a000-7c859d86f6f5	Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.
08b79e0d-5e97-45fb-ac83-0096b56f714b	less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy.
pancytopenia	HP:0001876,DOID:12450	72-84
c524ecf2-1ca6-4a9a-bedf-f0709124fa1b	The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group.
group	CHEBI:24433	30-35
group	CHEBI:24433	112-117
mean	BAO:0002173	58-62
donepezil hydrochloride	CHEBI:4696	82-105
6d549a9b-47bf-4369-962b-2759cfd7051e	the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD.
itraconazole	CHEBI:6076	76-88
596f20cf-299d-40a3-881a-cdd49bcb21f6	Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.
breast	UBERON:0000310	32-38
78ae19aa-6e26-4f9a-b381-cd77d92e4ecb	At least one patient in the primary trial suffered from Gastroesophageal reflux disease.
patient	HADO:0000008,OAE:0001817	13-20
gastroesophageal reflux disease	DOID:8534	56-87
1d4f9f95-6f97-4054-9dd8-fe78aa5fc685	Sam has recently received a liver transplant, he is not eligible for the primary trial, but is eligible for the secondary trial.
liver	UBERON:0002107	28-33
d4b2d877-34af-4944-84f7-046e22c2854e	all subjects in the primary trial must undergo a minor surgery.
surgery	OAE:0000067	55-62
d3ca3729-2795-4cd5-9968-666781d17fac	cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure.
congestive heart failure	HP:0001635,DOID:6000	96-120
fb85a3a5-b9a1-48f4-84f3-2e2307e2f104	There were 0 observed cases of Tibia or Fibula fractures in the primary trial.
b98c7a50-ed79-41ff-9733-fff143f630be	Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial.
fever	HP:0001945	83-88
47aa5686-75af-4ed8-b4ff-715b458ce40a	laboratory biomarker analysis is used in the secondary trial and the primary trial.
biomarker	CHEBI:59163	11-20
e89fdc93-d624-4ba7-aa64-574a278e982b	the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.
1739541a-2d3f-4a13-b956-769a1cbed4d7	1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma.
patient	HADO:0000008,OAE:0001817	2-9
clear cell renal cell carcinoma	HP:0006770,DOID:4467	64-95
c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9	One patient in the primary trial suffered from sepsis, due to the presence of an implanted device.
patient	HADO:0000008,OAE:0001817	4-11
sepsis	HP:0100806	47-53
206fc00c-2c34-42bc-8fca-44be696e03c9	Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.
irinotecan	CHEBI:80630	77-87
4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d	Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group.
median	BAO:0002174	0-6
year	UO:0000036	76-80
sunitinib	CHEBI:38940	122-131
group	CHEBI:24433	132-137
group	CHEBI:24433	182-187
83cef795-d4a8-486c-8ac1-34a9acee9672	Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial.
breast cancer	DOID:1612	25-38
excluded	HP:0040285	67-75
b3cee7a6-cec1-4676-974d-7cfb3ccd9919	the primary trial recorded one patient with a catheter-related complication, whereas in the secondary trial none where observed.
patient	HADO:0000008,OAE:0001817	31-38
007de11b-4265-4695-b18e-e0d6909a347a	Patients with HER2 positive tumors are excluded from the primary trial, but may be included in the secondary trial.
excluded	HP:0040285	39-47
ce621235-b584-439b-bb11-ab2fa04c3195	Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire.
biomarker	CHEBI:59163	84-93
f358f023-2393-44eb-9535-3f0e1851318d	the secondary trial and the primary trial both use irradiation techniques in their studies.
0e963b25-0d2b-4fc6-89c6-1eb068bc092e	Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.
patient	HADO:0000008,OAE:0001817	6-13
tipifarnib	CHEBI:141969	44-54
paclitaxel	CHEBI:45863	70-80
doxorubicin hydrochloride	CHEBI:31522	82-107
390b08d3-e147-47f9-82d7-0643b8d5c8ae	There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.
2570cb04-4edd-48c9-b634-9f2e086469de	Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial.
f6a7e279-b923-45e3-8ad5-e81e17c0a682	60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.
3d82851c-f302-4988-bd78-232583e04e96	Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial.
excluded	HP:0040285	73-81
5c9f5916-37d3-4f6f-977b-be70204cf57c	All the primary trial participants have the same number of calories in their diets throughout the duration of the study.
duration	PATO:0001309	98-106
0c5f2498-4c10-4e51-8915-d86b37b08156	Participants in the primary trial are assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned.
cancer	DOID:162	82-88
c54dc963-671a-4384-8b1f-d8058a832131	There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial.
left	HP:0012835	58-62
a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4	A total of 32 patients in the primary trial had Diarrhoea.
91adb350-ab20-41a6-944d-c13b55cf33f2	Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none.
78949f1f-6738-4220-a233-e7831902e6f3	Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.
135311d8-c579-4568-913e-937be00dde7e	In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups.
0984431d-4997-41dc-9ba4-07134568c3fa	Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some.
eribulin mesylate	CHEBI:70710	51-68
d9dc4a6d-a913-46ac-b0aa-d50823ff2305	Patients with Platelet count over 100,000/mm¬¨‚â•, ANC < 1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial.
platelet count	CMO:0000029	14-28
hemoglobin	CHEBI:35143	75-85
9d9ab190-cdcf-4320-b69a-12f2dad9dba9	the secondary trial and the primary trial use non comparable evaluation metrics, and significantly different time frames.
time	PATO:0000165	109-113
89fdf182-7474-4e70-baf7-03c8920c4ff3	Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial.
group	CHEBI:24433	87-92
9f2fd0cc-af87-433d-9d2f-6235591d6cb1	Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.
breast	UBERON:0000310	73-79
90364098-7e9a-47be-ab2e-f66958cfb09d	The interventions in the primary trial and the secondary trial are applied daily for a period of several months.
021c3f62-8067-49e3-9d4b-c7641feb2548	 The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial.
6893c9b4-d3a3-47a8-ada9-8aef67de2375	Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic.
breast cancer	DOID:1612	41-54
b88cde11-ae29-48e8-832b-4b9cb2596c30	Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from the primary trial.
ovarian cancer	DOID:2394	20-34
excluded	HP:0040285	93-101
ebe7078c-fd8b-439a-b1f5-7bd482071ead	the primary trial studies changes in tumour diameter, whereas the secondary trial investigates changes in heart failure rate.
diameter	PATO:0001334	44-52
heart	UBERON:0000948	106-111
rate	BAO:0080019	120-124
d0b9c11c-50f2-4803-a96c-fff3ca90cf36	Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.
irinotecan	CHEBI:80630	77-87
b620e1c5-69c4-4c30-9006-faa346200b60	the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Trastuzumab, a type of chemotherapy.
0900325b-6ecd-46f1-b3f1-a2ce1605d151	There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the increase in Gy has no notable effect.
size	PATO:0000117	44-48
increase	BAO:0001251	98-106
6f10e1f3-1197-464e-b574-d697fb49331d	Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial. 
breast cancer	DOID:1612	21-34
breast cancer	DOID:1612	138-151
cbf91beb-829b-488f-8e80-3b08b891a181	the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis.
985df98b-b397-4dbc-8fad-43ada30927d7	Patients needing active supportive care can participate in the primary trial.
active	PATO:0002354	17-23
0d4fdeef-89b2-463b-8252-66fa51d9ce8c	The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall.
breast	UBERON:0000310	205-211
chest	UBERON:0001443	215-220
2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe	27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response.
fatty acid	CHEBI:35366	27-37
minocycline hydrochloride	CHEBI:50697	99-124
494c1f01-5a2d-409e-b614-5871f408fbe6	In the primary trial group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. 
group	CHEBI:24433	21-26
group	CHEBI:24433	131-136
increase	BAO:0001251	75-83
area	PATO:0001323	93-97
17881072-2517-483f-9c03-1edad21a58cf	In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial.
58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7	Patients with cancer cells that have metastasised into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter the primary trial.
cancer	DOID:162	14-20
lymph	UBERON:0002391	67-72
da6ce3a9-b653-47b2-9271-f831e4de3f19	Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.
66979ae5-a709-4adf-9067-287f0f92b9e2	A higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1.
fever	HP:0001945	76-81
0af6799b-655f-4b8b-a192-ce8dcbb2fcff	Only Black women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.
brain	UBERON:0000955	109-114
3a3e2387-c4c7-48e6-b3ca-1257de7019c2	Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial.
breast	UBERON:0000310	25-31
lymph	UBERON:0002391	53-58
46ac8a9f-77ab-40cf-9421-64aad4ae6976	participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD.
anastrozole	CHEBI:2704	110-121
d2b7253b-0654-4bb1-a9a4-b203714d64f9	the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame.
time	PATO:0000165	108-112
9a896e4a-ae6b-468c-a7c0-32c1514c0b48	Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events.
adverse event	OAE:0000001	78-91
adverse event	OAE:0000001	178-191
adverse event	OAE:0000001	259-272
41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4	The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically.
0931065d-35e4-4f82-8ef6-ac6db900127a	Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial, but not the primary trial.
breast cancer	DOID:1612	15-28
chest	UBERON:0001443	67-72
70912726-ba1b-47ef-9005-9584c8caf559	Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for the primary trial.
breast cancer	DOID:1612	43-56
breast cancer	DOID:1612	150-163
family history	HP:0032316	108-122
6743f85c-8318-49cc-acba-94aeb1f57130	Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.
patient	HADO:0000008,OAE:0001817	74-81
ddffa26d-2581-477a-955c-ebf0c2ab0f97	Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial.
breast	UBERON:0000310	20-26
breast	UBERON:0000310	27-33
f1a45b47-498d-45c8-b6d9-6c8f035da30b	1 patient in the primary trial was affected by Sepsis.
patient	HADO:0000008,OAE:0001817	2-9
affected	HP:0032320	35-43
sepsis	HP:0100806	47-53
a5272c37-0e32-42db-a44a-d17df7bd70ff	There were no pain related adverse events observed in the primary trial.
pain	HP:0012531	14-18
4c67a7b4-36fa-4c20-a15a-122609550973	Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial
year	UO:0000036	15-19
breast cancer	DOID:1612	73-86
history	BFO:0000182	153-160
120c6aa7-fcaa-4eaa-b520-6382968a6724	the primary trial tests two different dental imaging modalities, namely Mammography and gamma imaging.
e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645	the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD).
zoledronic acid	CHEBI:46557	36-51
zoledronic acid	CHEBI:46557	87-102
bone mineral density	CMO:0001226	167-187
ac997ae1-7e48-48e2-af9e-f7e289622250	the primary trial and the secondary trial investigate different outcome measures for different interventions.
59328f44-6755-4dcb-b04c-4e0ce2ba3ac8	The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month, the patient with the longest OS was in cohort 1.
median	BAO:0002174	18-24
month	UO:0000035	121-126
patient	HADO:0000008,OAE:0001817	50-57
patient	HADO:0000008,OAE:0001817	132-139
441c0760-ca4a-4f1d-864e-a77395fd1f18	The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group
lapatinib	CHEBI:49603	4-13
group	CHEBI:24433	14-19
group	CHEBI:24433	156-161
collagen	CHEBI:3815	122-130
fbe60029-8944-4e12-b4b2-3413037a10cc	57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery.
surgery	OAE:0000067	93-100
fe1782aa-a871-4608-a7cb-8f83b7f76d8a	Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial.
gemcitabine	CHEBI:175901	0-11
a153ecbf-11ac-4c40-a3af-9dbb0e12c49b	There is no overlap in treatments used in the primary trial and the secondary trial.
bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e	Patients intracranial metastasis may be eligible for the primary trial.
4dc22366-3ff3-41c8-aa4c-7342d7b7085d	The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate.
progressive	HP:0003676	54-65
disease	DOID:4,BAO:0002927,OGMS:0000031	66-73
rate	BAO:0080019	113-117
196c2132-c735-4b79-bf03-3a830fcaf0fc	the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not.
central nervous system	UBERON:0001017	34-56
72619b0a-57c2-465c-8428-72019b59f8ae	In the primary trial, all cases of Enteritis, Vertigo and Cardiac failure occurred in cohort 2.
vertigo	HP:0002321	46-53
b8663fa7-585a-4cd9-afd2-89e8e1a58b82	Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial.
heart	UBERON:0000948	32-37
month	UO:0000035	56-61
excluded	HP:0040285	82-90
7c92d075-ba9d-45b5-9834-83b09d2753bc	the primary trial and the secondary trial both administer treatments to their patients through IV.
0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8	If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday.
ketoconazole	CHEBI:47519,BAO:0000796	26-38
9a346aac-46c2-4a50-8f3a-309b3b7bc295	Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention.
magnesium oxide	CHEBI:31794	62-77
mometasone	CHEBI:6970	91-101
949d79e0-95db-47a2-802a-6280c0255923	Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood.
patient	HADO:0000008,OAE:0001817	20-27
patient	HADO:0000008,OAE:0001817	105-112
blood	UBERON:0000178	154-159
6e080a1e-a03e-4547-a7c4-c9d5a80de977	Patients participating in the primary trial and the secondary trial experienced serious eye disorders.
eye	UBERON:0000970	88-91
63218fb2-3f5b-4738-bea8-11fbbc560949	Patients with severe malabsorption disorders are ineligible for the primary trial, unless they are able to receive intravenous (IV) alimentation.
severe	HP:0012828	14-20
malabsorption	HP:0002024	21-34
d7fa4f81-e108-491f-9b08-c147a33863e8	Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously.
f24afb09-ea65-457f-9f9b-0db3cc3101ac	Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.
breast	UBERON:0000310	108-114
3cd79df2-e6dd-41dd-b819-4d993b5f7aed	There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial.
leukopenia	HP:0001882,DOID:615	23-33
arrhythmia	HP:0011675	47-57
d2d6f646-5881-42a2-b965-0c6f79e89463	Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.
month	UO:0000035	65-70
428d5165-560b-4783-8c4b-5fd3a3289cab	There were no patients in either cohort of the primary trial with a PFS exceeding one year.
year	UO:0000036	86-90
6e7df2e4-11b3-4183-aefc-760f85809515	the primary trial and the secondary trial both administer Zometa to their patients through IV, although in different doses.
45e6b4b6-ca31-4318-936e-5b27cbca47a2	One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.
patient	HADO:0000008,OAE:0001817	4-11
functional	BAO:0000010	70-80
volume	PATO:0000918	87-93
22a6d10e-55c5-4a8c-8010-3e8252bcb279	Patient who have recently undergone External beam radiation therapy are eligible for the primary trial.
patient	HADO:0000008,OAE:0001817	0-7
7fd1ae1e-bfdb-4c37-aaea-ed97663758e3	the primary trial treament last for a shorter period of time than the secondary trial treatment, but is administered much more often.
time	PATO:0000165	56-60
50d119f6-a657-4619-918e-7617ac57f052	Cohort 1 of the primary trial reported one case of AML.
e436827b-10db-4179-bf8f-07786ee6145b	There are no racial criteria for entry into the primary trial, however there are gender criteria.
fcc6708a-b0fc-4215-a45f-02b1e0e2d30a	Patients with hemophilia are excluded from the primary trial.
excluded	HP:0040285	29-37
d63706f1-4fb8-488d-8f86-c1a19df341d4	Patients with tumors underexpressing HER2 are excluded from the primary trial, but may be included in the secondary trial.
excluded	HP:0040285	46-54
ab357056-67a7-4227-966d-8c96eb1640fd	Candidates for the primary trial are expected to be capable of holding their breath for half a minute.
minute	UO:0000031	95-101
0359eef3-6339-485e-95bc-0cb6fa7bcd12	Patients with Breast cancers that have estrogen receptors are excluded from the primary trial.
breast	UBERON:0000310	14-20
estrogen	CHEBI:50114	39-47
excluded	HP:0040285	62-70
57ef3c6c-b4e1-4302-b423-aa9faca21200	the primary trial and the secondary trial do not use the same route of administration for their interventions.
29d5779b-c228-4b82-9ca8-075beadae879	There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia.
neutropenia	HP:0001875,DOID:1227	33-44
neutropenia	HP:0001875,DOID:1227	117-128
neutropenia	HP:0001875,DOID:1227	134-145
4e124d90-68d7-40bd-a8b1-27cb49d64c64	the primary trial patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles.
trametinib	CHEBI:75998	35-45
inhibitor	CHEBI:35222	51-60
0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3	the route of administration for both interventions in the primary trial is a topical skin cream.
f4c7dae5-012f-4f05-b5ba-da072fe1359c	One patient in the primary trial was observed suffering from Enteritis.
patient	HADO:0000008,OAE:0001817	4-11
927bbb75-37da-4b75-9483-252d31a0fd98	Unlike the secondary trial, the primary trial does not provide a duration of cycles or any dosages in the intervention section.
duration	PATO:0001309	65-73
80a5cdbc-0721-41b6-af1a-28e3f46557ce	1 patient in the primary trial had a cardiac related adverse event.
patient	HADO:0000008,OAE:0001817	2-9
adverse event	OAE:0000001	53-66
af710d36-8062-4412-8d11-1c57a14b5e5a	the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial.
rate	BAO:0080019	48-52
c91c7dc1-17b7-4475-9aec-38999a18a306	There were several patients who contracted Pneumonia in the primary trial.
pneumonia	HP:0002090,DOID:552	43-52
5357ce66-7f7b-4ffd-926c-f6116f5a2e20	the primary trial and the secondary trial observed a different number of adverse events in their patients.
3c7ecca8-5397-41f5-b72b-84217bf3acd2	Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial.
chronic obstructive pulmonary disease	DOID:3083	11-48
2c53e14a-719c-4994-9090-73f9bddb60ba	the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.
7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a	In total more participants in the primary trial had no tumor Response, than partial response, and only 3 patients had a complete response.
bfb617c8-51ae-4ab2-be05-6346daad5437	the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries.
food	CHEBI:33290	152-156
dcc5c3b0-848b-4ef4-afe6-e9c9933e33af	Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial, unless treated with herbal medicines.
18fcd396-cb03-4e80-bb2d-ee03c12ba32a	Throughout both the secondary trial and the primary trial there was only one case of pregnancy, in cohort 1 of the secondary trial.
694c5820-ebb6-4271-8685-a0b51c637f7f	There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.
exemestane	CHEBI:4953	95-105
exemestane	CHEBI:4953	136-146
celecoxib	CHEBI:41423	108-117
b87abb47-13b6-4dbe-9cfd-e63075b676aa	on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions.
target	BAO:0003064	84-90
target	BAO:0003064	99-105
eb025223-1b4a-4df7-a85e-2eeeb62a6bf5	Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for the primary trial.
anastrozole	CHEBI:2704	38-49
year	UO:0000036	29-33
year	UO:0000036	77-81
23df2cc2-6aae-4251-a8a7-e2f5a65f176a	None of the adverse events which occurred in the primary trial were not GI related.
1bd51c93-d7a8-4da4-825d-ada625033c34	Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial.
liver	UBERON:0002107	33-38
oral contraceptive	CHEBI:49325	78-96
58c58b68-fc9a-438c-8a85-9233dde714c9	The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort.
breast cancer	DOID:1612	20-33
843778c6-a320-49a1-93a0-5dc6239b822a	The most common adverse events in the primary trial where Infection and Stomatitis.
stomatitis	HP:0010280,DOID:9637	72-82
a5486f80-69e5-4a5a-8435-f82f39cddf85	There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1.
c2c60b25-f255-48ba-bcb7-2bcd2de4315d	There are four types of adverse events in the primary trial, for which no occurences are recorded.
a8167a90-8ccf-4024-a4cc-8c1b047fd548	the primary trial and the secondary trial do not employ the same route of administration for their interventions.
bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75	the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression.
pemetrexed	CHEBI:63616	58-68
month	UO:0000035	84-89
disease	DOID:4,BAO:0002927,OGMS:0000031	117-124
277f5d17-36cc-44c5-9b94-7e052f2bdb2c	Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section.
duration	PATO:0001309	64-72
drug	CHEBI:23888	87-91
fcb195de-2143-44d8-8c46-136104554e2d	There less than 1% of either cohort of the primary trial was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy.
pancytopenia	HP:0001876,DOID:12450	71-83
70337af9-3d4a-44bc-bbfa-0d97ea88553c	Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial.
9cf89221-5801-4709-a098-de763b6e702e	A Female patients with a mastectomy would be excluded from the primary trial.
female	PATO:0000383	2-8
excluded	HP:0040285	45-53
f89883ea-dd60-4d5f-9354-13fbca2aeec8	Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in the primary trial.
brain	UBERON:0000955	54-59
a289f67c-ff56-44a9-b3da-152fb0d20271	Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial.
adverse event	OAE:0000001	19-32
duration	PATO:0001309	57-65
10ed1242-c6ab-4ad0-b93c-4738857f543a	Patients with ICDs may be eligible for the primary trial.
683b9885-4027-4108-b37e-61255611538a	Asian, white british and white irish women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.
brain	UBERON:0000955	135-140
a47e048a-56aa-49e0-9903-563f53797b6e	Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2.
frequency	HP:0040279	64-73
690de5e2-3d7f-407e-8eb9-783adf58841b	Women of any age can participate in the primary trial and the secondary trial.
age	PATO:0000011	13-16
f5477a02-dde7-44c8-80b5-2cdb9fa66f23	More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial.
dc184dcb-a22d-4cac-bee1-6c182692e522	Patients must have a life expectancy over a year to participate in the primary trial.
year	UO:0000036	44-48
4dfbdeba-cae0-48b2-a38d-07338512904e	Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions.
breast	UBERON:0000310	10-16
62489179-bb30-4b96-a904-ea907dd05e23	Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.
patient	HADO:0000008,OAE:0001817	6-13
adverse event	OAE:0000001	98-111
45891239-bb78-4f83-8306-8edceb8247fe	All patients in the primary trial must have a bilateral breast mammography prior to study entry.
bilateral	HP:0012832	46-55
breast	UBERON:0000310	56-62
9ec1e3f0-64a2-4629-aee8-cdb516fd27f3	Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat, whereas both cohorts in the secondary trial receive some of both.
eribulin mesylate	CHEBI:70710	51-68
vorinostat	CHEBI:45716	72-82
91f23b55-38b6-41c4-af30-baa15e989aa7	Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia.
receptor	BAO:0000281	36-44
receptor	BAO:0000281	66-74
receptor	BAO:0000281	116-124
progesterone	CHEBI:17026	53-65
growth factor	BAO:0002024	102-115
breast cancer	DOID:1612	151-164
dysphagia	HP:0002015	187-196
7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d	the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients.
lapatinib	CHEBI:49603	59-68
a2d489d5-3677-43ef-b03a-33d571c0c3b2	Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as long as they do not have uncontrolled Hypertension.
class iii obesity	HP:0025501	14-31
hypertension	HP:0000822,DOID:10763	159-171
943ff737-4edd-4dbd-a3c9-213e3e0234d8	the primary trial and the secondary trial both report cases of confusion in their patient cohorts.
confusion	HP:0001289	63-72
patient	HADO:0000008,OAE:0001817	82-89
be50c45f-ec51-40c8-904f-ffc200d39d9d	Only patients capable of understanding english are eligible for the primary trial.
f53c8212-6da8-470f-a392-1bb037ed90e8	Intervention 1 for the secondary trial and the primary trial either include no treatment at all, or a placebo.
7b7e6e8b-aa62-4fcd-af1e-c243995243d1	There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.
74a53536-bb9d-4c64-9280-679d7b660cdd	the primary trial does not investigate the effects of its intervention on patient tpCR.
patient	HADO:0000008,OAE:0001817	74-81
6b35c306-a699-44f2-8606-a58d58fc18f3	There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases.
adverse event	OAE:0000001	13-26
62f50fe5-a83d-4f07-9dc7-8f495254d398	Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial.
breast	UBERON:0000310	0-6
breast	UBERON:0000310	7-13
edcae553-8a0a-45d2-a0fa-4db68608ef03	the primary trial requires participants to have a primary tumor > 5cm in longest dimension. 
a1b3667f-bfa5-426a-975a-20ed350c12c0	Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.
month	UO:0000035	76-81
month	UO:0000035	127-132
903617fa-7c40-45ac-a03c-498f51879408	The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month.
median	BAO:0002174	18-24
month	UO:0000035	142-147
9436e18a-a055-41c3-980f-bf451b4da7ee	There are four types of adverse events in the primary trial, for which one occurence is recorded.
f57403d9-7278-481e-bcb9-066bf31b6158	1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
affected	HP:0032320	35-43
affected	HP:0032320	72-80
sepsis	HP:0100806	47-53
ec601f6b-6ce3-4df7-b7b3-fbde1a241e93	Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events.
0f0e5a8e-3972-46c2-84dd-7436e82a9787	The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent.
duration	PATO:0001309	4-12
frequent	HP:0040282	103-111
420e4977-ce75-4fab-99e0-3e7db837d521	The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group.
time	PATO:0000165	12-16
disease	DOID:4,BAO:0002927,OGMS:0000031	20-27
capecitabine	CHEBI:31348	97-109
group	CHEBI:24433	110-115
d07b4a30-e74f-468a-8420-7ade791d372d	the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%
breast cancer	DOID:1612	65-78
412b2743-8f76-494a-af97-f7bf9541a890	At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial.
fd43feb6-4a55-4de6-b21d-25ff723b0959	Patients may be forced to take part in the secondary trial and the primary trial, even against their consent, as long as it is in their best interests.
e1fa68ac-42b4-4223-a362-a89c43562e06	The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).
adverse event	OAE:0000001	16-29
neutropenia	HP:0001875,DOID:1227	63-74
ejection fraction	CMO:0000180	137-154
6f5570c0-4114-47ee-9611-b2e4be91cf9a	2 patients in the primary trial suffer from DVT, 0 in the secondary trial.
13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef	Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.
diameter	PATO:0001334	83-91
6495c223-f7d9-459f-8c57-66a2caac5ee4	All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks.
central nervous system	UBERON:0001017	44-66
eb61fee2-30fc-42f9-80bd-4d73d6af592c	the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies.
breast	UBERON:0000310	87-93
79c698bf-a756-4a73-8075-38c3c5eb7a04	Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).
mean	BAO:0002173	49-53
percent change	BAO:0001252	55-69
f7be0a6e-6c63-473e-af00-df009f3d7d46	Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial.
breast	UBERON:0000310	0-6
diffuse	HP:0020034	20-27
patient	HADO:0000008,OAE:0001817	70-77
6f686de9-f110-4be0-9cd8-1ceb0ce6f073	Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily.
gel	BAO:0010018	71-74
pain	HP:0012531	173-177
duloxetine	CHEBI:36796	187-197
2c602b4d-c8a5-4606-8e3a-a87ee7bbc480	Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in the primary trial.
ffa913b7-9875-458e-8a28-476f9e788bb0	There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial.
group	CHEBI:24433	132-137
5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5	the primary trial records a total of 7 different types of infections.
d8e47fe7-be41-4f74-881b-a80cd3a1e95f	There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial
duration	PATO:0001309	36-44
frequency	HP:0040279	48-57
e77e15a3-d851-4174-80c3-7b5156e7f987	the primary trial and the secondary trial do not use any of the same drugs in their interventions.
c003dd08-af3b-44cc-b31c-6fbdadfa1d83	In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years.
patient	HADO:0000008,OAE:0001817	18-25
8ddf49c7-316e-4c7c-b2dd-423182a37612	Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death, in cohort 1 of the secondary trial.
death	OAE:0000632	107-112
d9e41be5-1e37-4dff-b51a-166576f351d0	For all adverse event types in the primary trial, at least one case was recorded.
adverse event	OAE:0000001	8-21
ee2287bd-af76-4232-9575-d371fe3257dc	Every adverse event in the primary trial occurred once.
adverse event	OAE:0000001	6-19
e5495b51-5f42-4e97-80ec-c215652bd3ab	Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial.
immunohistochemistry	BAO:0000415	17-37
result	BAO:0000179	43-49
excluded	HP:0040285	60-68
9b6bd158-a66d-42b6-8fe6-843ff05e0c8d	children and illiterate adults are able to take part in the primary trial, unless they are can read and write in italian. 
9ae51f9c-8544-4764-b731-e4efe9ae0ba6	1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities.
5b1915da-1819-4504-81bd-3f44a83b5e95	Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.
leukopenia	HP:0001882,DOID:615	68-78
edb1e4c0-7669-4b8c-878b-ea8ca060c350	Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.
adverse event	OAE:0000001	14-27
915939cf-7813-43e7-b503-e14a7eb4e568	Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2.
126c1169-b375-4f89-95b2-52e971d19565	Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious.
enterocolitis	HP:0004387	65-78
11235250-3627-427e-aae9-099507484456	Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.
8a9f2247-7c51-44be-910b-5091d9abb2ea	the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography.
paclitaxel	CHEBI:45863	58-68
gemcitabine	CHEBI:175901	73-84
positron	CHEBI:30225	150-158
tomography	BAO:0002525	168-178
7e283897-4d9e-4353-8331-00f8db16cc7e	The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane.
patient	HADO:0000008,OAE:0001817	4-11
tamoxifen	CHEBI:41774	87-96
exemestane	CHEBI:4953	100-110
54b15068-023b-4e60-bb82-2a22512fda62	Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial.
male	CHEBI:30780,PATO:0000384	0-4
systemic lupus erythematosus	HP:0002725,DOID:9074	19-47
excluded	HP:0040285	52-60
78764961-52be-4235-a2b7-e581497d0099	The two groups in the primary trial receive the same drug treatment, but different doses.
drug	CHEBI:23888	53-57
e09fe98c-ec5c-49cf-9f49-92ba8824e82e	The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment.
active	PATO:0002354	71-77
patient	HADO:0000008,OAE:0001817	101-108
a83d98c9-e3da-4449-878b-5fa2f3bee8cf	the primary trial is not testing a novel Physiotherapy or radiotherapy intervention.
physiotherapy	OAE:0002476	41-54
radiotherapy	OAE:0000235	58-70
41db854e-1565-4eda-8236-550556043b47	To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.
carcinoma	HP:0030731,DOID:305	69-78
chorionic gonadotropin	CHEBI:81570	122-144
urine	UBERON:0001088	145-150
f559cacb-30e7-47cf-9ac6-5929c1a508f7	There were no MRSA infections in either the secondary trial or the primary trial.
79362f6d-ef2c-4b93-8719-be361d0b5acc	Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.
female	PATO:0000383	0-6
ductal carcinoma in situ	HP:0030075,DOID:0060074	162-186
54918996-1b4d-48bd-a0ca-13d8e259767b	Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, even if they have uncontrolled Hypertension.
class iii obesity	HP:0025501	14-31
hypertension	HP:0000822,DOID:10763	149-161
a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5	Patients in the secondary trial and those in the primary trial did not share any of the same adverse events.
52c8361f-75dc-45f1-a35c-79180a22b931	There are no recorded cases of thrombocytopenia in the primary trial.
thrombocytopenia	HP:0001873,DOID:1588	31-47
f2f05760-cc22-4fe8-a24f-f6d43f9c9a86	Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year.
group	CHEBI:24433	24-29
median	BAO:0002174	57-63
year	UO:0000036	96-100
year	UO:0000036	159-163
db8ffa86-bf52-47bb-89f7-42e7ae47b84d	In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.
afatinib	CHEBI:61390	89-97
afatinib	CHEBI:61390	133-141
paclitaxel	CHEBI:45863	146-156
vinorelbine	CHEBI:480999	160-171
group	CHEBI:24433	192-197
5a01d00f-8601-4c17-b814-be87e63b0d8a	the primary trial cohorts are not seperated based on patient characteristics.
patient	HADO:0000008,OAE:0001817	53-60
7577f05f-04e9-44de-9e00-b7411ff4010f	Patients currently prescribed laxatives are not excluded from the primary trial.
excluded	HP:0040285	48-56
3b0440e6-cf85-4236-8a1d-2e3572143946	Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events.
6f342205-ef33-482a-b74a-74644537538b	Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.
female	PATO:0000383	32-38
target	BAO:0003064	57-63
5b63fffb-0a75-414f-8744-5fea78395f28	100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.
afatinib	CHEBI:61390	24-32
group	CHEBI:24433	50-55
9e655973-7d1d-4528-8394-a9cbcf0b978f	Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial.
adult	EFO:0001272	0-5
breast cancer	DOID:1612	61-74
excluded	HP:0040285	146-154
ea62355f-aab9-4796-8658-746c0b669ca7	There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as placebo.
group	CHEBI:24433	31-36
suramin	CHEBI:180911	83-90
55eaae8d-611c-4dbb-b162-de664902e059	In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.
intestinal obstruction	HP:0005214,DOID:8437	46-68
c3438bb2-4a49-4f14-ae50-a46fb48d0208	the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified.
cyclophosphamide	CHEBI:4026	4-20
8f505cec-6ad4-4142-a861-1771e3ae5cdd	the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.
imiquimod	CHEBI:36704	45-54
day	UO:0000033	90-93
day	UO:0000033	113-116
day	UO:0000033	127-130
8f4f9793-041d-448b-9da8-b0c787a875bb	Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial.
function	BAO:0003117,BFO:0000034	40-48
d13e5689-2a9e-4295-b3f8-e4a18fe42bf1	the secondary trial is testing a surgical intervention, unlike the primary trial.
61d56c2a-089f-4fa3-9e97-3a9007576077	the primary trial do not receive any intervention by IV, orally or by surgery during the study.
surgery	OAE:0000067	70-77
5b90b8de-97b9-4ed7-b5a4-e3724fd38c41	If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month.
ketoconazole	CHEBI:47519,BAO:0000796	26-38
month	UO:0000035	149-154
bad4d3e7-a05a-44fd-937a-c94a23655c03	Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine.
naproxen	CHEBI:7476	47-55
frequency	HP:0040279	68-77
pilocarpine	CHEBI:39462	141-152
b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2	There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial.
0c435231-a09c-4424-924a-13840c6b7068	In the primary trial there was 1 case of jaundice.
jaundice	HP:0000952	41-49
0812dcc1-eab5-4d5f-9d51-934f9b1f05ca	Prior exposure to exemestane is not allowed for patients in the secondary trial, however, the primary trial may accept patients despite this.
exemestane	CHEBI:4953	18-28
a29e6a86-65f3-4565-93e2-81f49fa837e4	Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression.
anemia	HP:0001903,DOID:2355	79-85
dyspepsia	HP:0410281	87-96
nausea	HP:0002018	98-104
depression	HP:0000716	108-118
2470d8d1-27cd-41a5-9e5d-f62d4bbdd049	Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial.
34bb7f09-3b2b-464f-96df-c8d80b1206fc	All cancer stages are accepted for the primary trial and the secondary trial.
cancer	DOID:162	4-10
e9824c27-bb70-4707-9599-ff20281f873e	Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins.
varicose veins	HP:0002619,DOID:799	63-77
43fcba9b-4edd-433d-86a7-370cbbf56853	The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial.
median	BAO:0002174	4-10
median	BAO:0002174	178-184
time	PATO:0000165	11-15
time	PATO:0000165	185-189
disease	DOID:4,BAO:0002927,OGMS:0000031	70-77
death	OAE:0000632	93-98
196c7a35-58a0-4d2d-a0a6-e9e3de077fb1	The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2.
median	BAO:0002174	4-10
time	PATO:0000165	11-15
death	OAE:0000632	38-43
27e0b995-b3d1-46a6-900a-d6e513504ff3	3/4 patients in the primary trial did not suffer any adverse events.
36a5357f-0c5f-4c64-a56a-a84aab165a16	the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry 
ct	BAO:0002125	92-94
c876167f-fe1e-4c3b-9183-dd3c1069ed0b	A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion.
patient	HADO:0000008,OAE:0001817	2-9
blood	UBERON:0000178	65-70
d6989b67-ae99-4c2a-a67d-c2285cc57058	The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group.
time	PATO:0000165	12-16
disease	DOID:4,BAO:0002927,OGMS:0000031	20-27
capecitabine	CHEBI:31348	99-111
group	CHEBI:24433	112-117
90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1	Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS.
median	BAO:0002174	82-88
886d3280-bc44-4a58-a5ba-66b018210332	The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year.
time	PATO:0000165	22-26
death	OAE:0000632	114-119
cancer	DOID:162	127-133
patient	HADO:0000008,OAE:0001817	142-149
year	UO:0000036	188-192
03dcb6d9-efae-40ec-87ee-68ef89424498	There were more cases of deteriorating mental health in the primary trial than the secondary trial.
b881b717-1c8a-41b8-9554-6ed9e8ee7c77	the primary trial records a total of 7 patients suffering from various infections.
20530faf-addb-47bf-896d-b9666e149223	In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.
52557c9f-f771-4f31-bb71-01f87f9f5821	Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial.
11472413-533f-45f9-9aac-c46bca318aab	Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months.
sunitinib	CHEBI:38940	76-85
paclitaxel	CHEBI:45863	90-100
duration	PATO:0001309	107-115
death	OAE:0000632	138-143
median	BAO:0002174	153-159
group	CHEBI:24433	173-178
3b8f5ef2-b0bb-42e8-a165-45a2d35780e0	Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial
indicator	CHEBI:47867	72-81
6446f085-c6b0-43ce-82ed-16d6952b549e	Only patients in cohort 2 of the primary trial undergo Trunk compression. However all patients in the secondary trial are treated with Trunk compression.
trunk	GO:0043198,UBERON:0002100	55-60
trunk	GO:0043198,UBERON:0002100	135-140
7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a	the primary trial participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane.
tamoxifen	CHEBI:41774	67-76
exemestane	CHEBI:4953	80-90
db90c9d8-b289-48e2-a7df-f41620b3feab	the primary trial and the secondary trial both reported cases of sepsis in their patients.
sepsis	HP:0100806	65-71
f2533676-1e72-444e-8aef-1fa826ceb804	There are no cases of agranulocytosis in the primary trial.
agranulocytosis	HP:0012234,DOID:12987	22-37
c15309b3-eb08-4d46-94ef-e4a504a111db	The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient.
active	PATO:0002354	169-175
patient	HADO:0000008,OAE:0001817	199-206
4885cd77-628c-4b8f-8345-6bce2165938c	Patients eligible for the primary trial and the secondary trial must live in the USA.
8809cc5e-36d5-4f7e-b06d-b1915a421f71	Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of the primary trial.
adverse event	OAE:0000001	9-22
breast abscess	DOID:0060323	26-40
f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1	Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial, unless they have an ECOG>2.
female	PATO:0000383	0-6
age	PATO:0000011	25-28
breast cancer	DOID:1612	66-79
disease	DOID:4,BAO:0002927,OGMS:0000031	105-112
ca27db58-14c4-4889-95b1-69be9c10a07a	More patients with a Low Platelet Count where found in the primary trial than in the secondary trial.
platelet count	CMO:0000029	25-39
5147b171-b5dc-46d6-a153-1a6d9a062ef1	All cancer stages are accepted for the primary trial.
cancer	DOID:162	4-10
a5ed3500-1ea1-40b6-b1cb-3d5ae776f713	the primary trial did not record any adverse events.
3c482d5e-bfad-4a46-9e98-ba9967f2d900	Patients with BCC are excluded from the primary trial and the secondary trial.
excluded	HP:0040285	22-30
48ccd744-abf1-4e98-bc86-8ecd625e6279	Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial.
adenocarcinoma	DOID:299	40-54
breast	UBERON:0000310	62-68
dce5d9c8-7da6-4732-b969-c492c876cdca	Women of any age can participate in the primary trial.
age	PATO:0000011	13-16
1882de62-2df2-4b73-a3d2-81811f85f661	2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy.
fatty liver disease	DOID:9452	53-72
161c852e-a42c-47c2-ab6a-2b7bd6a4b934	Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months.
eb152d1b-a0d6-428c-8d1d-eb5d862a8147	At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder.
patient	HADO:0000008,OAE:0001817	11-18
coagulation	GO:0050817	87-98
disorder	OGMS:0000045	99-107
0701ac32-45b3-4199-aa20-a71080ce9bf6	There are no cases of Vertigo in the primary trial or the primary trial.
vertigo	HP:0002321	22-29
866876f5-68de-44bd-b58a-e4b590aa4b39	Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a fitbit.
b4304362-1cb4-4606-9de4-03935ad509f1	There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.
9cddd86a-4340-4918-b000-7e6e593a3f7f	Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial.
stable	HP:0031915	32-38
c3f01101-2259-4677-add1-1b1f48a0202b	The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.
affected	HP:0032320	29-37
33b827a0-ada5-4204-abb8-d5239ea16f0b	In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.
ttp	CHEBI:63550	88-91
exemestane	CHEBI:4953	99-109
group	CHEBI:24433	110-115
group	CHEBI:24433	136-141
anastrozole	CHEBI:2704	124-135
40f1d3ce-2ff8-4177-9b11-0bf10b7f6591	the primary trial studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score.
fulvestrant	CHEBI:31638	40-51
anastrozole	CHEBI:2704	53-64
receptor	BAO:0000281	78-86
22bff413-a1bd-419b-b19b-2157dedc9948	Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.
group	CHEBI:24433	0-5
day	UO:0000033	74-77
day	UO:0000033	126-129
b64d6e41-7ec7-4e62-beda-c28559a6cee7	Only patients in cohort 2 of the primary trial undergo Trunk compression.
trunk	GO:0043198,UBERON:0002100	55-60
2ea80a50-0db3-4ff2-8ca0-71eb048649f7	More than 3 patients in the primary trial had a common cold.
common cold	DOID:10459	48-59
20545360-b2a1-4be9-997a-97040866b239	Patients with AIDS are eligible for both the secondary trial and the primary trial.
3b1bdc19-62cd-4ff1-9e30-424e124342f3	the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame.
patient	HADO:0000008,OAE:0001817	68-75
time	PATO:0000165	101-105
a44cd0d1-92b3-4add-badf-b8dd5a324138	the primary trial recorded one patient with congestive heart failure, the secondary trial did not record any.
patient	HADO:0000008,OAE:0001817	31-38
congestive heart failure	HP:0001635,DOID:6000	44-68
291bb67e-f02f-49d4-b967-29cc9f5098c4	Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.
cyclophosphamide	CHEBI:4026	0-16
cabozantinib	CHEBI:72317	18-30
55704a1f-eab2-44ea-a6de-8df508a28066	Patients with stage 4 cancer are eligible for the secondary trial and the primary trial.
cancer	DOID:162	22-28
6e1955b8-e6fa-42b2-a498-7ada9e733304	Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial.
aspartate	CHEBI:29995	14-23
excluded	HP:0040285	89-97
52337e14-7f51-40c1-b965-fb6aba8ae4e7	Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial.
bisoprolol	CHEBI:3127	25-35
labetalol	CHEBI:6343	39-48
8a6397e9-84cd-4a2e-ac6a-b56ee355d862	Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial.
cancer	DOID:162	14-20
breast	UBERON:0000310	44-50
8b5f946c-71d9-42cd-aa9a-1d3a4845c460	the primary trial designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast the secondary trial assigns interventions randomly.
hormone	CHEBI:24621	87-94
8f0aff7f-0d9e-498b-bcb6-05e6d309724c	the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose.
rate	BAO:0080019	61-65
b7936bbc-f0c0-444c-a199-2db323c30396	Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.
fulvestrant	CHEBI:31638	43-54
fulvestrant	CHEBI:31638	127-138
rate	BAO:0080019	98-102
6d6625ec-26b7-4157-a38c-87c770201323	Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial
product	BAO:0003067	9-16
product	BAO:0003067	87-94
e8b8c2b7-612d-4bab-b8a6-3dbc756cc210	Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive.
present	PATO:0000467	14-21
cancer	DOID:162	106-112
7e0259a3-073b-45f5-8e08-2cfaceecef0b	the primary trial tests MRI scanning as a technique for guiding biopsies.
c94ad26b-1f5e-4446-a4fe-bb949c5dc561	Patients must have BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial.
platelet count	CMO:0000029	35-49
4e31e4f8-a6da-49fc-8bfe-1309674ec2ee	30% of the primary trial participants had an increased level of CECs after 42 days of treatment.
5c00f992-5066-42f2-88d7-566b8b9104b5	On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity , whereas those in cohort 2 did not experience any Acute Toxicities.
rate	BAO:0080019	71-75
acute	HP:0011009,PATO:0000389	79-84
acute	HP:0011009,PATO:0000389	145-150
4c0ffc50-5cb2-4574-b954-335d142edbe4	Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial.
citalopram	CHEBI:3723	20-30
depression	HP:0000716	59-69
4e3379b9-f971-4ab6-8846-c395f1162bf2	Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial.
9872394c-18b7-4f88-849e-0e2831e6ebf0	Participants of the primary trial cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years.
rheumatoid arthritis	HP:0001370,DOID:7148	78-98
hormone	CHEBI:24621	152-159
history	BFO:0000182	198-205
breast cancer	DOID:1612	218-231
adf3bb50-ec36-467a-987a-f33c10380c60	Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial.
2ef37a06-a1ed-47eb-b8f4-2f97f46293d1	One patient in the primary trial suffered a cerebral infarction.
patient	HADO:0000008,OAE:0001817	4-11
cerebral infarction	DOID:3526	44-63
03cb39e4-1d21-47e5-9b09-ebe508eb2a17	59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.
stable	HP:0031915	144-150
disease	DOID:4,BAO:0002927,OGMS:0000031	151-158
dca6ba74-441e-482f-b667-6c45800ed8c1	Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs .
day	UO:0000033	73-76
death	OAE:0000632	127-132
aeecc244-13a9-4944-858e-27ef49585e90	Patients with incurable and unresectable Locally Advanced Breast Cancer are eligible for the primary trial.
breast cancer	DOID:1612	58-71
741ca5eb-4737-4a35-a9fd-4235d6552b4f	the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Neratinib, a type of chemotherapy.
neratinib	CHEBI:61397	131-140
b8e0458c-b834-42b5-b5fd-8791f89b0853	The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group
gemcitabine	CHEBI:175901	4-15
group	CHEBI:24433	16-21
group	CHEBI:24433	155-160
median	BAO:0002174	49-55
carboplatin	CHEBI:31355	143-154
1a112ed3-8318-493b-8973-10de01794892	Between the patients in the primary trial and the secondary trial, only a single one suffered from sepsis.
sepsis	HP:0100806	99-105
6044590d-0f89-4a6e-8be7-54ca0c0327d9	the primary trial does not have a Hypnotherapy based intervention, and the secondary trial does not have a Radiotherapy intervention.
radiotherapy	OAE:0000235	107-119
8d3378f7-caaf-4654-b12a-382a0e911eb1	Patients with a platelet count of 50 x 109/l are not eligible for the primary trial
platelet count	CMO:0000029	16-30
x	LABO:0000148	37-38
f701473d-e034-4a06-9829-d20cc483162c	the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant.
size	PATO:0000117	97-101
3889cecd-aa2d-4f58-857e-11d7209f9cf4	In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. 
19d0c9de-02ad-4a8e-937b-e9d0f0cc8051	No participants of the primary trial had a Progression Free Survival over 1 year.
year	UO:0000036	76-80
cb023dbc-3e99-4c32-a857-7f8d49ef5a96	the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts.
1d0ce237-70eb-45b4-9c77-f0b70d410387	A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial.
female	PATO:0000383	2-8
patient	HADO:0000008,OAE:0001817	9-16
age	PATO:0000011	26-29
cirrhosis	HP:0001394	51-60
93290529-38b1-444b-9ac8-fa32b98821c5	Patients wanting to take part in the secondary trial must be at a specific location, this is not necessary for the primary trial.
dad5ecc6-afcf-496c-8193-778a100c0318	Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA).
scoliosis	HP:0002650,DOID:0060249	14-23
surgery	OAE:0000067	100-107
excluded	HP:0040285	137-145
d0efe29c-1d76-4129-9cf5-2955564d1370	Patients with LVEF greater than or equal to 60% are eligible for the primary trial.
63ec91be-7e12-431e-84b0-ca401bfb157b	the primary trial recorded 2.38% more total adverse events than the secondary trial
fd5af11f-7270-49d5-924a-755ff399c463	Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months.
sunitinib	CHEBI:38940	71-80
paclitaxel	CHEBI:45863	85-95
duration	PATO:0001309	102-110
death	OAE:0000632	133-138
mean	BAO:0002173	148-152
group	CHEBI:24433	166-171
f07e932e-1d79-4e1f-9ac2-ed9e2db1c276	Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.
6a5ee728-7db9-4ec0-b98c-0500e9a6187e	One patient in the primary trial had abnormally low levels of AST, ALT and ANC.
patient	HADO:0000008,OAE:0001817	4-11
a495df61-260d-479c-8d5f-d586f295c672	Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID.
917afeec-5152-4424-89e3-7f3ffad6378f	Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.
week	UO:0000034	202-206
19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6	Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial.
healthy	HP:0032322	19-26
liver	UBERON:0002107	36-41
bone marrow	UBERON:0002371	46-57
f5aa1aa3-7be3-4518-8cc5-df2394e70e96	Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial.
estrogen	CHEBI:50114	27-35
receptor	BAO:0000281	36-44
45338f7c-5aaa-40fb-8503-7c943e1f3a29	Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.
fulvestrant	CHEBI:31638	52-63
venetoclax	CHEBI:133021	196-206
0964be32-f9e7-49ec-ad22-b030d483702a	Unlike the secondary trial, the primary trial does not administer any medication orally.
73cfc4ea-afc0-465b-a403-c1bd771ded33	Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial, as Psychological illnesses are not permitted.
citalopram	CHEBI:3723	20-30
depression	HP:0000716	59-69
75b67d63-9727-418d-afd5-c0fb867417b5	Patients suffering from Ulcerative colitis are excluded from the primary trial.
ulcerative colitis	HP:0100279,DOID:8577	24-42
excluded	HP:0040285	47-55
94cd9451-35a4-4035-a7de-2d385f771607	1/42 patients in cohort 2 of the primary trial fainted.
18310f83-54ca-4530-92f1-7c41419ab69e	More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.
neutropenia	HP:0001875,DOID:1227	67-78
4fa6b99e-0e70-465d-8b24-b728979b3689	There was the same number of anemic patinets in both cohorts of the primary trial.
e0fac0a4-a5ab-4089-8986-f601586506af	Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as it would prevent them from giving informed consent to study entry.
excluded	HP:0040285	55-63
85210693-996a-4ab9-92f4-62060571da21	Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial.
heart rate	CMO:0000002	21-31
minute	UO:0000031	56-62
f0fbdbf4-af12-4cde-a5f1-a56cc60658f4	Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia.
neutropenia	HP:0001875,DOID:1227	78-89
6a37e999-4b7e-4654-b9ac-7776a0720040	1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
eating disorder	DOID:8670	46-61
a625ff4b-9c91-4ab8-a78b-df833d15759a	the primary trial and the secondary trial both report cases of confusion in all their patient cohorts.
confusion	HP:0001289	63-72
patient	HADO:0000008,OAE:0001817	86-93
b25e7c40-a1db-4ae7-9613-0f65ddb4c040	At least one patient in the primary trial suffered from a life threatening bone fracture.
patient	HADO:0000008,OAE:0001817	13-20
bone fracture	HP:0020110	75-88
25f1f3b8-15ed-4339-bf56-1cf1e0c2909f	Cohort 1 of the primary trial recorded no deaths and no cases of Anemia.
anemia	HP:0001903,DOID:2355	65-71
c0ddffa9-4a88-4ee1-8525-a77e887c3d85	The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group.
eribulin mesylate	CHEBI:70710	4-21
group	CHEBI:24433	22-27
group	CHEBI:24433	155-160
64ea58e5-e28f-42bc-818e-31bbf347080c	Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial.
excluded	HP:0040285	76-84
7a0f4365-9775-4f1d-a1c7-4630b41b43ea	the primary trial only defines intervention dosage for cohort 2.
64dcb690-ef14-4cf2-85e5-670eb0645d7f	Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.
age	PATO:0000011	17-20
cacd1b1b-510e-421b-9adb-c5715f281794	More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.
adverse event	OAE:0000001	62-75
c3e5a015-e8b5-4281-828c-deb1f7fc7e3a	The maximum number of occurences for an adverse event in the primary trial was 3.
adverse event	OAE:0000001	40-53
7926bfa3-cf49-4589-8143-0a0826336b67	All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration.
drug administration	OAE:0000011	72-91
1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b	the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib.
triptorelin	CHEBI:63633	58-69
patient	HADO:0000008,OAE:0001817	88-95
capecitabine	CHEBI:31348	184-196
lapatinib	CHEBI:49603	201-210
a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42	Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial.
36957dd8-fe28-4b70-b651-8f6ea7d1d0e9	Cohort 1 of the primary trial and Cohort 1 of the secondary trial have the same total number of adverse events.
1aee22c7-96f2-4ea6-909a-48741f87ba07	There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.
constipation	HP:0002019,DOID:2089	32-44
nausea	HP:0002018	57-63
neutropenia	HP:0001875,DOID:1227	75-86
patient	HADO:0000008,OAE:0001817	94-101
d677707e-9ca9-4801-8fcd-7960a9f4f30a	paclitaxel is the only drug in the primary trial given by IV.
paclitaxel	CHEBI:45863	0-10
drug	CHEBI:23888	23-27
5335a9c9-bae1-42e9-9428-eb0eded62d7f	None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a weekly tablet.
e6c0f7af-b549-4aad-8f3c-15f367a04a50	Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.
group	CHEBI:24433	23-28
group	CHEBI:24433	267-272
target	BAO:0003064	128-134
target	BAO:0003064	228-234
diameter	PATO:0001334	216-224
1fc3aeac-3bc0-4a47-8222-ea267a822804	There are no cases of Febrile bone marrow aplasia in the primary trial.
bone marrow	UBERON:0002371	30-41
9e664bcb-38cc-4ca6-9738-28d96248b7f2	the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily.
lapatinib	CHEBI:49603	54-63
1b8403ac-7eb3-41cb-8b7e-a89af3492805	In the primary trial, all cases of Enteritis, Vertigo and Anaemia occurred in cohort 2.
vertigo	HP:0002321	46-53
ad853675-40ed-4a65-a401-d09ac3153570	Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial.
breast carcinoma	HP:0003002,DOID:3459	27-43
b43bee02-cc3f-4dc8-b13f-8a93de5dc422	Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2.
median	BAO:0002174	43-49
62258901-8207-413d-913f-a04682635add	the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD).
zoledronic acid	CHEBI:46557	36-51
zoledronic acid	CHEBI:46557	87-102
bone mineral density	CMO:0001226	153-173
d23aee47-e80f-42fe-b095-9cd81f9e0ed3	Both the primary trial cohorts reported identical results.
d23eb56e-c232-4754-94aa-903bc174cb35	The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm.
lapatinib	CHEBI:49603	72-81
1c0dcd29-4a04-4b78-abbf-b047d4c29597	Patients with breast implants are always excluded from the primary trial.
breast	UBERON:0000310	14-20
excluded	HP:0040285	41-49
b1a17048-dfe8-4173-ae80-6ec273244848	More than 20% of patients in cohort 1 of the primary trial experienced adverse events.
33652443-0bb4-493e-adfe-f5032b96b13d	the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS much longer than the study time frame of 38 months.
neratinib	CHEBI:61397	37-46
capecitabine	CHEBI:31348	52-64
time	PATO:0000165	102-106
74dba58a-8f5d-478b-a886-0e9758847fe3	Clinically anxious patients are not able to participate in the primary trial.
5344044c-127d-4a39-80dc-277538b5ad33	less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.
p	CHEBI:17802,BAO:0002175	13-14
p	CHEBI:17802,BAO:0002175	20-21
p	CHEBI:17802,BAO:0002175	39-40
p	CHEBI:17802,BAO:0002175	45-46
p	CHEBI:17802,BAO:0002175	54-55
p	CHEBI:17802,BAO:0002175	83-84
p	CHEBI:17802,BAO:0002175	99-100
p	CHEBI:17802,BAO:0002175	108-109
p	CHEBI:17802,BAO:0002175	116-117
p	CHEBI:17802,BAO:0002175	148-149
group	CHEBI:24433	41-46
ed43519d-9954-4e0f-9d42-39a3ed81e4a5	Hyperglycemia was the most common adverse event in cohort 1 of the primary trial.
hyperglycemia	HP:0003074,DOID:4195	0-13
adverse event	OAE:0000001	34-47
8d2fde27-a5e8-40ee-a35d-3d4697198a4e	There are no cases of Febrile neutropenia in the primary trial.
neutropenia	HP:0001875,DOID:1227	30-41
fc0da76b-e5b5-44e3-abaf-6231fff493c3	The the primary trial placebo group performed worse than the test group.
group	CHEBI:24433	30-35
group	CHEBI:24433	66-71
1a32e1c1-31b1-40e5-bbb6-84041ef796fe	cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure.
congestive heart failure	HP:0001635,DOID:6000	76-100
9a31db67-e28a-4114-a308-e899f9c22813	One patient in the primary trial suffered from an inflammation of the esophagus.
patient	HADO:0000008,OAE:0001817	4-11
esophagus	UBERON:0001043	70-79
f948a2d1-2e22-47c8-9345-0eb68569bd3f	Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial.
breast cancer	DOID:1612	24-37
e3265040-8316-4f62-969c-27af396ba18c	Patients that have previously been trated with bevacizumab are not eligible for the primary trial, unless they have also received carboplatin 2 weeks prior to study entry.
carboplatin	CHEBI:31355	130-141
6c25e195-47cd-48af-bb51-5b5c44772baa	Candidates with hyperparathyroidism are automatically excluded from the primary trial.
hyperparathyroidism	HP:0000843,DOID:13543	16-35
excluded	HP:0040285	54-62
382747d3-69df-41be-a771-4218407ce5d3	the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic).
zoledronic acid	CHEBI:46557	37-52
zoledronic acid	CHEBI:46557	119-134
bone mineral density	CMO:0001226	89-109
bone mineral density	CMO:0001226	165-185
patient	HADO:0000008,OAE:0001817	204-211
d05ec90a-f267-44be-aaa6-3be960a0d50c	Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.
stable	HP:0031915	96-102
disease	DOID:4,BAO:0002927,OGMS:0000031	103-110
37301690-9b68-48de-b280-6307e632043e	The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains .
b61e798c-d38f-4c72-91bb-4d3e28b6184c	Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial.
age	PATO:0000011	13-16
3ca27248-0728-4b10-b940-6e2603acef30	Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial.
breast carcinoma	HP:0003002,DOID:3459	35-51
c2da6504-96a1-4669-b609-16731a5330d3	Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial.
year	UO:0000036	15-19
breast cancer	DOID:1612	56-69
646959e4-25d0-4eb1-b7b0-2d7b1e02e132	Less than 5% of patients in the primary trial suffered an adverse event.
adverse event	OAE:0000001	58-71
0e6eebe9-46c2-4fa5-b9ed-e0997044960b	None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery.
radiotherapy	OAE:0000235	89-101
surgery	OAE:0000067	105-112
a781374c-99e1-47ee-a266-bff9267c2ed1	100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.
afatinib	CHEBI:61390	28-36
group	CHEBI:24433	54-59
9aea5a84-bced-4441-b8b8-154c307f5a03	The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.
group	CHEBI:24433	12-17
median	BAO:0002174	56-62
deb77d34-76a5-4e6e-bc9d-176cc30eca07	One patient in cohort 2 of the primary trial died in a motorcycle crash.
patient	HADO:0000008,OAE:0001817	4-11
bfe97430-fcec-4c4a-9621-51f6ec05d8d3	More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2.
death	OAE:0000632	59-64
progressive	HP:0003676	65-76
disease	DOID:4,BAO:0002927,OGMS:0000031	77-84
568beebd-b350-4ba1-b8fc-c43f4d6ed517	the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment.
6bcc18b7-b063-49a1-8ab7-773636c02f1d	The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.
death	OAE:0000632	114-119
cancer	DOID:162	127-133
patient	HADO:0000008,OAE:0001817	142-149
dfa2ecee-96cf-4551-875e-aedd8aac5df9	There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.
mean	BAO:0002173	40-44
duration	PATO:0001309	45-53
neutropenia	HP:0001875,DOID:1227	65-76
81c85a29-d449-4f79-a3b3-682ba5f288ca	In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia.
leukopenia	HP:0001882,DOID:615	53-63
leukopenia	HP:0001882,DOID:615	217-227
9c48c5d6-83fd-42cc-aacc-2e888099bcdb	Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis.
imatinib	CHEBI:45783	39-47
letrozole	CHEBI:6413	62-71
79a3bb0d-315f-4c39-8786-2aa98e2e3f6f	Males are not eligible for the primary trial.
cea17554-6736-4b52-b76c-b3c5dc9ecb77	All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan.
b250a17c-9d4d-405d-ba64-40f7eda16707	the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 .
paclitaxel	CHEBI:45863	74-84
698849c5-78fa-4c15-a1dc-f44eb9c970c2	At least one patient in the primary trial suffered from impaired mobility.
patient	HADO:0000008,OAE:0001817	13-20
4b4e6ac7-107c-46f4-adbb-c77c01f51935	The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels.
adverse event	OAE:0000001	16-29
hemoglobin	CHEBI:35143	70-80
6b73dee4-0291-455e-90c2-786f0c2371d4	Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years.
rheumatoid arthritis	HP:0001370,DOID:7148	78-98
history	BFO:0000182	159-166
breast cancer	DOID:1612	179-192
2a1d9064-fde9-4645-95ab-7ddaea4ad322	Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.
847de3fe-b584-4d43-b82d-93263ce88830	 Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity.
pazopanib	CHEBI:71219	46-55
day	UO:0000033	87-90
disease	DOID:4,BAO:0002927,OGMS:0000031	109-116
3c798991-6366-43e2-94ca-0523629930c2	Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial, but not for patients in the secondary trial.
anthracycline	CHEBI:48120	13-26
64fe54a2-8897-4324-af88-f627c1c208ed	Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia.
thrombocytopenia	HP:0001873,DOID:1588	61-77
4eac6a2d-64cd-4289-a545-211eb835f0e9	The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.
3ee1c60e-46ce-4f25-af52-31d5c6d8eba1	the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames.
time	PATO:0000165	143-147
da1e1019-adb5-47bf-8093-e03352ca9e51	Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial.
hour	UO:0000032	37-41
day	UO:0000033	68-71
e7fb6490-1ec7-48ff-95b1-715d79faec92	Patients must be english to participate in the primary trial.
d5ea3443-103f-4d29-9be3-522210b84152	the primary trial and the secondary trial only record 2 of the same adverse events.
d54cae08-3ac9-4460-bf6d-7338b45d8cd7	Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial.
age	PATO:0000011	26-29
608c5521-c9a6-47de-9ebf-791ce317a02d	All of the patients in cohort 1 of the primary trial experienced an adverse event.
adverse event	OAE:0000001	68-81
14a8e9e9-0a46-4537-bc07-53c786bcbe97	Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial.
2d97bfa0-336f-4976-95e5-1262327a730b	the primary trial recorded 2 more total adverse events than the secondary trial
e68dddc8-ea04-49b2-ae91-ff7b4fcb1240	The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	102-109
patient	HADO:0000008,OAE:0001817	147-154
group	CHEBI:24433	12-17
percent	UO:0000187	35-42
disease	DOID:4,BAO:0002927,OGMS:0000031	139-146
8c83330f-f2f3-48e1-9905-dc2ba1970c54	Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions.
group	CHEBI:24433	16-21
group	CHEBI:24433	109-114
physiotherapy	OAE:0002476	83-96
4613834d-c178-475c-b9fd-c9c66d5681eb	Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.
b4555685-6e25-4797-8616-bcab5b06a135	the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.
fulvestrant	CHEBI:31638	40-51
receptor	BAO:0000281	76-84
c1b90c18-45f4-4e28-b50a-a00b0eadc523	Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial, but not the primary trial.
breast	UBERON:0000310	15-21
33ef3abf-97c0-4d15-909d-258fb47ac54a	Only patients with HER2 positive breast carcinoma are eligible for the primary trial.
breast carcinoma	HP:0003002,DOID:3459	33-49
a381e340-18b1-4baa-91ce-0c420bcb411c	the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity.
age	PATO:0000011	111-114
cancer	DOID:162	116-122
15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b	the primary trial is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage.
drug	CHEBI:23888	35-39
8e246d8f-e063-4f2e-a382-5d201a946b87	Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.
patient	HADO:0000008,OAE:0001817	13-20
congestive heart failure	HP:0001635,DOID:6000	56-80
active	PATO:0002354	88-94
8154bd8c-90a2-4b2f-8090-fcc89aeae30c	Patients of any ethnicity can participate in the primary trial.
537781f9-3693-479e-af22-824cdd827b9c	the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs).
5feefe8b-ddca-4eb8-af68-d1e211963d1f	2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland.
gland	UBERON:0002530	92-97
2a5d8ca7-1608-4607-b996-490fc447b593	All the primary trial subjects are required to take the intervention tablet PO daily.
178c50cc-49ee-4083-bc8e-b5832037498a	4 patients in the primary trial experienced a grade 3 or above adverse event.
adverse event	OAE:0000001	63-76
92ace4fa-4426-4f34-af52-ee62913e60aa	There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.
left ventricular systolic dysfunction	HP:0025169	34-71
7dbde84d-f1c9-4197-9d44-500fd337bebd	At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events.
peritoneum	UBERON:0002358	62-72
breast	UBERON:0000310	89-95
824da29f-b2ff-440e-8b78-7a8291cbd6d2	A total of 89 patients in the primary trial had Supraventricular tachycardia.
supraventricular tachycardia	HP:0004755	48-76
6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1	1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland.
patient	HADO:0000008,OAE:0001817	2-9
thyroid gland	CHEBI:9584,UBERON:0002046	81-94
052ee533-7daa-4cbf-a64c-bc9a50444173	the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events.
hemoglobin c disease	DOID:2859	53-73
1d7dbb44-049d-4887-8bd6-6aefc77aa1e9	A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.
leukopenia	HP:0001882,DOID:615	69-79
9b622b9b-3ad3-4cff-acb3-4127d0304de0	occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial.
patient	HADO:0000008,OAE:0001817	68-75
825ba6fd-8c08-49d2-941b-3338ef01e7fd	African American patients are eligible for both the primary trial and the secondary trial.
0421750d-66c6-47be-bde7-0c41ee43a28b	Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation.
severe	HP:0012828	14-20
malabsorption	HP:0002024	21-34
95345dbe-446f-4999-8f3e-a429b77ea554	Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin 11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial.
blood	UBERON:0000178	28-33
hemoglobin	CHEBI:35143	121-131
phosphatase	GO:0016791,BAO:0000295	172-183
creatinine	CHEBI:16737	225-235
b05fde86-4004-427f-8baf-2ea4a0a535c7	the primary trial all undergo surgery twice, first at 2 weeks and then again a month later.
surgery	OAE:0000067	30-37
month	UO:0000035	79-84
21e24c6c-d282-48fb-8d68-3e723458794e	Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.
excluded	HP:0040285	54-62
month	UO:0000035	162-167
d1e579e2-b057-43da-8a2f-64dad964b789	the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle.
imiquimod	CHEBI:36704	45-54
day	UO:0000033	99-102
day	UO:0000033	121-124
day	UO:0000033	135-138
5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6	Heart-related adverse events were recorded in the secondary trial, but not the primary trial.
d130c981-f602-4f17-b1cb-11a7ad632b92	the primary trial more than 6 different types of cardiac related adverse events.
c1f9982f-c4c9-48dc-887a-7ae05f508c21	the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles
niraparib	CHEBI:176844	40-49
day	UO:0000033	93-96
e966302f-9378-4681-b2c6-9d8b5b5f709f	The majority of patients in the primary trial experienced an adverse event.
adverse event	OAE:0000001	61-74
75130da8-77be-45d1-bc32-dfc97c1a1dae	the secondary trial has a much longer duration than the primary trial.
duration	PATO:0001309	38-46
c71cbcd6-3786-4b90-8991-b3c6e159ae77	the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib.
triptorelin	CHEBI:63633	42-53
capecitabine	CHEBI:31348	86-98
lapatinib	CHEBI:49603	103-112
ed48936e-4933-437b-a7ba-e65b4c1fd276	Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial. but not the primary trial.
radiotherapy	OAE:0000235	47-59
b01e966e-6624-4740-b477-a8bbbd8eec50	In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.
lymphangitis	DOID:9317	87-99
bone marrow	UBERON:0002371	101-112
shock	HP:0031273	137-142
92acd36d-ea44-4b98-acbc-e51382233089	Diarrhea was the most common adverse event in cohort 1 of the primary trial.
diarrhea	HP:0002014,DOID:13250	0-8
adverse event	OAE:0000001	29-42
01280892-ca31-4e46-831b-a076426f65e5	A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
excluded	HP:0040285	141-149
959bd67a-1b2a-48da-ae44-211cbab4b665	Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.
median	BAO:0002174	0-6
month	UO:0000035	76-81
sunitinib	CHEBI:38940	121-130
group	CHEBI:24433	131-136
group	CHEBI:24433	181-186
92923765-76d4-4a27-a240-101690d9fea4	the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.
cyclophosphamide	CHEBI:4026	44-60
methotrexate	CHEBI:44185	99-111
437cb2c2-63e8-4d9b-a501-4b6a35db8d2b	Unlike the secondary trial, the primary trial does not administer any medication orally or intravenously.
5a5695e8-9b84-42ad-9f34-6dd043153943	Adequate renal, hepatic and blood work is required for entry to the primary trial and the secondary trial, this includes the following criteria; hemoglobin 11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN.
blood	UBERON:0000178	28-33
hemoglobin	CHEBI:35143	145-155
phosphatase	GO:0016791,BAO:0000295	196-207
creatinine	CHEBI:16737	249-259
33634c51-0fb9-4de1-966d-14784bca93f8	Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.
heart rate	CMO:0000002	21-31
minute	UO:0000031	57-63
8e46dc77-fa36-4231-a124-0ff6392891a1	Cohort 2 of the secondary trial and the primary trial are control groups.
d11b0673-42a9-46c0-887f-d5a9b038264f	Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.
week	UO:0000034	68-72
disease	DOID:4,BAO:0002927,OGMS:0000031	117-124
e08c196a-e3f0-420b-a252-7e2818949038	All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial.
83511f04-e07c-438d-bf1e-f680fa49b384	Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.
fever	HP:0001945	69-74
c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94	There was one genitourinary adverse events recorded in the primary trial.
72bb3c6e-66b0-4380-9da2-5a5867d715fd	compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2. 
adverse event	OAE:0000001	82-95
1b433096-f36a-4205-b16e-f9a370be3d05	More than 18 participants in the primary trial had radiation dermatitis.
dermatitis	DOID:2723	61-71
076ead15-ce03-4c33-9050-1f6eb13764a1	The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section.
0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76	There were more cases of Pulmonary embolisms in the primary trial than the secondary trial.
3e1037fd-cc1e-4229-892f-95d0987d9a68	The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg.
mtd	BAO:0001248	28-31
f25adbc7-c0a0-44ed-af93-02f4bced7208	Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole.
pilocarpine	CHEBI:39462	56-67
itraconazole	CHEBI:6076	120-132
99951bae-37c8-4299-8ec1-4577a97d0b81	the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial.
pleural effusion	HP:0002202	36-52
compression fracture	HP:4000047	64-84
b66b62c4-902d-4e19-929e-2086b349bd93	Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial.
anthracycline	CHEBI:48120	13-26
c789e79c-a254-4bb1-9d15-73d1726da8a6	There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.
age	PATO:0000011	12-15
pneumonia	HP:0002090,DOID:552	130-139
pulmonary fibrosis	HP:0002206,DOID:3770	143-161
2b182323-9357-486a-87aa-09ddc6230bf1	There is only 1 adverse event in the primary trial that occurred more than once.
adverse event	OAE:0000001	16-29
9681ec15-7545-455e-ac8c-1052fc199b11	The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.
group	CHEBI:24433	14-19
group	CHEBI:24433	129-134
8ca512c3-72d8-4179-a63e-51d83d76445f	the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center.
cancer	DOID:162	96-102
171d0a20-8943-4994-a48a-7dff124e62ee	cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily.
25cc9a6e-656d-44ee-a301-93f5879407a0	Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days.
d9b4d4aa-0094-405e-83a3-cf2978cfda38	56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.
lapatinib	CHEBI:49603	49-58
progressive	HP:0003676	74-85
disease	DOID:4,BAO:0002927,OGMS:0000031	86-93
week	UO:0000034	97-101
caa55802-329d-4a1f-a9a7-b99afc44fd67	The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane.
patient	HADO:0000008,OAE:0001817	4-11
tamoxifen	CHEBI:41774	105-114
exemestane	CHEBI:4953	118-128
6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0	Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo.
group	CHEBI:24433	12-17
0880bb0b-9e8d-4fce-8795-2ec6526d9bfb	In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients. Whereas all the primary trial participants receive the same treatment.
breast cancer	DOID:1612	42-55
baea8eb9-a6e7-4473-9b4b-28a4fdb531ad	Both cohorts of the primary trial are administered the same drugs in different doses .
01f89936-1621-4dd5-93b7-8b0c64b397fd	A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
severe	HP:0012828	15-21
syndrome	DOID:225	30-38
ee7fe82e-de91-45c7-bd12-bff5d6c887a3	the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.
lapatinib	CHEBI:49603	54-63
888a8d39-3ad6-401e-acf2-cf5e01a73bf2	the primary trial had a much higher rate of adverse events than the secondary trial.
rate	BAO:0080019	36-40
13466cbb-9f78-46ff-a983-09e2e9ad5a2c	1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat.
patient	HADO:0000008,OAE:0001817	2-9
fever	HP:0001945	43-48
cough	HP:0012735	74-79
throat	UBERON:0000341	90-96
0beaef44-a39a-462c-a084-d3f824857673	the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.
lapatinib	CHEBI:49603	59-68
rate	BAO:0080019	216-220
8e45da73-f016-4ca0-b106-a3fabc960b36	the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate.
methotrexate	CHEBI:44185	99-111
37dc56a4-4756-4ab0-8055-7637bf579740	the primary trial and the secondary trial are both single arm clinical trials.
65e370b7-7726-477e-8730-8cea734d1609	Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix.
lipid	CHEBI:18059,BAO:0000171	69-74
rate	BAO:0080019	93-97
peritoneum	UBERON:0002358	220-230
affdd551-15e2-4a47-8c20-209cc01570ec	One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.
patient	HADO:0000008,OAE:0001817	4-11
condition	PDRO:0000129	71-80
adverse event	OAE:0000001	164-177
diarrhea	HP:0002014,DOID:13250	182-190
2152f503-4fa4-4f32-b766-a05a4c69742f	Neither the primary trial or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention.
adverse event	OAE:0000001	58-71
radiotherapy	OAE:0000235	94-106
a7903e59-9620-457a-8d83-eb6eb5dd8a2b	At least 1 participant in each cohort of the primary trial showed signs of poor liver function.
liver	UBERON:0002107	80-85
function	BAO:0003117,BFO:0000034	86-94
dc7e7fbe-eed9-4307-b584-30ecaeb77c95	Patients with E2 outside the premenopausal range are ineligible for the primary trial.
range	LABO:0000114	43-48
a34c6194-b6d9-49c3-8ddb-72de10c8a18c	Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines.
intensity	PATO:0000049	56-65
da00532d-57a8-4fe2-a2de-acc525161fd9	At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder.
patient	HADO:0000008,OAE:0001817	11-18
coagulation	GO:0050817	68-79
disorder	OGMS:0000045	80-88
f90364e9-caee-4075-b444-2db1bf846d3a	Patients with prior chemotherapy are excluded from the secondary trial and the primary trial.
excluded	HP:0040285	37-45
deb78676-8f04-44c4-a5f6-389740d8a268	Prior exposure to doxatel is obligatory for patients in the primary trial.
a06d1ca5-c890-4157-b1d2-0b70fd0092bd	There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial.
5bc0d21d-a040-4d30-b0c7-8793cba6aba8	Patients in the control group of the primary trial had a median Overall Survival of less than a year.
group	CHEBI:24433	24-29
median	BAO:0002174	57-63
year	UO:0000036	96-100
9bcbadcc-ae56-4254-ac8b-ab5d35e80eba	Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses.
5a1358af-f51b-49f8-b1c0-99a0b108b0a2	There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia.
neutropenia	HP:0001875,DOID:1227	33-44
neutropenia	HP:0001875,DOID:1227	110-121
leukopenia	HP:0001882,DOID:615	50-60
leukopenia	HP:0001882,DOID:615	127-137
ed0e1b04-aea7-4da0-922f-2be69c768c09	Patients with implantable cardioverter defibrillators are excluded from the primary trial.
excluded	HP:0040285	58-66
73d323e7-1a38-49d4-97f4-a15f1664fb3e	One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average.
patient	HADO:0000008,OAE:0001817	4-11
increase	BAO:0001251	48-56
functional	BAO:0000010	70-80
volume	PATO:0000918	87-93
02dea6a3-d94f-4650-bf4f-be8fdb0a382f	A patient has recently had an oophorectomy,they are excluded from the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
excluded	HP:0040285	52-60
4c8a124b-f015-42e2-8ad3-6168f21fe705	The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion.
mean	BAO:0002173	28-32
duration	PATO:0001309	33-41
day	UO:0000033	119-122
fb43432d-6c1b-4ff7-aea8-72bc2519a12d	Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.
d6df95f5-472f-4b14-9cd4-5d5ef238175a	There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial.
patient	HADO:0000008,OAE:0001817	49-56
disease	DOID:4,BAO:0002927,OGMS:0000031	77-84
bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5	A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	29-36
sarcoidosis	DOID:11335	42-53
excluded	HP:0040285	63-71
age	PATO:0000011	106-109
52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83	Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.
hormone	CHEBI:24621	90-97
3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70	CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and saline is used in both of the study groups in the secondary trial.
part of	BAO:0090002,BFO:0000050	19-26
f820384b-0bf5-4f2e-96fd-2c8b13a4646c	the primary trial and the secondary trial share at least one drug in their chemotherapy regiment.
drug	CHEBI:23888	61-65
f7410166-82a7-4d15-8a04-47287ef6884c	Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial.
patient	HADO:0000008,OAE:0001817	61-68
80726ab0-e8e4-4c42-860b-fdedad407517	Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included.
f2e1c4f6-2f62-4a5e-b033-d798ba781d1d	Neither the primary trial or the secondary trial have placebo groups.
d42054cd-deb6-4436-941c-9e3a06c713cc	In total Less than 10% of patients in the primary trial either had a disease relapse or died.
disease	DOID:4,BAO:0002927,OGMS:0000031	69-76
0507fbf8-3557-4ace-b015-5e106b96f6a9	the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements.
49ecc5a6-89be-48b6-85c5-c809c83f5baf	Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month.
excluded	HP:0040285	54-62
month	UO:0000035	162-167
68792f63-d7b5-4570-bf8e-95e4cb8094e9	Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole.
pilocarpine	CHEBI:39462	55-66
itraconazole	CHEBI:6076	121-133
2ddd64c7-98ef-4b06-9f01-e59d3731e8ca	There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial
intestinal perforation	HP:0031368,DOID:2074	24-46
chest pain	HP:0100749	48-58
death	OAE:0000632	60-65
erysipelas	HP:0001055,DOID:11330	67-77
pneumonia	HP:0002090,DOID:552	82-91
a1a5767f-07e7-4a33-a26f-586cf71a208d	We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial.
9c80fb61-66dc-4b3d-82b9-4fb62db89422	Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial.
myocardial infarction	HP:0001658,DOID:5844	14-35
vein	UBERON:0001638	44-48
thrombosis	DOID:0060903	49-59
excluded	HP:0040285	89-97
6755a378-08bf-4e9b-a6de-166733d0307b	The only difference between the interventions used in the primary trial is the patients location.
b7f3e657-638b-4463-9639-4fb0da2be042	In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients.
breast cancer	DOID:1612	64-77
5498a85b-a086-4d5d-b677-9ae44646a382	There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the primary trial.
vertigo	HP:0002321	22-29
neutropenia	HP:0001875,DOID:1227	55-66
f3d2337e-6cd9-4e8c-b327-cbc48557b8dd	antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial.
f25d63c8-9033-4db6-9c15-2151d82e2a6d	between the two Arms of the primary trial, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response.
5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea	A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
breast cancer	DOID:1612	42-55
4fd10abc-81d1-44f4-825a-26e2eaeae979	There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.
brain	UBERON:0000955	131-136
a12a46de-9d3e-4c6a-becb-d43653040bf0	the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles.
week	UO:0000034	27-31
66ee10ac-1bfe-44d6-9b91-8a2bb1983606	the secondary trial has 5 more patients cohorts than the primary trial.
714c540c-1fa1-47c7-ac13-1e8f056d1e31	A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event.
adverse event	OAE:0000001	83-96
3948b30d-934d-485c-b324-b3571e2957a3	The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.
neutropenia	HP:0001875,DOID:1227	79-90
45cf29ce-25f5-4719-8468-69d94893c9e7	the primary trial recorded 4 life-threatening adverse events.
7502090d-1bcb-4be9-9358-81afb9440a17	Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for the primary trial.
89f84928-82a9-413e-ab25-400657002c55	the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy.
79dbf7bf-e08d-4eae-a804-0daeb83d6f01	The most frequent adverse event in cohort 1 of the primary trial was lymphopenia.
frequent	HP:0040282	9-17
adverse event	OAE:0000001	18-31
lymphopenia	HP:0001888,DOID:614	69-80
c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed	The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group.
exemestane	CHEBI:4953	4-14
group	CHEBI:24433	15-20
group	CHEBI:24433	130-135
group	CHEBI:24433	222-227
median	BAO:0002174	55-61
abiraterone acetate	CHEBI:68639	97-116
abiraterone acetate	CHEBI:68639	189-208
prednisone	CHEBI:8382	119-129
prednisone	CHEBI:8382	211-221
patient	HADO:0000008,OAE:0001817	149-156
23040754-d1ad-4660-aacf-3298aefa5dae	There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial.
e3be834c-c311-4132-8529-d354b9e620b9	The only adverse event recorded in the primary trial was one single case of pleural effusion.
adverse event	OAE:0000001	9-22
pleural effusion	HP:0002202	76-92
8115b5e3-e178-433b-b114-09d97daaa8d7	Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial.
myocardial infarction	HP:0001658,DOID:5844	14-35
vein	UBERON:0001638	91-95
thrombosis	DOID:0060903	96-106
bbcfc019-2d60-413f-88f9-04cacec55e30	There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial.
e7899445-9b80-4429-b4c3-d47bd36a2347	Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial.
breast	UBERON:0000310	28-34
colon carcinoma	DOID:1520	38-53
2a50cc2a-281b-4bc6-9f18-6bd9686c682d	Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial.
anastrozole	CHEBI:2704	38-49
26419cec-e256-46a7-9026-94dbe026c63d	The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.
group	CHEBI:24433	12-17
median	BAO:0002174	56-62
8ef93fe0-0a12-4a7e-93aa-c40af7154a57	the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP. 
f5d50d87-b419-4537-87ec-7c9d23b765db	the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic).
zoledronic acid	CHEBI:46557	37-52
zoledronic acid	CHEBI:46557	119-134
bone mineral density	CMO:0001226	89-109
bone mineral density	CMO:0001226	195-215
patient	HADO:0000008,OAE:0001817	234-241
f52ab54b-7a78-4449-9dfe-5fc67323e5c2	Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications.
c0277198-6eef-4cf3-9527-dea5d01a4000	There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial.
neutropenia	HP:0001875,DOID:1227	40-51
neutropenia	HP:0001875,DOID:1227	68-79
leukopenia	HP:0001882,DOID:615	53-63
fea87f74-c8ef-4efd-944a-053f5e5a752f	In order to participate in the primary trial, participants must have 20/20 vision and a hiistologically confirmed, measurable, invasive breast carcinoma.
breast carcinoma	HP:0003002,DOID:3459	136-152
43560d8e-0767-40ce-b2fb-1b8dda231bdf	There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.
pericardial effusion	HP:0001698,DOID:118	46-66
2417fea2-7c8e-4f03-a918-c3cfcbe97425	The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.
neutropenia	HP:0001875,DOID:1227	28-39
neutropenia	HP:0001875,DOID:1227	49-60
pancytopenia	HP:0001876,DOID:12450	65-77
55391bc6-41a8-4686-82d6-6814166d32b8	Patients must have LVEF < 50% to be eligible for the primary trial.
06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b	cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur).
median	BAO:0002174	46-52
percent change	BAO:0001252	54-68
15553950-e26b-4fbb-a576-8455e6bb7b23	The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial.
duration	PATO:0001309	83-91
58838d25-bf87-44e7-a604-23468d67a1e3	Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever.
intensity	PATO:0000049	66-75
radiotherapy	OAE:0000235	148-160
02426c34-ebf9-4bd4-9d55-86fad89baf20	In total only 20% of participants in the primary trial did not achieve Pathological Complete Response.
9e28c807-8d88-4eea-87ee-48a42bd002ab	the primary trial and the secondary trial only record 4 of the same adverse events.
80ac126e-c756-4031-9541-e50d51c18b38	Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial.
leukemia	HP:0001909,DOID:1240	14-22
hepatitis	HP:0012115,DOID:2237	24-33
polycystic kidney disease	DOID:0080322	37-62
1a1d7d1d-ec49-46db-b6bc-dfd94575e46c	Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis.
enzalutamide	CHEBI:68534	49-61
fulvestrant	CHEBI:31638	67-78
68a9f2f0-cf11-4cd4-847c-53b8befd6002	Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial.
surgery	OAE:0000067	15-22
breast cancer	DOID:1612	44-57
breast	UBERON:0000310	44-50
breast	UBERON:0000310	62-68
9bcd40cf-8221-4383-8891-76a4bcc5c766	Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial.
breast cancer	DOID:1612	76-89
excluded	HP:0040285	120-128
341156fc-9cbd-492f-8e9e-8fbf98191625	It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours.
time	PATO:0000165	68-72
44ae021e-241b-4dbf-b88f-0b9d41eab555	There were no cases of Oesophageal spasming observed in the primary trial.
523a44a3-6b90-4be7-ab46-6b6addd7b5b9	There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1.
thrombocytopenia	HP:0001873,DOID:1588	27-43
258a51ca-e1f0-4d9a-88a6-8749f4822034	Participants in the primary trial receive different interventions depending on their cancer hormone status, so Triple-Negative patients are seperated from HER2+ patients for example, whereas all patients in the secondary trial took the same intervention.
cancer	DOID:162	85-91
hormone	CHEBI:24621	92-99
83bacd68-871a-4777-ba23-1f9a3df9227d	Recurrence-free Survival, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. 
rate	BAO:0080019	102-106
patient	HADO:0000008,OAE:0001817	187-194
fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9	One patient in the primary trial had a Confirmed tumor partial response, in contrast thirty patients in the secondary trial had partial tumor response.
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	92-99
1a451f2e-0818-4a86-8808-0e4cce700aef	In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia.
neutropenia	HP:0001875,DOID:1227	40-51
anemia	HP:0001903,DOID:2355	95-101
52333afb-0e7a-4823-ae9b-746e0ce57c8c	Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems. 
4216b27f-4d3e-4029-9637-2e6dade15b73	There was only one patient cohort in the primary trial.
patient	HADO:0000008,OAE:0001817	19-26
14a32a42-424b-4b97-bae9-05f4bb2b415b	Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial.
4d83c630-d767-40cf-9aec-c871c6fc7f38	Patients with stage I, II, III or IV breast cancer may be eliglbe for the primary trial.
breast cancer	DOID:1612	37-50
4fd230f2-caf1-44d6-81f2-4f51dda6da3a	Any patients with Karnofsky Index < 80 are eligible for the primary trial.
7a3d1ca7-8776-4ace-bbc0-107635b93583	The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.
group	CHEBI:24433	29-34
increase	BAO:0001251	68-76
e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0	Only men and postmenopausal women are eligible for the primary trial.
1196db61-0846-4185-afc9-dc4b2fccd059	A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
surgery	OAE:0000067	38-45
year	UO:0000036	53-57
excluded	HP:0040285	88-96
567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64	All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time.
letrozole	CHEBI:6413	104-113
duration	PATO:0001309	127-135
time	PATO:0000165	139-143
7e629f62-2981-4462-a4c1-f0cc9c24777a	Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.
cholecystitis	HP:0001082,DOID:1949	65-78
c660faec-58d8-4ba9-8e18-1775b1135819	Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2.
frequency	HP:0040279	64-73
a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2	Cohort 2 of the primary trial reported one case of AML.
3ee5742b-6bc3-400f-92eb-641384a75201	Patients in the primary trial do not receive any extra medication for the study, whereas in the secondary trial they are given an oral medication.
f6af788f-ee96-4308-8dec-12d0c46e957a	Patients with irrational fear of confined spaces are not elligible for the primary trial.
2e09a2ec-149e-46b4-b60a-ed421fdbc9b3	Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial.
year	UO:0000036	73-77
e0b7a120-8735-413d-9a47-8508b2feffb3	Less than 20 the primary trial participants achieved partial response (PR).
1393c5d9-d2be-433b-9abf-9449b46588c4	Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from the primary trial.
breast	UBERON:0000310	27-33
excluded	HP:0040285	102-110
abfa5699-2863-4319-9386-4b359f2062f2	Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group.
group	CHEBI:24433	43-48
group	CHEBI:24433	94-99
4038f7c3-87e2-47d6-811b-fd2b21679577	Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin.
cyclophosphamide	CHEBI:4026	130-146
5097f4cd-9118-473d-a2a0-72f0cd12c7a5	Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial.
brain	UBERON:0000955	54-59
68e6a088-ab80-4a89-90d4-39308bccb1c2	All the primary trial subjects are required to take the intervention PO daily.
a4c49b44-91b3-4a3c-bfbf-b3758cc398f1	the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.
08917306-11b0-44ad-8f45-9a67d7f6073e	Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial.
result	BAO:0000179	30-36
9702cb6a-bdb1-415f-bb99-3b740728a4ea	There are no placebo or control groups in the primary trial or the secondary trial.
7afa2d1f-7922-4b09-b52a-43bd9a4788a9	participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial.
rate	BAO:0080019	99-103
dfd5acc2-6824-4b63-93ad-34e6a0a4c621	Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial.
alcohol	CHEBI:16236	15-22
cirrhosis	HP:0001394	60-69
excluded	HP:0040285	99-107
97e9967e-6525-4082-bd11-8c30e14d23fd	Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial, but are always excluded from the secondary trial.
disorder	OGMS:0000045	54-62
excluded	HP:0040285	117-125
d11dd4ae-28be-4ad2-a452-4374c48f08d1	the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.
day	UO:0000033	102-105
capecitabine	CHEBI:31348	124-136
capecitabine	CHEBI:31348	167-179
increase	BAO:0001251	142-150
3b6229a9-00a1-4d26-9285-6d9f6a25fd77	Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea.
erysipelas	HP:0001055,DOID:11330	70-80
9eab20ad-ffc6-473f-8087-c6c3f06f356f	the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status.
92680a4c-a1e0-47d2-9b7f-cacb20cd1fde	the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg.
vorinostat	CHEBI:45716	74-84
b3dd4e23-f78c-4bf9-9268-d1018c966980	Patients must have cancer that can be felt by touch to be eligible for the primary trial.
cancer	DOID:162	19-25
553d7721-289e-4ab1-a9b9-7b2c939f47c1	The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year.
year	UO:0000036	87-91
01c6f82e-710d-4fa4-aa62-2d26e72f4533	There were no adverse event in the primary trial which occurred more than 71 times.
adverse event	OAE:0000001	14-27
2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc	Patients with unexplained fever exceeding 39¬¨‚àûC are excluded from the primary trial but may be included in the secondary trial.
fever	HP:0001945	26-31
excluded	HP:0040285	55-63
862c0bfe-10a6-453c-9ada-929dd00141a0	the secondary trial and the primary trial employ non comparable outcome measures.
9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f	A patient who had an oophorectomy in the last month would not be eligible for the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
month	UO:0000035	46-51
5501dae3-0d3c-4812-96c2-35ca863e24a5	On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.
day	UO:0000033	3-6
doxorubicin hydrochloride	CHEBI:31522	47-72
cyclophosphamide	CHEBI:4026	82-98
dexamethasone	CHEBI:41879	100-113
ondansetron	CHEBI:7773	131-142
ece8e7df-790d-4e26-9c34-40cf66d2abf5	All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time.
degarelix	CHEBI:135961	99-108
duration	PATO:0001309	148-156
time	PATO:0000165	160-164
550a36e2-43bb-40af-b0c8-49498fbe2c8c	the primary trial investigates a novel radiotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.
radiotherapy	OAE:0000235	39-51
95869347-6c3d-4de8-a325-a9a652f11edf	In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation .
sinus bradycardia	HP:0001688	82-99
bone marrow	UBERON:0002371	101-112
constipation	HP:0002019,DOID:2089	128-140
8df8e2c0-a0ca-4ea2-ba83-494f250c4bef	3/112 patients (2.68%) in the primary trial had Diabetes insipidus 
diabetes insipidus	HP:0000873,DOID:9409	48-66
1d4a385f-1c72-4c61-8d49-9ada0e3b716a	Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study.
day	UO:0000033	107-110
week	UO:0000034	117-121
b15aa13a-fbd9-4b2e-9dd2-b16628084d07	The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of the primary trial, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17
mtd	BAO:0001248	28-31
paclitaxel	CHEBI:45863	103-113
c9214d06-2733-4c78-99e5-a42015908eae	Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment.
cancer	DOID:162	6-12
median	BAO:0002174	78-84
a318fc31-4f28-4356-b09a-59741bb7c97a	the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is not.
70ec4bc8-f8fa-4901-aa7a-2388b53960c6	The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.
00dc0e37-1d0b-4f53-a037-86bf9799dae6	Female patients with a womb cannot take part in either the secondary trial or the primary trial.
female	PATO:0000383	0-6
a1a421cc-01c9-4afb-8f09-6b10b0ff5094	Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial.
9316ef0d-55b0-4547-88ae-887e0132a263	Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment.
median	BAO:0002174	65-71
5d815fac-c66c-43fe-9ac8-a352b6e47a5b	the primary trial and the secondary trial are both utilising test and control groups in their interventions.
7b9fdeaa-5cb7-4453-b174-07b44bb58234	More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations.
c330f152-c64e-47ab-8568-5129a1a2099e	None of the 60+ patients in cohort 2 the primary trial experienced any adverse events.
e3b88c8c-241d-4ead-8573-534a46210707	The majority of patients in the primary trial did not experience Left ventricular dysfunction.
left	HP:0012835	65-69
e621f354-dea0-4d0f-a252-5480028c1712	At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event.
patient	HADO:0000008,OAE:0001817	11-18
radiotherapy	OAE:0000235	56-68
adverse event	OAE:0000001	77-90
ee209156-74dc-475e-87af-ae51160982ef	30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.
maleate	CHEBI:30780	96-103
edf813c0-2271-49ca-a040-a355bf71d8b4	There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.
median	BAO:0002174	43-49
duration	PATO:0001309	50-58
neutropenia	HP:0001875,DOID:1227	70-81
352475ea-1b17-4d1a-a5e3-71f1b87cffd8	Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial.
adenocarcinoma	DOID:299	51-65
immunohistochemistry	BAO:0000415	75-95
c7c745d6-03ee-4740-9ef4-641fb6546e46	Every adverse event in the primary trial occurred more than 8 times.
adverse event	OAE:0000001	6-19
c5c8ab0b-8062-4467-8ecd-bb15f35f54c0	the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial.
601e9c47-ed82-4fa6-8a28-b3c71cc7c71b	The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin.
breast cancer	DOID:1612	20-33
eribulin	CHEBI:63587	122-130
8f1959e4-b93a-4112-9726-27a4034f0e07	Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial
indicator	CHEBI:47867	52-61
e1782960-8d44-4acc-aaae-bfa4f8e38de0	Patients must have an ECOG score below 3 to participate in the primary trial.
61bd93b2-b38f-496d-acd9-f8b188d28a39	Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial
x	LABO:0000148	43-44
x	LABO:0000148	84-85
x	LABO:0000148	169-170
history	BFO:0000182	106-113
blood	UBERON:0000178	117-122
excluded	HP:0040285	168-176
741c95c7-825c-4321-8d12-9037bb701ab8	the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women.
adjuvant	CHEBI:60809	114-122
letrozole	CHEBI:6413	123-132
6ce047b6-c18f-4f63-90ec-8643f5145efe	At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). 
d647aad0-47f7-4b77-a265-e77dcf5e0983	The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, in contrast a full year of daily physical exercise is explicitly required for the secondary trial.
year	UO:0000036	129-133
74fed085-3389-49c6-bdd2-a95c97071f2d	All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial.
986ffe33-8e8b-4cbf-8408-eb9489fb2314	There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial.
radiotherapy	OAE:0000235	91-103
aeac5b1c-26f9-44bc-b1c4-3bd0d498914e	There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial
intestinal perforation	HP:0031368,DOID:2074	24-46
chest pain	HP:0100749	48-58
death	OAE:0000632	60-65
hyperglycemia	HP:0003074,DOID:4195	67-80
pneumonia	HP:0002090,DOID:552	85-94
3f98cd71-ec28-4fd1-9ca0-2184eef3390a	Patients with tumors that are HER2 +, PR and ER -, are eligible for the primary trial.
11138479-1666-4973-84c2-c6779b5444f5	In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the same intervention.
35c62055-2832-4119-9080-5603beea1934	There were no cases of Pneumopathy in either the primary trial or the secondary trial.
59ff0501-f6af-4739-bd07-71e12e8cd8a7	Patients with undetermined human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial.
growth factor	BAO:0002024	43-56
receptor	BAO:0000281	57-65
ab52c559-5712-44ff-becd-1c491e107472	Men are not eligible for the primary trial.
4619b957-3368-47b9-b949-01ec91208f96	the secondary trial recorded more cardiac related adverse events than the primary trial.
5bb09d7b-622f-4bdd-8dfd-809ea014a278	A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial.
percent	UO:0000187	9-16
07327b61-973b-48bb-b42b-dfde1efcfb7d	The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial.
patient	HADO:0000008,OAE:0001817	4-11
3307a083-0c8a-47b8-94cb-0bf4095b9c3b	Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial.
carcinoma	HP:0030731,DOID:305	57-66
bda2752e-082e-4d06-926a-04ade3f61c26	11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial.
liver disease	DOID:409	47-60
d4d73d33-4f71-46b2-b0c1-eac6741fd8f3	Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response.
patient	HADO:0000008,OAE:0001817	27-34
lapatinib	CHEBI:49603	53-62
tamoxifen	CHEBI:41774	72-81
f418c027-439a-4b19-bfb0-e1c1241886d8	There were 4 more cases of Dyspnea than Dehydration in the primary trial.
dyspnea	HP:0002094	27-34
dehydration	HP:0001944	40-51
4805e49a-b99e-46d8-b937-13ac2501c4a4	Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial.
surgery	OAE:0000067	56-63
lymph	UBERON:0002391	74-79
9a3cb836-66a8-4c68-980c-97e5841f331f	The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17
mtd	BAO:0001248	28-31
paclitaxel	CHEBI:45863	103-113
45d4f78f-04d4-434c-9679-fd92291e97b6	A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	29-36
sarcoidosis	DOID:11335	42-53
excluded	HP:0040285	63-71
prolonged	HP:0025297	123-132
5338f894-aecb-4678-bb67-fe058653e12b	Less than a quarter of participants in the primary trial had radiation dermatitis.
dermatitis	DOID:2723	71-81
2cebae78-f4a3-4e09-ac54-cd2388670274	Patients receiving intervention 1 of the primary trial, will be administered medication topically and intraveinously.
d8a98ace-009c-47e4-a812-3bc0df91ed2b	the primary trial and the secondary trial have non comparable results as the metrics they records are completely different.
c8cfd67e-5fac-4bff-9296-6e42dcb09f80	Participants of the primary trial are assigned an intervention depending on their hormone recpetor status.
hormone	CHEBI:24621	82-89
57cf3760-1692-439f-bbe2-82a6bc8862ce	Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.
gel	BAO:0010018	71-74
duloxetine	CHEBI:36796	172-182
7db1447c-b4e8-49c6-a125-8161bcd98560	Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial.
626a05e9-2caf-4e73-a132-5432a5b2c7d9	over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia, with the majority of those coming from the secondary trial.
myocardial infarction	HP:0001658,DOID:5844	78-99
arrhythmia	HP:0011675	103-113
fe6f3faf-8be6-4ec6-8622-b4d36e8c2876	There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial.
night blindness	DOID:8499	22-37
b1cd4818-9623-45e5-a2b3-4c80016e3c82	Patients with E2 outside the premenopausal range are ineligible for the primary trial.
range	LABO:0000114	43-48
3050bca2-a8bc-412e-b679-5be1055e3749	Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study.
duration	PATO:0001309	94-102
a49666fd-f278-4dcf-b6bf-287ace3969aa	No cases of Metastasis to the CNS were recorded in the primary trial.
f6c014af-63db-4578-9b2d-74ea95901842	the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame and the same unit of measure.
time	PATO:0000165	108-112
c8ef1457-63a9-4eac-a98b-edb805afd35b	the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is evaluating the impact of regular exercise and dieting.
515d0710-429b-4c28-b881-8a6531ee973e	Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial.
disease	DOID:4,BAO:0002927,OGMS:0000031	63-70
b4d261a4-9b42-4158-9b21-159859b59e2a	Neither cohorts of the primary trial receive any medication orally or by IV.
1c043d17-15a9-496c-a69b-9ec95a7ab8df	Males are not eligible for the primary trial, because they do not produce oestrogen.
79c69498-7dd5-41fa-8946-36d452a5b9ec	Patients with a COPD diagnosis through spirometry are ineligible for the primary trial.
93fc76a9-5f3d-490b-8802-21d0fa806728	Cohort 2 of the primary trial reported worse results than cohort 1.
9f5e55af-8a94-4531-ab00-f16199795b64	Neither cohorts of the primary trial receive any medication orally, by IV or by radiation.
ee85e355-3d0a-4e40-8a8d-6a0b71c77148	patients with Multicentric breast cancer can be accepted for the primary trial.
breast cancer	DOID:1612	27-40
c4a2ca0b-c4a7-4366-92c7-145dadd38af3	Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from the primary trial.
peripheral neuropathy	HP:0009830,DOID:870	14-35
excluded	HP:0040285	79-87
c6ca8c6a-7eae-4671-9eff-c44a1222fadb	Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for the primary trial.
rheumatoid arthritis	HP:0001370,DOID:7148	11-31
e591b3bb-0628-46e7-9d60-28989fd6a3d0	One patient in the primary trial was observed vomiting blood.
patient	HADO:0000008,OAE:0001817	4-11
vomiting	HP:0002013	46-54
blood	UBERON:0000178	55-60
75da6329-e8a1-4808-bb0f-78fd3a2dde9c	Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.
dab9d582-eaf3-443f-bdb9-073aec304ee6	the secondary trial recorded more cardiac related adverse events than the primary trial.
8b9bb672-1de3-4220-956c-9e86ed78063d	One case of hematolysis was recorded in the primary trial, none in the secondary trial.
3194a043-d156-49d6-97bb-81867ed188f0	Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV.
inhibitor	CHEBI:35222	117-126
8c3ab1eb-c473-4399-b18c-512ef16e4a47	To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.
carcinoma	HP:0030731,DOID:305	69-78
chorionic gonadotropin	CHEBI:81570	122-144
urine	UBERON:0001088	145-150
aeac1009-91c3-40ad-8583-5b548e1f4b3b	the primary trial and the secondary trial only have test cohorts in their studies.
3058d104-172e-41be-b641-9f0f9cb172be	At least one participant of the primary trial survived over 200 days without documented disease progression.
disease	DOID:4,BAO:0002927,OGMS:0000031	88-95
bc845a3d-1f69-41a3-bf84-36a62e8127a4	In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.
69ced998-f3c9-460a-a272-b2c95421b89d	Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial
female	PATO:0000383	0-6
45fb84a3-674c-40f5-ac8c-26a3c7844e7b	Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole.
simvastatin	CHEBI:9150	76-87
anastrozole	CHEBI:2704	91-102
c349cad6-8b63-4e5e-9b87-4fc08bb6fc30	Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb.
f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9	More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.
b3effb24-6ec0-4fa3-9c91-74a45bcc4602	the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels.
radiotherapy	OAE:0000235	31-43
lymph	UBERON:0002391	180-185
9026c2ff-2dd8-4aa9-b2fb-f6bef856189d	Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks.
341c0861-b9a3-491d-8d49-aa61a8501a4f	The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.
adverse event	OAE:0000001	41-54
16d6e554-a1df-42f9-b051-947d70595cbb	The only cases of Leukopenia in the primary trial occurred in cohort 1.
leukopenia	HP:0001882,DOID:615	18-28
8f0159ce-1044-4f31-94b7-e394cf91d4e1	Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial.
recurrent	HP:0031796	48-57
cancer	DOID:162	58-64
cancer	DOID:162	72-78
breast cancer	DOID:1612	65-78
ccc5e420-dda4-4fb9-8d68-82551d69017f	Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms.
89f8ba8c-e626-4bd4-9994-3d0264018932	Patients with end-stage liver disease are excluded from the primary trial.
liver disease	DOID:409	24-37
excluded	HP:0040285	42-50
0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d	In the primary trial patients in the test group had better health outcomes than the control group.
group	CHEBI:24433	42-47
group	CHEBI:24433	92-97
57e6f0e1-6157-43bc-8bdf-c3649ed49133	More than half the participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients.
300dbe96-0be8-4ca0-aa3b-41bc059bac7f	Neither the primary trial or the secondary trial have control groups.
f40c8d92-2921-45fd-8389-15048b08e229	Neutropenia was the most prevalent adverse event in the primary trial.
neutropenia	HP:0001875,DOID:1227	0-11
adverse event	OAE:0000001	35-48
31387af4-aad1-4f3c-bd81-641340ad4096	the primary trial and the secondary trial use completely different drugs and techniques for their interventions.
eabe9a78-965e-4984-82c2-25598b6b35da	The median TTP in cohort one of the primary trial is just under 27 months.
median	BAO:0002174	4-10
ttp	CHEBI:63550	11-14
006f6b4e-6245-4f09-9786-327bbed3d766	The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.
88b13330-b937-4bbc-80ea-4bf8ccc17bd1	3/4 participants in the primary trial suffered from Dose-limiting toxicities.
e90e2368-808d-454d-8080-30427235b89d	There are no racial criteria for entry into the primary trial, but there are for the secondary trial.
d375ef3f-8b35-40eb-b9c0-3fc9592d9bec	Patients with both type 1 and 2 Diabetes are not suitable for the primary trial.
2f2301cd-b8fa-47cc-94cc-e31150ce8f9e	the primary trial and the secondary trial only have test groups, so all patients are receiving novel (FDA approved) interventions.
eea73ae4-0985-4f74-957d-e2aad7ab453c	Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial.
year	UO:0000036	15-19
breast cancer	DOID:1612	56-69
6550c068-14e6-4e93-8f98-756338c91e35	Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.
fulvestrant	CHEBI:31638	43-54
fulvestrant	CHEBI:31638	123-134
rate	BAO:0080019	94-98
0f5b81f0-b422-4000-8e0e-9f09c612ebc3	None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course.
radiotherapy	OAE:0000235	89-101
group	CHEBI:24433	115-120
f6bba549-3d18-4a53-8685-96b4e321b1a7	the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not.
immune system	UBERON:0002405	34-47
1fe36432-40f8-4c53-ac2b-0f8e50e5743f	Several treatments in the secondary trial and the primary trial are administered by mouth.
mouth	UBERON:0000165	84-89
3576f3e7-a1b9-4a75-934a-1ad2165b69dd	There were more cases of Anemia and vomiting in the primary trial than the secondary trial.
anemia	HP:0001903,DOID:2355	25-31
vomiting	HP:0002013	36-44
de71f285-4382-465f-9e7e-d163662f6d9c	the primary trial only had a total of 66 patients in across both its cohorts.
406247fb-003a-47b7-8fe4-b6b963b98f08	the primary trial does not record any pain related adverse events.
pain	HP:0012531	38-42
47553222-0aff-4394-bcfc-9f19c0863835	the secondary trial does not have a defined end date, whereas the primary trial lasted 2 weeks.
e4756896-55c2-46e1-be19-14697ad3b39f	One patient in the primary trial had blood calcium levels far above normal.
patient	HADO:0000008,OAE:0001817	4-11
blood	UBERON:0000178	37-42
calcium	CHEBI:22984,BAO:0000874	43-50
594c9a79-d601-46b4-ae30-0b48a1117693	The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons.
size	PATO:0000117	25-29
99e8ee0e-d72d-4e19-9424-20e5891bb2b6	It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial, despite the difference in cohort size.
size	PATO:0000117	154-158
f1b0653f-b5ce-4558-b325-56244940c0cd	There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial.
dyspnea	HP:0002094	33-40
24b24d36-2500-4841-99a3-13cba905d77d	the primary trial at least 8 different types of cardiac related adverse events.
0797ff90-f847-4442-92fd-017c539bb38f	1 patient in the primary trial suffered from a blood clot blocking their trachea.
patient	HADO:0000008,OAE:0001817	2-9
blood	UBERON:0000178	47-52
trachea	UBERON:0003126	73-80
6b595151-7e51-4062-b587-3207ea251677	the primary trial tests positron emission tomography as a technique for guiding a medical procedure.
positron	CHEBI:30225	24-32
tomography	BAO:0002525	42-52
medical procedure	OAE:0002807	82-99
e802b1f6-62fb-4759-b261-c69dbdc1d7ef	Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.
0a24a07e-2cb4-4591-aea4-a370f462cc49	the primary trial treament last for a shorter period of time than the secondary trial treatment.
time	PATO:0000165	56-60
97d0bbf0-c2c5-409b-820b-6e14a6326b06	A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
estrogen	CHEBI:50114	40-48
progesterone	CHEBI:17026	68-80
growth factor	BAO:0002024	120-133
breast cancer	DOID:1612	145-158
brain	UBERON:0000955	174-179
history	BFO:0000182	204-211
bbb5ebc0-83c8-46cb-89b4-e1c67e042350	Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from the primary trial.
ovarian cancer	DOID:2394	20-34
excluded	HP:0040285	97-105
620106e8-2a7f-4078-80b6-d5f1840c66e1	the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab.
94a7b007-0332-4d01-979e-9677e5da4316	In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.
group	CHEBI:24433	60-65
group	CHEBI:24433	170-175
breast	UBERON:0000310	107-113
2849d0ce-fed2-4c49-bec1-777c440caaeb	More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole.
aa6a20f8-ee49-42b7-9b9b-64caa8b22e35	Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once.
adverse event	OAE:0000001	17-30
01a57096-0278-4c70-be43-acd57010cd6f	There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.
blood	UBERON:0000178	53-58
49213077-0a5b-4368-a48a-282d2ca9d77a	Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study.
enzalutamide	CHEBI:68534	49-61
fulvestrant	CHEBI:31638	67-78
426d3ecd-73e3-4226-83c6-cfcb9212ed62	All the primary trial subjects either had Progressive disease, Complete CNS objective response rate or partial response rate.
progressive	HP:0003676	42-53
disease	DOID:4,BAO:0002927,OGMS:0000031	54-61
rate	BAO:0080019	95-99
rate	BAO:0080019	120-124
7c12676c-7973-4e9d-b1fc-3b14d241d0c8	20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years.
letrozole	CHEBI:6413	39-48
disease	DOID:4,BAO:0002927,OGMS:0000031	76-83
3419e901-5880-488d-912c-023e8d1b51c7	the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more.
patient	HADO:0000008,OAE:0001817	31-38
cd645637-0a31-4f54-bc75-4a52349cf100	Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle
adfc79ba-2996-47ce-9986-7d287931df89	A total of 3 patients in the primary trial experience a Herpes related adverse event.
adverse event	OAE:0000001	71-84
414ae027-b420-4f01-afd5-164cd8146a30	16 participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients.
45b2b9ec-ba58-4323-810a-4baed9c84a0e	the primary trial participants will not receive any Lapatinib post WBRT.
lapatinib	CHEBI:49603	52-61
72ffdfbf-aa72-4d44-814a-1d6ab8883898	Patients must have already participated in a specific clinical study to participate in the primary trial.
db613a72-e300-41a7-987f-788c306d94a4	There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial.
leukopenia	HP:0001882,DOID:615	23-33
arrhythmia	HP:0011675	37-47
2667d301-2efb-4d92-bc12-ccfc869e4835	The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.
60bff573-0251-4f05-b2b7-dec74c7363cc	In total, across both cohorts of the primary trial, there was at least 2 fatigued patients.
f6f8a0d3-6288-44cf-9b34-27444110dd10	histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial.
breast carcinoma	HP:0003002,DOID:3459	68-84
result	BAO:0000179	91-97
8b0482c1-74d4-48ae-96bc-d80f8f1a0f50	Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously.
paclitaxel	CHEBI:45863	95-105
878dcfeb-c3db-4077-9a3e-8098efa80a99	Patients cannot be excluded from the primary trial on the basis of race or ethnicity.
excluded	HP:0040285	19-27
fc5dbfec-ba79-4c5d-9e38-3c97d0397570	Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet.
patient	HADO:0000008,OAE:0001817	4-11
a8514489-cb31-4c8a-abca-e1f7b3a8d4ce	No cases of Anaphylaxis occurred in either the primary trial or the secondary trial.
64411610-090b-42d2-a176-d2b13ffef591	Unlike the primary trial, the secondary trial has no control group.
group	CHEBI:24433	61-66
82bd50ac-9407-413b-9eb8-653cef49706c	warm saline solution is used in both the primary trial and the secondary trial.
solution	CHEBI:75958	12-20
470611af-16b2-4094-ae2a-c9c6155e2672	The intervention section for the primary trial does not detail the type or duration of the intervention, unlike the secondary trial.
duration	PATO:0001309	75-83
f3a03aec-194d-4538-9be3-cea8281d995c	the primary trial recorded less than 3 different Adverse Events .
14a5e557-b223-4649-9867-0ff0e9001f5e	the primary trial and the secondary trial do not explain their interventions in the intervention section.
c8df3461-4063-4fb0-ae48-f57062eb0a68	the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy.
niraparib	CHEBI:176844	40-49
day	UO:0000033	93-96
1cd7cf90-bf66-480b-9227-2f7d2eccd647	the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments.
15f9d033-ebf7-44b3-94e2-3b8ee90b862b	There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial.
ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d	None of the patients in cohort 1 of the primary trial had Acute coronary syndrome.
acute coronary syndrome	HP:0033678	58-81
51cf1333-78b1-410a-82fe-aabfaa00a840	A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
glomerular filtration	GO:0003094	21-42
rate	BAO:0080019	43-47
severe	HP:0012828	57-63
allergy	HP:0012393	83-90
breast	UBERON:0000310	119-125
tissue	UBERON:0000479	126-132
d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d	on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions.
target	BAO:0003064	84-90
target	BAO:0003064	99-105
aef2367d-78a5-4dc7-a6f7-d96415082362	There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial.
29ae75a2-d8d2-4427-bba3-ab2c411d5718	There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial.
thrombosis	DOID:0060903	70-80
985c4cb3-2684-4a67-a479-998602044a0d	compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2. 
sudden death	HP:0001699	54-66
adverse event	OAE:0000001	107-120
39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3	Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event, and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events.
adverse event	OAE:0000001	78-91
adverse event	OAE:0000001	178-191
adverse event	OAE:0000001	261-274
d695120e-db68-481d-9023-881e48654e29	Patients with Extracranial metastases are still permited to enter in the primary trial.
5319ac1a-07ae-4531-bf93-5fce83016c87	Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan.
exemestane	CHEBI:4953	50-60
087aba29-40c6-4453-a44b-e63c3867e5b4	A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial.
year	UO:0000036	5-9
year	UO:0000036	96-100
female	PATO:0000383	14-20
patient	HADO:0000008,OAE:0001817	21-28
c66f3e9e-f232-4035-b705-2785946d1542	A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	14-21
dementia	HP:0000726,DOID:1307	37-45
excluded	HP:0040285	55-63
c679f426-b235-4ae9-ad6c-4f1a46a494d2	All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration.
122b1aef-4506-464d-9852-47caa508b047	Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 8 more cases of Leukopenia than cohort 2.
neutropenia	HP:0001875,DOID:1227	85-96
leukopenia	HP:0001882,DOID:615	131-141
4a4f3e9e-6a29-4715-8000-2eec90e9bb5d	All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial.
9f7dc38b-1945-4035-a0ff-e08ead55145b	Patients who completed a trastuzumab regiment, to treat the current breast cancer > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.
breast cancer	DOID:1612	68-81
excluded	HP:0040285	150-158
b259774e-410a-49aa-b5d4-31b8d9505fc3	People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial.
breast cancer	DOID:1612	45-58
gene	BAO:0000582	59-63
e09a11e4-afc8-4351-a5bc-d847424c79ce	Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues.
heart	UBERON:0000948	66-71
d22f01f0-b2be-45b9-8996-11727750b91e	the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial.
anastrozole	CHEBI:2704	44-55
fulvestrant	CHEBI:31638	57-68
exemestane	CHEBI:4953	73-83
893d5684-03f8-4acd-86e4-6d38eea3ce16	There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.
4b46164d-a4c2-4738-be36-588ab231ceb1	There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts.
dysphagia	HP:0002015	27-36
fever	HP:0001945	40-45
d9236874-7f3d-4402-9699-2889db9f5c61	Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.
leukopenia	HP:0001882,DOID:615	57-67
e33825f1-45df-41f5-ba07-e9059636a146	DLT occurence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. 
rate	BAO:0080019	91-95
patient	HADO:0000008,OAE:0001817	176-183
5b0295e1-a322-40af-9acf-9cc1d55d3e64	the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment.
3658f2f7-a497-4abb-badb-c877036456f2	Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial.
female	PATO:0000383	32-38
target	BAO:0003064	59-65
37bc71d5-d9c0-4174-8da5-725d2d53a91b	The Cohort of the primary trial which received D+C and Taxane Na‚àö√òve, produced marginally better results than the other cohort.
taxane	CHEBI:36064	55-61
51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c	The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for the secondary trial.
8bcc9fa3-0317-471a-a5b5-b115b5b72dea	Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.
patient	HADO:0000008,OAE:0001817	5-12
median	BAO:0002174	48-54
insulin	CHEBI:145810	55-62
52610141-321d-4e3d-8660-ebc14b9f1696	the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, triples patient OS, compared to Capecitabine alone.
day	UO:0000033	102-105
capecitabine	CHEBI:31348	124-136
capecitabine	CHEBI:31348	170-182
patient	HADO:0000008,OAE:0001817	146-153
90203158-6477-4486-b8d9-09dcaca63617	There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial.
03334f23-49ab-47e5-b420-a6753ce6e832	There were no cases of Myocardial ischaemia in the primary trial or the secondary trial.
a847cfc1-9556-4a55-9698-69c22696148f	There were 2 cases of Angina in the primary trial.
fcbb7e0f-d106-44bd-a252-9b57adc6f071	No mental health issues were observed in the primary trial.
f82d94fe-c633-4bae-b28d-074196a08577	Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib.
fulvestrant	CHEBI:31638	52-63
neratinib	CHEBI:61397	197-206
e5379a89-f880-44c1-bee0-a0d8ad2abfce	the primary trial has a 5 year long intervention, the duration of the secondary trial is not specified in the intervention section.
year	UO:0000036	26-30
duration	PATO:0001309	54-62
d811aaec-b3bd-4376-a9d6-d14eacae875a	Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria.
surgery	OAE:0000067	15-22
breast cancer	DOID:1612	44-57
breast	UBERON:0000310	44-50
breast	UBERON:0000310	62-68
99312d82-614c-4422-b6e6-104fe5a7fa54	Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial.
lymph	UBERON:0002391	61-66
b02c99f3-70bd-4404-8d80-c57c6dfef7b7	There is are the same total number of patients in the primary trial as in the secondary trial.
3cbf2726-ddb0-460c-9dd2-082b8dda495d	Less than half of patients in cohorts 1 in the primary trial experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events.
e7741151-2b2c-4e78-a4df-fe998c580714	In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1.
8cff36b0-a022-4469-8d14-7120be891cb1	Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.
stable	HP:0031915	106-112
disease	DOID:4,BAO:0002927,OGMS:0000031	113-120
4ce24508-3d12-499f-ab7f-4b437ea51366	A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial.
2514da19-b30a-44bb-8853-4545e97295da	The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.
ixabepilone	CHEBI:63605	4-15
ixabepilone	CHEBI:63605	108-119
group	CHEBI:24433	26-31
group	CHEBI:24433	130-135
cb9f8a52-b88e-4b04-bb28-a0eabead1439	There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case.
adverse event	OAE:0000001	13-26
c921d3a1-bd6e-41c9-b0e9-23babf7ead7c	A patient with stage 2B , pathologically confirmed estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
estrogen	CHEBI:50114	51-59
breast cancer	DOID:1612	78-91
358a1d3c-9ccc-48fc-badc-1644e326c8cb	The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain.
adverse event	OAE:0000001	17-30
abdominal pain	HP:0002027	107-121
60a86c87-7387-4eae-b5dd-6245f8bf541e	WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial if they are a UK resident.
excluded	HP:0040285	43-51
bd3055c6-09aa-47f0-89ed-67ad3798a580	Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded.
month	UO:0000035	65-70
excluded	HP:0040285	181-189
21d7d726-8557-459f-a307-fae3e08f45d8	Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial.
hyperparathyroidism	HP:0000843,DOID:13543	16-35
excluded	HP:0040285	54-62
9a8157a9-82fc-4d7e-9254-295123459430	The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above.
ff37494d-2c61-4c06-86c1-d6bcfbe9e360	Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis.
myocarditis	HP:0012819,DOID:820	105-116
pericarditis	HP:0001701,DOID:1787	121-133
eb00b609-f17b-4595-87bd-d0843ec9e39a	the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does.
magnesium oxide	CHEBI:31794	51-66
8bc9ea31-b731-4799-a1cc-a5ba63da00c1	Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial where the intervention must be applied during sexual activity.
active	PATO:0002354	41-47
0864493d-9f64-49d1-a585-21be71704c59	In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia.
thrombocytopenia	HP:0001873,DOID:1588	239-255
c49428a7-cc55-474e-a773-88ff2019de1b	Both cohorts of the primary trial are administered the same doses of their respective drugs .
78136809-c8de-4c40-9a7e-1d61d879ba27	the primary trial and the secondary trial administer their interventions at different frequencies.
b430ea52-fa55-4280-9e23-8a7392afca58	Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial.
surgery	OAE:0000067	56-63
lymph	UBERON:0002391	74-79
adfeff22-7bdd-4868-ab6e-90dd43d9621d	There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.
exemestane	CHEBI:4953	83-93
exemestane	CHEBI:4953	124-134
celecoxib	CHEBI:41423	96-105
51b8964b-86b8-4e93-9fb1-cb4b6f7f3451	There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials.
sepsis	HP:0100806	120-126
276f5523-f45b-45b0-ad30-b737f2c1b1d0	the primary trial recorded several skin infections in their patients.
884ba067-d3fe-4837-ad2a-a802b671b53c	Patients with an ECOG score between 3-5 are eligible for the primary trial.
6619c75a-4073-47e9-8586-5070be1b3d39	Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish.
breast cancer	DOID:1612	55-68
d81fafa4-1196-407b-a8c2-27d7b5da2f4f	Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in the primary trial, or the secondary trial, unless they present LVEF below 50% 
breast cancer	DOID:1612	64-77
present	PATO:0000467	153-160
6d8b4720-e600-47d7-b6c5-3b8627f2358f	There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients.
adverse event	OAE:0000001	13-26
1b84007d-0002-4ab6-8e05-609e7de58684	the secondary trial and the primary trial do not use topical medications in their studies.
dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009	Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible.
function	BAO:0003117,BFO:0000034	41-49
function	BAO:0003117,BFO:0000034	172-180
severe	HP:0012828	147-153
dc7c4409-32e5-4211-83fe-0a97b6176ca0	Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2.
neutropenia	HP:0001875,DOID:1227	8-19
73e7447b-a940-4126-a1d9-fffd7c56c900	Several patients in the Eribulin Mesylate group in the primary trial survived less than a year.
eribulin mesylate	CHEBI:70710	24-41
group	CHEBI:24433	42-47
year	UO:0000036	90-94
c160ae6e-4dfe-47a4-ac9a-7497babbc2a2	Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial.
peripheral neuropathy	HP:0009830,DOID:870	14-35
neuropathy	DOID:870	25-35
neuropathy	DOID:870	56-66
excluded	HP:0040285	72-80
9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063	Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial.
excluded	HP:0040285	76-84
a7106a35-36da-423a-a6b3-3da62fc0eea8	Prior exposure to taxane is obligatory for patients in the primary trial.
taxane	CHEBI:36064	18-24
f4f50a05-9d63-4006-9680-b7ef68dbb5fe	Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO.
f34760f4-965e-4bbb-b88f-8b63a7045808	Patients with HER2 positive tumors are ineligible for the primary trial.
f4a33395-7e6b-46b9-b222-af3bbfff1591	Less than 2% of patients in the primary trial experienced an adverse event.
adverse event	OAE:0000001	61-74
e7d00591-381f-45e2-abdb-2ae1e568b193	More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells.
blood	UBERON:0000178	109-114
59da1fb5-2636-4ca8-8970-6cb45dedbed3	Patients' appetites were not affected in the primary trial or the secondary trial.
affected	HP:0032320	29-37
f144c34b-9428-4836-bf01-5f7030eb579c	Intervention 1 for the secondary trial and the primary trial are for the control groups.
e7e87023-2227-4594-931a-0a3d89ec686e	Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial.
day	UO:0000033	49-52
methadone	CHEBI:6807	78-87
buprenorphine	CHEBI:3216	91-104
ca4a190a-9007-4f8f-a199-b8fe4064e55b	Several adverse events which occurred in the primary trial were not heart related.
heart	UBERON:0000948	68-73
4f790768-7fa4-4729-bcd6-cf7bcb44fa3c	the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial.
cb133915-dc40-4f93-a6a7-076e4d7f07a1	the primary trial and the secondary trial have the same number of study groups, but are testing different interventions.
1f0825b6-8e32-44ff-96b7-ab082e24b493	WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial.
excluded	HP:0040285	43-51
db96c4d6-ffcd-401a-8af3-807f665f16f7	Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial.
osteonecrosis	DOID:10159	24-37
excluded	HP:0040285	77-85
b74dc1bc-76c3-4ce6-9735-634e7a507ff5	Patients with LVEF equal to 53.5% are eligible for the primary trial.
f078c722-b879-40f2-ac72-c733001b93dd	the secondary trial and the primary trial only accept 18 year olds.
year	UO:0000036	57-61
c33d78e5-13be-4cde-b36e-7cc097f180a2	the primary trial and the secondary trial use the same outcome measurements, same drugs and the same cohort sizes.
58dbc33b-d32c-4e91-a940-ca1148bbdae4	the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant.
fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e	Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route.
mouth	UBERON:0000165	62-67
2c462296-35f5-482a-9ece-3b4ed4c2f53a	Urosepsis was the only recorded adverse event in the primary trial.
adverse event	OAE:0000001	32-45
16358be6-3895-48f7-8006-4effeb3f74b3	Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy.
6d4ecb16-6586-4ea8-a1dc-f825e951e060	Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.
liver	UBERON:0002107	32-37
5bb009f0-bc19-4a85-85b8-bd7bf0675f3f	Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting.
anemia	HP:0001903,DOID:2355	79-85
dyspepsia	HP:0410281	87-96
nausea	HP:0002018	98-104
vomiting	HP:0002013	108-116
2731552d-195a-4f43-b6b5-02a3fbda81d9	the secondary trial and the primary trial do not have comparable Outcome Measurements.
8fee5ce4-3e46-4731-842e-a5b1df451c7d	Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR).
def4199f-a22d-4939-b15d-66fd073fb280	Cohort 2 of the primary trial is the control group.
group	CHEBI:24433	45-50
c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2	1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma.
patient	HADO:0000008,OAE:0001817	2-9
clear cell renal cell carcinoma	HP:0006770,DOID:4467	52-83
d97c3981-50f9-4221-aec6-60661b831c8e	A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	14-21
occasional	HP:0040283	33-43
memory	GO:0007613	44-50
excluded	HP:0040285	65-73
86c1430c-553b-4388-a034-b82f78afdc0d	Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial.
inhibitor	CHEBI:35222	24-33
pain	HP:0012531	112-116
sensory neuropathy	HP:0000763,DOID:2491	128-146
b7cef0e1-7bd8-4c0e-a044-b11708cf927c	both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies.
breast cancer	DOID:1612	94-107
0b55d5b7-5e71-497f-96ad-9dc2f872c4aa	A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.
leukopenia	HP:0001882,DOID:615	72-82
225f95a5-7c22-4cb7-a463-1c57d5b69d7a	Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial.
exemestane	CHEBI:4953	18-28
5464e8a7-159c-4e00-8710-45a44ceaeda3	Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study.
duration	PATO:0001309	94-102
98965d07-e2db-41bf-ac3e-a5c130513275	Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis.
sepsis	HP:0100806	92-98
784cc905-937f-43fd-96a6-34ea8dce9e8d	Patients with end-stage liver disease are excluded from the primary trial and the secondary trial.
liver disease	DOID:409	24-37
excluded	HP:0040285	42-50
2e3f2fde-569e-46ef-958d-710599fec9a1	the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density, the results from these two studies are therefore not directly comparable.
target	BAO:0003064	54-60
bone mineral density	CMO:0001226	113-133
d1080199-2591-44bd-bdad-0dea3830e657	the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.
pemetrexed	CHEBI:63616	61-71
disease	DOID:4,BAO:0002927,OGMS:0000031	127-134
c37c21f5-19a0-4fcc-af92-89690fb64091	The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics.
omega-3 fatty acid	CHEBI:25681	94-112
patient	HADO:0000008,OAE:0001817	187-194
bea7f10e-09d6-42c3-9e89-dfd1112a33d5	0 patients in the primary trial or the secondary trial died.
3d41d86b-f53f-4bf9-a4dd-eae2412c485e	Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy .
letrozole	CHEBI:6413	43-52
0159bfb3-231e-4711-b3ee-2798c66f5f6a	Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts.
patient	HADO:0000008,OAE:0001817	98-105
9e7628cd-931e-4b1f-b4c1-f03f0449ac27	the primary trial records two different types of pain in its adverse events, in the cranial and foot area, the secondary trial does not record any types of pain in its participants. 
pain	HP:0012531	49-53
pain	HP:0012531	156-160
area	PATO:0001323	101-105
f1108cbc-db27-431d-9154-1a267278bda4	Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial.
cardiomyopathy	HP:0001638,DOID:0050700	9-23
leukopenia	HP:0001882,DOID:615	28-38
8eb69e3e-ac08-4e85-98be-211aecd4525d	Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet.
patient	HADO:0000008,OAE:0001817	4-11
baf7e338-91fd-47d0-b766-a4e039efc5d7	None of the patients in either cohort of the primary trial experienced DLT.
9401b12d-3888-4a41-93a1-b2075930098b	Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial.
patient	HADO:0000008,OAE:0001817	0-7
surgery	OAE:0000067	69-76
c7aa030a-6b76-4bd7-a934-f02a4638a1ac	Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial.
female	PATO:0000383	0-6
age	PATO:0000011	25-28
breast cancer	DOID:1612	66-79
disease	DOID:4,BAO:0002927,OGMS:0000031	105-112
94f9a957-33bb-4409-8878-ba734d6b0d5c	several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts.
peritoneum	UBERON:0002358	59-69
breast	UBERON:0000310	86-92
breast	UBERON:0000310	138-144
04fd88c2-cf92-468d-bbc4-567cae19948d	the primary trial recorded less patients with nausea than the secondary trial.
nausea	HP:0002018	46-52
8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd	There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial.
8074c35f-b74c-4250-94f1-9ad22fa315d7	Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial.
osteoporosis	HP:0000939,DOID:11476	24-36
excluded	HP:0040285	76-84
afc4a45b-6592-4ca8-b174-033fb6a0624a	Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial.
2e1d4811-ae58-4b81-b53a-dbcb8c980a08	Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial.
breast cancer	DOID:1612	28-41
d4f738c5-c99a-4d8d-b335-5821ce97fbd5	Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.
excluded	HP:0040285	138-146
f27b25bd-c28e-4aac-8ad6-951fd7381ce4	More than 1 patient in the primary trial suffered an adverse event.
patient	HADO:0000008,OAE:0001817	12-19
adverse event	OAE:0000001	53-66
5311216c-94e0-4d04-acd2-b95b932ddc02	the primary trial recorded at least one patient with an infection, whereas in the secondary trial none where observed.
patient	HADO:0000008,OAE:0001817	40-47
01dfa37b-ce65-4e90-addc-395241c92f5f	Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events.
43588c50-7dc4-4d46-a53d-e94576e8ab55	Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial.
f419f810-ca53-4168-86fd-d1d9a9154d3a	sufferers of hyperthyroidism are excluded from the primary trial.
hyperthyroidism	HP:0000836,DOID:7998	13-28
excluded	HP:0040285	33-41
630a8241-b776-4799-a7ca-b1fddf17686c	The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.
8f3fddf2-97ab-4456-bff7-8f83b27e3849	Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial.
immunohistochemistry	BAO:0000415	17-37
result	BAO:0000179	43-49
excluded	HP:0040285	60-68
11617367-193f-4f6b-bc3e-e58ea76d1052	the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD.
cyclophosphamide	CHEBI:4026	4-20
882f22f6-36d9-4c2f-8f49-52469d570977	the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer.
skin cancer	DOID:4159	84-95
8f5423c9-17b5-4f66-aa9f-1fc9763958b2	None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.
thrombocytopenia	HP:0001873,DOID:1588	46-62
heart	UBERON:0000948	64-69
pancytopenia	HP:0001876,DOID:12450	79-91
acute coronary syndrome	HP:0033678	93-116
atrial fibrillation	HP:0005110,DOID:0060224	120-139
0c45a782-1a3d-4e9b-a258-136ab080dbb6	None of the adverse events recorded for the primary trial occurred less than twice.
4e42302d-2cd9-4a91-9338-8e3b0ffb9292	Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial.
adenocarcinoma	DOID:299	40-54
breast	UBERON:0000310	62-68
a5d5e6da-f3cd-49c7-92a7-f789468c4c4c	60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.
da2ea2e9-3109-433e-9033-9ae322c30c4b	Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial.
breast	UBERON:0000310	27-33
excluded	HP:0040285	80-88
c77c8e02-7abb-4b63-8917-01babe5cd372	There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.
disseminated intravascular coagulation	HP:0005521,DOID:11247	54-92
f2b14720-6ff2-4ff7-a5bc-3841b93f647e	the primary trial does not explain its intervention in the intervention section.
03e9368b-18a7-4643-a38b-a7b002403bf1	Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.
age	PATO:0000011	39-42
excluded	HP:0040285	158-166
c5dbd52d-01d4-4919-bfe9-2b7885490d6a	Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.
breast	UBERON:0000310	73-79
83115abd-1c07-4ee7-8ba5-b4575be2d50f	Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial.
excluded	HP:0040285	58-66
784872db-8ccf-4ddc-a432-6ee00fd0b0cc	the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention.
magnesium oxide	CHEBI:31794	32-47
adae7d81-bc8e-48e4-b966-27c2633eb72d	over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.
p	CHEBI:17802,BAO:0002175	9-10
p	CHEBI:17802,BAO:0002175	16-17
p	CHEBI:17802,BAO:0002175	35-36
p	CHEBI:17802,BAO:0002175	41-42
p	CHEBI:17802,BAO:0002175	50-51
p	CHEBI:17802,BAO:0002175	79-80
p	CHEBI:17802,BAO:0002175	95-96
p	CHEBI:17802,BAO:0002175	104-105
p	CHEBI:17802,BAO:0002175	112-113
p	CHEBI:17802,BAO:0002175	144-145
group	CHEBI:24433	37-42
4ee4061e-a532-459e-8d03-3055bd92419c	Throughout the duration of the primary trial, pariticpants receive tipifarnib more often than Fulvestrant.
duration	PATO:0001309	15-23
tipifarnib	CHEBI:141969	67-77
fulvestrant	CHEBI:31638	94-105
4cbb7f8f-ea60-453d-b4ab-e967944426d3	Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once.
adverse event	OAE:0000001	17-30
47f11df7-6c82-4c50-9249-5085313a5064	A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial, but not for the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
breast cancer	DOID:1612	41-54
millimeter	UO:0000016	64-74
diameter	PATO:0001334	84-92
3114ff0f-184c-48ba-b33d-631505cffeef	the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.
ascites	HP:0001541	58-65
asthenia	HP:0025406	67-75
gastritis	HP:0005263,DOID:4029	80-89
edf31a43-a774-4f2a-8a02-89b84de941bb	27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response.
fatty acid	CHEBI:35366	27-37
omeprazole	CHEBI:7772	109-119
ffdc4c5b-a091-4fa6-b2c1-49a131d7d109	There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts.
dysphagia	HP:0002015	37-46
fever	HP:0001945	50-55
patient	HADO:0000008,OAE:0001817	23-30
patient	HADO:0000008,OAE:0001817	106-113
df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5	the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight.
lapatinib	CHEBI:49603	59-68
capecitabine	CHEBI:31348	90-102
body weight	CMO:0000012	125-136
5a076708-c8d4-4341-9c1d-3ee762f57be5	There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial
98a946b0-2be1-474c-b373-043f329ba261	Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib.
rate	BAO:0080019	112-116
b82e6861-3908-43e9-8e54-cf60c7d96a4e	Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial.
b8e5baf7-ddc5-407f-84d3-4c93224477cd	More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event.
patient	HADO:0000008,OAE:0001817	18-25
patient	HADO:0000008,OAE:0001817	103-110
adverse event	OAE:0000001	60-73
adverse event	OAE:0000001	178-191
79c34b71-a90f-4ddb-9aee-5f61f71f0846	the primary trial is not testing a novel Physiotherapy or chemotherapy intervention.
physiotherapy	OAE:0002476	41-54
e1f6d1b3-92eb-4ad8-8c00-e44b58650e62	A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
glomerular filtration	GO:0003094	21-42
rate	BAO:0080019	43-47
breast	UBERON:0000310	82-88
tissue	UBERON:0000479	89-95
02d5fe7a-60e2-422f-98c0-92461b8fa13f	the primary trial and the secondary trial have a topical intervention, to be applied to the breast or face.
breast	UBERON:0000310	92-98
face	UBERON:0001456	102-106
869e413e-01c5-4a9e-8a4a-b6079f7ae300	Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial.
breast cancer	DOID:1612	39-52
c0b528ef-ae9f-4c01-8915-b47856f07c95	the primary trial accepts patients with grade 3 neuropathy.
neuropathy	DOID:870	48-58
b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e	By week 48 of the primary trial the majority of patients had Stable Disease, none of them had complete or partial response.
week	UO:0000034	3-7
stable	HP:0031915	61-67
disease	DOID:4,BAO:0002927,OGMS:0000031	68-75
da15fae6-7fa1-4fe0-b61c-e043df3e9e74	All patients in the primary trial must have a bilateral breast MRI prior to study entry.
bilateral	HP:0012832	46-55
breast	UBERON:0000310	56-62
8ce665b5-20fb-44a3-b3c9-25493e8dd7ff	Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial.
01236718-14da-450c-8051-0207d31743a5	The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2.
median	BAO:0002174	4-10
time	PATO:0000165	11-15
death	OAE:0000632	38-43
month	UO:0000035	68-73
3419af1a-7923-419d-a673-2de96d41eabb	Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2.
hormone	CHEBI:24621	60-67
breast cancer	DOID:1612	89-102
2048912d-9e9f-4cbc-89cc-19020f20a976	A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
bilateral	HP:0012832	26-35
year	UO:0000036	54-58
excluded	HP:0040285	89-97
f5907902-d4d1-4d73-a196-7fbe0dcb44ad	the primary trial and the secondary trial both have control groups. 
93a8e018-ac25-48b2-81d2-fd5b01be8f37	A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial.
d72c45e5-6654-4afe-91a0-1f47b0c13dc0	Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial.
year	UO:0000036	13-17
female	PATO:0000383	22-28
adenocarcinoma	DOID:299	88-102
breast	UBERON:0000310	110-116
e68b5690-11fd-4567-8dcc-dec91d1e4bb8	The only adverse event recorded in the primary trial was one single case of spinal fracture.
adverse event	OAE:0000001	9-22
e1417a26-2f40-4dd6-b598-e66e57312595	Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER.
disorder	OGMS:0000045	59-67
disorder	OGMS:0000045	137-145
6ee89773-958b-4eb9-bc67-18fa98a70c2d	the primary trial only recorded one type of acute adverse event.
acute	HP:0011009,PATO:0000389	44-49
adverse event	OAE:0000001	50-63
4d776c28-8ed1-4f3f-9837-0821029d3775	None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 were constipated. 
50e54a67-9cfb-4259-b810-2e9bc0b09b4c	the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy.
9f23f617-b8ec-4665-ad0b-9a9bc8b19691	The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.
neutropenia	HP:0001875,DOID:1227	79-90
b76c9c21-64f7-487b-bf08-e232a9da0174	The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment.
radiotherapy	OAE:0000235	183-195
66aaca41-f5f9-4ed4-b165-9510b7c64456	Only patients who identify as female are eligible for the secondary trial and the primary trial.
female	PATO:0000383	30-36
611317e3-83f9-4e8d-9a9d-3dcda62fb6cb	A patient in the primary trial had a fungal infection of the mouth.
patient	HADO:0000008,OAE:0001817	2-9
mouth	UBERON:0000165	61-66
d6b09c0f-979c-4151-87f9-830b964e275d	Urosepsis was the most common adverse event in the primary trial.
adverse event	OAE:0000001	30-43
92da8d30-a7e9-4fb4-95e4-484b53279ad7	the primary trial and the secondary trial monitor the DFS of their patient cohorts, however the secondary trial reports the % of patients with DFS >= 5 years whereas the primary trial reports % of participants with DFS >= 2 years.
patient	HADO:0000008,OAE:0001817	67-74
patient	HADO:0000008,OAE:0001817	129-136
762c3b23-547a-40cb-86c9-767294f4a142	A 56 year old patient with a masectomy would not be eligible for the primary trial, due to her age.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	14-21
age	PATO:0000011	95-98
95a509d6-2990-49ac-b36c-aedf842f17ee	There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.
constipation	HP:0002019,DOID:2089	32-44
neutropenia	HP:0001875,DOID:1227	76-87
patient	HADO:0000008,OAE:0001817	95-102
9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6	One patient in the primary trial experienced a grade 4 adverse event.
patient	HADO:0000008,OAE:0001817	4-11
adverse event	OAE:0000001	55-68
19c2c2d7-4c33-4842-9ed4-02cfae663ce2	There was 1 case of night blindness in the primary trial, and 0 in the secondary trial.
night blindness	DOID:8499	20-35
1fdaafdc-766b-488e-9cc4-cbcad74ade97	In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib.
doxorubicin	CHEBI:28748,BAO:0000639	84-95
veliparib	CHEBI:62880	100-109
2e591059-5a3b-4a69-84c5-59d9604394a8	All genders are eligible for the primary trial.
94a54cdf-4c1c-4994-929a-ced7a33f2b43	Less than 1% of patients in the primary trial became depressed.
b217583e-2dbb-4951-8f73-cac08e365a7a	Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion.
42086f11-1fb1-4041-8d1e-e150d4cc09ea	A minimum bodyweight of 50kg is required to participate in the primary trial.
0d75c493-58ce-4a45-8823-a9a1126751b3	the primary trial is testing a combination of chemotherapy and radiotherapy.
radiotherapy	OAE:0000235	63-75
d0d4e184-0764-4c28-9af7-4535c7ed1aad	Cohort 2 of the primary trial produced marginally better results than cohort 1.
e45886af-1edd-4987-a280-2609a86fd3dd	Females over the age of 20 that have recieved chemotherapy in the last 4 weeks , are eligible for the primary trial.
age	PATO:0000011	17-20
c207ff16-b7d0-49e4-9177-0597044f3008	Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection.
35234f08-cf01-478f-b739-600b5a6ea3d9	16/179 patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2.
87adb323-6f56-4e1a-a04d-8437ac571eab	Patients with Lactiferous duct carcinomas are eligible for the primary trial.
duct	UBERON:0000058	26-30
94410f2c-9c1c-4130-b479-738e343ba9f7	There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial.
b811e872-90ef-4649-9c8d-f5488f316ccc	Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial.
ductal carcinoma in situ	HP:0030075,DOID:0060074	19-43
f66f4c30-2d39-4e29-876a-487bca9a8ccf	the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions 
radiotherapy	OAE:0000235	73-85
34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6	7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities.
011991a5-724d-4b95-b9ab-9e1371d77368	All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia.
leukopenia	HP:0001882,DOID:615	65-75
neutropenia	HP:0001875,DOID:1227	88-99
8421197a-3a35-4738-b1c8-83cce0ac4115	the secondary trial recorded more total occurences of cardiac adverse events than the primary trial.
d09091f1-3fc5-498b-8c59-4678590c8464	Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.
enterocolitis	HP:0004387	60-73
203a2e22-cae9-4bfe-b82d-6dc665a66ce6	Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial.
bisoprolol	CHEBI:3127	25-35
labetalol	CHEBI:6343	39-48
atrial fibrillation	HP:0005110,DOID:0060224	58-77
excluded	HP:0040285	82-90
f4909215-5b14-42d9-bda4-4d112cf2a108	More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event.
adverse event	OAE:0000001	71-84
9c27202c-7090-4be5-840e-351992aeb81c	the primary trial and the secondary trial reported the same number of dehydrated patients during the studies.
fc7d8ffd-9896-4806-a095-d435cde83c88	The total number of patients affected by adverse events in cohort 2 the primary trial, is larger than the cohort size of the secondary trial.
affected	HP:0032320	29-37
size	PATO:0000117	113-117
23116aca-0064-4426-b147-7af688a82443	Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial.
ulcerative colitis	HP:0100279,DOID:8577	19-37
excluded	HP:0040285	42-50
7dd79595-4bdf-48e6-af94-fe39aa2e5fd4	The only criterias for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and british.
female	PATO:0000383	99-105
age	PATO:0000011	116-119
98850daf-738c-4005-b476-8c5479ad3b79	Mark has HER2 positive breast cancer, he is eligible for the primary trial.
breast cancer	DOID:1612	23-36
fd8ddc92-4625-4392-b7ef-0ea218e2eb1c	the primary trial is testing a combination of capecitabine once daily with radiotherapy.
capecitabine	CHEBI:31348	46-58
radiotherapy	OAE:0000235	75-87
a4ed4cc0-9444-4a5d-863c-578fd42b8794	Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly.
afatinib	CHEBI:61390	41-49
a4dcb9b6-7b6f-4467-a159-d6e770f6762f	Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the nursing infant from the study interventions.
be1c82e6-200d-4bef-b723-c78655fa40e5	the primary trial does not specificy the route of administration of its intervention.
790047b1-43e3-486e-b41c-eaa89026eae7	In the primary trial 11.1% of patients had serious adverse events, no patients had serious Adverse Drug Reactions, and over half of patients had Unexpected adverse events.
drug	CHEBI:23888	99-103
fc8ed290-e2b3-4eea-a837-d369dcd9b5da	None of the 3 patients in cohort 1 of the primary trial experienced any adverse events.
207b0895-91de-4238-8d50-e2b8b7420fb0	In total there were more adverse events in the secondary trial than in the primary trial.
1340769c-b55c-480c-a4c4-130034e128ce	Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial.
a4d6e27f-737b-4597-86e1-79b3f064cbee	Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds.
3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43	Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial.
size	PATO:0000117	60-64
030eded8-6513-4028-b1fe-fefd6dd388ad	Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial
platelet count	CMO:0000029	16-30
x	LABO:0000148	42-43
412d3ee2-bbfb-4e24-b159-684ae144e742	A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
severe	HP:0012828	38-44
left	HP:0012835	64-68
coronary artery	UBERON:0001621	74-89
d1d77877-9c85-41c8-9eca-6fd75b254a15	Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial due to her age.
triclosan	CHEBI:164200	74-83
age	PATO:0000011	138-141
c32d1b74-07ab-4afb-9db6-878e20727661	Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial.
adult	EFO:0001272	0-5
breast cancer	DOID:1612	70-83
surgery	OAE:0000067	186-193
excluded	HP:0040285	198-206
ba0c0dc6-826b-426f-8738-eec23e47f6b0	Sharone had a hip replacement 2 months prior, she is not elgible for the primary trial.
hip	UBERON:0001464	14-17
77982c81-d147-48d9-909c-18b9a98224e9	Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial.
duration	PATO:0001309	45-53
7f1af51d-e22b-4285-aea4-3dc80c3ab2ec	Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxe and Trastuzumab.
2e03f6f1-0d4f-4ebf-8781-20918d70d78f	A 56 year old patient with a masectomy would not be eligible for the primary trial
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	14-21
57e74ef2-f170-47bd-a908-2a7b3cec150d	Patients with No QT prolongation are excluded from the primary trial.
excluded	HP:0040285	37-45
b5957a75-140f-445b-99dc-199b8182b8ed	pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial.
duct	UBERON:0000058	41-45
142cc983-b0cc-4f9f-b3ef-4eb57e2a317b	The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently.
f57350c2-ac90-47ea-92b4-d903509bf07a	patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever. 
neutropenia	HP:0001875,DOID:1227	65-76
time	PATO:0000165	100-104
77c61307-567d-4ac2-a7f7-85feffd30473	Patients do not need to have a known hormone receptor status to participate in the primary trial.
hormone	CHEBI:24621	37-44
receptor	BAO:0000281	45-53
35dd977f-53d8-4400-b5cb-34caaa938e78	The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months.
group	CHEBI:24433	29-34
increase	BAO:0001251	68-76
54554da5-e67f-4da5-819b-a85b7bc5d52c	Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment.
rate	BAO:0080019	83-87
592edd64-7841-4c19-ba75-583066308137	On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.
doxorubicin hydrochloride	CHEBI:31522	50-75
cyclophosphamide	CHEBI:4026	85-101
dexamethasone	CHEBI:41879	103-116
ondansetron	CHEBI:7773	134-145
a1d207c8-2d57-4c49-89fa-60ceacf65829	Clinically depressed patients are not able to participate in the primary trial.
4a8f0562-355b-4a68-8790-c283d93ce766	the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies.
04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4	Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial.
diarrhea	HP:0002014,DOID:13250	55-63
dyspepsia	HP:0410281	68-77
3cd353ed-af0d-4356-8f45-efc1e91a2a0d	Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial.
excluded	HP:0040285	106-114
b8473ae8-11c9-4578-aab8-ee96e6287715	Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial.
4243dc45-5a64-486d-ae2a-11448db00dcf	Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial.
fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5	cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial.
median	BAO:0002174	50-56
f616e3d8-6c1a-4b99-ac79-ea87895e37b7	Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial.
group	CHEBI:24433	45-50
group	CHEBI:24433	79-84
2f700407-8baf-4e5f-8fc0-378a294512f5	Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions.
cebee448-235d-49ff-8e87-56639399548b	Informed consent is optional for entry in the primary trial.
d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710	Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial.
age	PATO:0000011	17-20
7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5	sepsis, due to the presence of an implanted device was a common adverse event in the primary trial
sepsis	HP:0100806	0-6
adverse event	OAE:0000001	64-77
af677d94-a376-42ea-93fe-91963a071199	Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial.
dysphagia	HP:0002015	14-23
6579e25e-8dcf-44b5-a50d-7c84672cba89	Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial, as long as they are over the age of 20.
cancer	DOID:162	52-58
age	PATO:0000011	193-196
1ac9c526-91e6-4e0d-8570-0a78e3ec78db	Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events.
79c07f36-daf9-4844-ad8a-f362fbbaaf81	Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial.
vomiting	HP:0002013	75-83
bced9c90-5ce0-416c-a168-f9e74359b332	The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group.
exemestane	CHEBI:4953	4-14
group	CHEBI:24433	15-20
group	CHEBI:24433	119-124
group	CHEBI:24433	210-215
median	BAO:0002174	55-61
abiraterone acetate	CHEBI:68639	86-105
abiraterone acetate	CHEBI:68639	177-196
prednisone	CHEBI:8382	108-118
prednisone	CHEBI:8382	199-209
patient	HADO:0000008,OAE:0001817	138-145
ce88c763-0062-48dc-b5e1-f81af32f2628	Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial.
982469a3-2fc1-40b4-92a9-d531b6c0ab5d	the primary trial administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day.
acid	CHEBI:37527	46-50
day	UO:0000033	127-130
71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625	There is no age limit for either the secondary trial or the primary trial.
age	PATO:0000011	12-15
e6901a45-4c97-4618-bfcb-6f6dd046ef0c	In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group.
ttp	CHEBI:63550	102-105
exemestane	CHEBI:4953	113-123
group	CHEBI:24433	124-129
e94ea1b1-1816-4bac-b1ca-f6d66b95702a	Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study.
0e3c62f7-a152-4370-9d09-b69a715c0a21	the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies.
breast	UBERON:0000310	84-90
7191b5e9-4f29-4261-8a64-51653ee151fe	In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.
median	BAO:0002174	72-78
639ccada-370d-4709-bdd7-1b29bbcc8769	ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial.
8c6e6c06-c409-4c42-b195-e9d2a1065b97	All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet.
stomatitis	HP:0010280,DOID:9637	53-63
b5183c1c-adb5-4877-b061-50a16d6a5b52	None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial.
69f57cdb-22e9-4a3a-8f19-6095c66c6497	the secondary trial uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.
rate	BAO:0080019	159-163
ea505463-c509-416e-ad88-11576764b734	Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial.
81669281-db01-4493-a797-0d60f448f706	The overall most frequent adverse event in the primary trial was Dehydration.
frequent	HP:0040282	17-25
adverse event	OAE:0000001	26-39
dehydration	HP:0001944	65-76
40dbf023-ead5-45fc-bdce-bf40e1955578	Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention.
magnesium oxide	CHEBI:31794	62-77
magnesium oxide	CHEBI:31794	89-104
mometasone	CHEBI:6970	108-118
b64ae9c9-956a-421e-a41f-1886408fec2a	One of the cohorts in the primary trial had more than 5% of patients experiencing side effects.
e0980234-0611-44de-9165-54bdd086663d	the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments.
3366c10a-3d41-48ae-bfa8-26b9e655761e	There were 8 cases of pharyngitis in cohort 2 of the primary trial.
pharyngitis	HP:0025439,DOID:2275	22-33
be29030a-98e8-40ad-9138-90076fdb50d3	Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.
blood	UBERON:0000178	50-55
a31298d5-20ae-4a3d-a57b-e97288fff6c0	Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.
patient	HADO:0000008,OAE:0001817	6-13
adverse event	OAE:0000001	74-87
54e93334-0f21-4ea2-b0f2-34473385da53	The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients.
adverse event	OAE:0000001	16-29
affected	HP:0032320	90-98
fbedd8fc-05e8-4438-b780-d7483aed3b45	Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial.
4bd9f061-6420-443d-8f84-b703733644ac	100% of patients in the primary trial suffered life threatening adverse events.
e6d3354b-b36a-42b9-b406-61a9af594686	cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily.
62b3d09e-6b2a-4827-8ceb-96ccafca18d4	prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial.
adjuvant	CHEBI:60809	49-57
065a6cfe-3991-4dd5-8a55-22b9b31d1fc3	Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months.
breast cancer	DOID:1612	104-117
85c315e5-7ae4-4764-8b02-87d36f67a159	Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial.
gemcitabine	CHEBI:175901	0-11
497188e0-9d88-406f-b163-c154516cb12c	There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.
abc437e1-9e38-4d68-ab9f-fdbaf37d20f3	Patients with BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial.
platelet count	CMO:0000029	30-44
f26fb90b-a9a5-4614-9680-2e9f6f0ba649	Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.
90dd042b-c16c-4ea7-b360-625bd5e64590	A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.
year	UO:0000036	5-9
year	UO:0000036	96-100
female	PATO:0000383	14-20
patient	HADO:0000008,OAE:0001817	21-28
9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7	In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.
afatinib	CHEBI:61390	89-97
afatinib	CHEBI:61390	133-141
paclitaxel	CHEBI:45863	146-156
vinorelbine	CHEBI:480999	160-171
group	CHEBI:24433	192-197
20cc98f8-a71a-466d-a39c-735899791613	INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial.
fa1c6f63-ae37-4c18-918b-7b9ba445fd81	In total there were 32 cases of Febrile neutropenia in the primary trial.
neutropenia	HP:0001875,DOID:1227	40-51
6d0b2acc-11f4-479f-9a86-004e2f5f7599	IV is used as route of administration by the interventions in the primary trial and the secondary trial.
7e9c3980-9f12-40c7-920e-76594db26fd1	The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics.
omega-3 fatty acid	CHEBI:25681	110-128
patient	HADO:0000008,OAE:0001817	183-190
c83e003d-d12d-4f72-ab1f-c39f3a13326b	In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.
female	PATO:0000383	93-99
age	PATO:0000011	110-113
breast cancer	DOID:1612	177-190
cae58656-76e7-447a-940e-dfcc78159173	the primary trial monitors the occurrence of anemia in its adverse events.
anemia	HP:0001903,DOID:2355	45-51
94c4c3fc-7bcb-407b-86b5-6699305d3dbd	There are no adverse events in the primary trial that occurred more than once.
103fbaa8-1852-402a-9368-36bbf6c747b2	At most 3 patients in the primary trial suffered from Neutropenia.
neutropenia	HP:0001875,DOID:1227	54-65
731dc36f-983d-4d4c-97ac-6e3eeee23a40	Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial.
breast cancer	DOID:1612	25-38
excluded	HP:0040285	60-68
b2883781-f4e9-405e-9231-7a07e46c35b0	Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram.
932c2135-381a-4675-a782-e683eca8d935	the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time.
vaccine	VO:0000001	51-58
duration	PATO:0001309	144-152
time	PATO:0000165	156-160
6461007d-fc18-43e2-a797-11cb0a4512ce	the primary trial has a shorter time frame than the secondary trial.
time	PATO:0000165	32-36
819e85b0-2d4e-4535-b920-4e18868da883	Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial.
excluded	HP:0040285	64-72
cc0d6fe8-69c4-49d3-b321-00e47c155db6	There results from cohort 3 of the primary trial were inconclusive.
0fbb4fb4-620b-4ee9-aaa8-956992026cef	Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events.
69b12ff4-6bb4-4207-b400-67795709c3c8	Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events.
patient	HADO:0000008,OAE:0001817	6-13
9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7	Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial.
female	PATO:0000383	0-6
peripheral neuropathy	HP:0009830,DOID:870	21-42
excluded	HP:0040285	60-68
9872cf9f-6f43-44d3-97ce-e205e0e5fc6c	Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial.
year	UO:0000036	13-17
female	PATO:0000383	22-28
adenocarcinoma	DOID:299	75-89
breast	UBERON:0000310	97-103
efc15257-5e19-4b7e-8b51-da94840784d8	the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.
patient	HADO:0000008,OAE:0001817	29-36
patient	HADO:0000008,OAE:0001817	103-110
blood	UBERON:0000178	75-80
0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1	19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.
eating disorder	DOID:8670	55-70
7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9	Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.
e4961c1a-83e2-40ed-93ac-64d5cef1f84a	All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study.
duration	PATO:0001309	113-121
9cb1c975-0d49-4437-af56-1a4f97e30aef	There is no maximum or minimum age defined for participation in the primary trial or the secondary trial.
age	PATO:0000011	31-34
51699ae8-d297-4635-95c1-4ed38c8706c3	Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial.
refractory	HP:0031375	14-24
ventricular fibrillation	HP:0001663	25-49
month	UO:0000035	68-73
excluded	HP:0040285	90-98
c2c73b99-f89c-4dd3-8362-295f9a7965f3	In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry, 
inhibitor	CHEBI:35222	107-116
180d7b66-9ee9-40fb-b4c7-a6060e6f67b7	Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.
rate	BAO:0080019	58-62
949ac54b-a871-4134-a507-c98a4de55720	the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial.
compression fracture	HP:4000047	59-79
02407f87-235d-4240-98fe-498b352cce75	Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial.
growth factor	BAO:0002024	35-48
receptor	BAO:0000281	49-57
61a524d4-1697-4a10-b36a-a0c6cda79526	Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for the primary trial.
breast cancer	DOID:1612	53-66
304977b6-9742-4c3b-84fd-e5ef1737a143	ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial.
87c65217-85d9-4f05-87aa-f4dfacd9f25a	patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial
phosphoinositide	CHEBI:16749	14-30
inhibitor	CHEBI:35222	40-49
19e89ebc-a417-47a8-bfa7-1778baead178	Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial.
group	CHEBI:24433	75-80
561a0631-1eb3-48d1-baa2-81eb3fa79b98	the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain.
patient	HADO:0000008,OAE:0001817	29-36
patient	HADO:0000008,OAE:0001817	93-100
chest pain	HP:0100749	42-52
abdominal pain	HP:0002027	106-120
bc617e84-a0c1-400b-9ad5-88b56d1805e8	1/42 patients in cohort 1 of the primary trial fainted.
8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5	Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial.
adult	EFO:0001272	0-5
bilateral	HP:0012832	56-65
breast carcinoma	HP:0003002,DOID:3459	66-82
bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe	Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin.
anastrozole	CHEBI:2704	76-87
simvastatin	CHEBI:9150	96-107
b059e44b-9830-4c45-858e-ebd007fbaf69	Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia.
neutropenia	HP:0001875,DOID:1227	86-97
fec065ca-fbde-476d-ab0d-7e7054e29858	Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study.
scoliosis	HP:0002650,DOID:0060249	14-23
surgery	OAE:0000067	100-107
excluded	HP:0040285	137-145
ct	BAO:0002125	214-216
ea3bd229-001c-487f-9cda-edf2e699dbb2	Patients in the primary trial receive vorinostat at the same frequency, dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.
vorinostat	CHEBI:45716	38-48
frequency	HP:0040279	61-70
576e519a-1ef3-43e5-a13c-6058ad71f388	Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.
breast cancer	DOID:1612	71-84
excluded	HP:0040285	168-176
699d0cb5-1ebb-441d-aa7e-041a48923b00	the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks.
6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b	Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial.
6e882de6-e55f-40a4-95a1-bdb176e68a18	None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome.
acute	HP:0011009,PATO:0000389	58-63
acute	HP:0011009,PATO:0000389	78-83
acute coronary syndrome	HP:0033678	78-101
525ed182-07e9-4548-87b3-c831e0b7389e	Patients with lymphopenia can participate in the primary trial.
lymphopenia	HP:0001888,DOID:614	14-25
233d2ec1-1383-4088-90af-c5a948847631	the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients.
sepsis	HP:0100806	77-83
8e3fe244-d47d-48ce-ab29-4a5226024aad	There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial.
neutropenia	HP:0001875,DOID:1227	47-58
neutropenia	HP:0001875,DOID:1227	75-86
leukopenia	HP:0001882,DOID:615	60-70
670443b0-89bf-4af4-a9ab-4cdff26d09a8	T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial.
adenocarcinoma	DOID:299	9-23
breast	UBERON:0000310	31-37
455748bf-8e12-4834-8126-ab77cab16200	All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane.
letrozole	CHEBI:6413	60-69
exemestane	CHEBI:4953	133-143
d29bd9dd-b52e-4b18-82ea-e2914dfb9579	the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval) Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.
neratinib	CHEBI:61397	37-46
capecitabine	CHEBI:31348	52-64
capecitabine	CHEBI:31348	201-213
mean	BAO:0002173	71-75
lapatinib	CHEBI:49603	186-195
2649c857-f98d-4529-9a4a-4f8b17813cb8	The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial.
median	BAO:0002174	4-10
0a6e8720-ea47-4520-bd02-e0eb8fcd880f	The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group
group	CHEBI:24433	34-39
group	CHEBI:24433	176-181
collagen	CHEBI:3815	142-150
ce6630d3-d3b7-4870-a486-9b6284a454f0	More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort.
27e31574-5a73-4a68-997d-daa84797a65a	Both the primary trial and the secondary trial at least partly administer their interventions intravenously.
e21171de-ad49-4fc5-9c5d-aa362ca61c8a	Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41.
5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32	Cohort 2 of the primary trial is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days.
group	CHEBI:24433	45-50
breast cancer	DOID:1612	82-95
38f47a03-f71d-4072-a005-b954fb6069da	The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year.
median	BAO:0002174	4-10
length	PATO:0000122	11-17
time	PATO:0000165	21-25
patient	HADO:0000008,OAE:0001817	33-40
disease	DOID:4,BAO:0002927,OGMS:0000031	86-93
year	UO:0000036	130-134
e41917b8-d921-4797-b845-0121a75104a4	More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat.
throat	UBERON:0000341	115-121
bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541	Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2.
3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7	Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size.
diarrhea	HP:0002014,DOID:13250	55-63
dyspepsia	HP:0410281	68-77
size	PATO:0000117	166-170
27397dfc-b6cf-41a3-862c-a99ccd2ddd5d	The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group
gemcitabine	CHEBI:175901	4-15
group	CHEBI:24433	16-21
group	CHEBI:24433	147-152
median	BAO:0002174	49-55
carboplatin	CHEBI:31355	135-146
6214280f-f665-48d3-b33f-9d798deff71f	the secondary trial uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.
rate	BAO:0080019	158-162
108b54a9-b5cc-4f31-956f-e4e2e653d756	In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response.
662f4992-0155-4a82-926f-b1821539aab7	57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery, compared to 60% in cohort 1 of the secondary trial.
surgery	OAE:0000067	93-100
398f744b-97cf-4f95-b162-99ec6652d327	There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial.
anemia	HP:0001903,DOID:2355	25-31
leukopenia	HP:0001882,DOID:615	36-46
43421f19-878e-46f7-b456-8031835af649	the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.
lapatinib	CHEBI:49603	59-68
capecitabine	CHEBI:31348	90-102
area	PATO:0001323	129-133
13fa44e7-38be-48fb-a0eb-6b212549f526	the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group.
group	CHEBI:24433	125-130
group	CHEBI:24433	179-184
12ae2315-cc50-43ac-a595-762c85c1ec58	There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.
brain	UBERON:0000955	131-136
11403f92-661b-4334-8dfb-098586610ec6	Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial.
2823adfc-b3a4-4626-9690-0c292aa8da04	the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks.
fluocinonide	CHEBI:5109	85-97
face	UBERON:0001456	104-108
1cda051f-27d0-4027-94cf-7b5340173ca2	the primary trial and the secondary trial do not have the same number of study groups.
2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3	The patient with the shortest PFS was in the secondary trial, at only 5 days, and the longest recorded PFS was in the primary trial at 78 months.
patient	HADO:0000008,OAE:0001817	4-11
1e91c023-96e8-459b-9070-02df13339617	In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.
group	CHEBI:24433	60-65
group	CHEBI:24433	181-186
a15b4c0c-232b-4209-bf60-35d160e41d2c	One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.
patient	HADO:0000008,OAE:0001817	4-11
condition	PDRO:0000129	71-80
adverse event	OAE:0000001	164-177
anemia	HP:0001903,DOID:2355	182-188
795d634a-9f9c-49a2-a4e7-ec99bd3600f2	the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women.
e2d4c56c-a68f-4751-907d-9c2355c9528b	A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial.
50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9	Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial.
age	PATO:0000011	26-29
9ad3444c-143d-4c28-a08a-e0c9cda44900	the primary trial and the secondary trial did not observe any of the same adverse events in their patients.
43061a8b-c1b2-4b5e-b935-73733d674fb4	the primary trial designates specific interventions to its patients depending on their tumour response, patients with complete response go to cohort A and all other in cohort B, in contrast the secondary trial assigns interventions randomly.
fc7369dc-0fc5-4823-a8eb-5ac85188fd60	Patients suffering from ovarian or lung cancer are excluded from the primary trial.
lung cancer	DOID:1324	35-46
excluded	HP:0040285	51-59
25ec56f0-e472-4423-92ae-8d4840b067b5	Participants in the primary trial receive different interventions depending on their pre-diagnosis, whereas all patients in the secondary trial took the same intervention.
2c9e9407-e990-41bd-a87b-9d294c78f727	the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions.
f3cebdf7-be0c-45ad-85bd-bde827524e20	the primary trial recorded less than 5 different Adverse Events .
b5c7bfd2-d491-400c-8444-8bc424cd5dbf	A patient in the primary trial suffered from Kidney stones.
patient	HADO:0000008,OAE:0001817	2-9
kidney	UBERON:0002113	45-51
53c62057-d6ea-4639-adaf-98cb1544a394	Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.
day	UO:0000033	68-71
disease	DOID:4,BAO:0002927,OGMS:0000031	152-159
599b37cd-f380-48ac-864d-e766a7af963e	the primary trial and the secondary trial monitor the % of their patient cohorts with DFS < 6years.
patient	HADO:0000008,OAE:0001817	65-72
c428ec76-4d22-4d2d-8c06-1675bd431d41	Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.
breast cancer	DOID:1612	55-68
6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38	the primary trial has two cohorts.
a9d5c664-896f-4bb1-95e7-1deaa88848ef	Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for the primary trial but not the secondary trial, due to her age.
week	UO:0000034	34-38
adenocarcinoma	DOID:299	75-89
breast	UBERON:0000310	97-103
disease	DOID:4,BAO:0002927,OGMS:0000031	136-143
age	PATO:0000011	258-261
62b5fe62-470d-46e3-82a6-d57cd6cab452	Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial.
de349a2d-80ee-4c34-ab9f-38eb467c77d7	the primary trial and the secondary trial are not studying patient PFS, ORR or DLTs.
patient	HADO:0000008,OAE:0001817	59-66
0d37bf26-bc74-4a01-9bc9-61e2fa3051da	the primary trial and the secondary trial have no overlap in the drugs they use for their interventions.
69f7a93d-7134-40ec-aff3-50acd7119d2c	the secondary trial and the primary trial both measure PFS of their patient cohorts.
patient	HADO:0000008,OAE:0001817	68-75
8de31b0f-7127-4c8b-b5e0-060e7a83fae5	Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for the primary trial.
history	BFO:0000182	16-23
hepatitis	HP:0012115,DOID:2237	27-36
age	PATO:0000011	64-67
207a1d82-a61b-4b5f-bebf-0706def6729d	In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial.
968aeaf1-44b9-4454-8c99-e3c207037485	There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial.
neutropenia	HP:0001875,DOID:1227	30-41
heart	UBERON:0000948	46-51
2b79f9cc-4262-4353-ad28-91cda07a9b9a	Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial.
d56ffd81-4007-477b-b3c3-0fdb89806931	Patients with diabetes insipidusare not suitable for the primary trial.
f62e6c20-862b-4ce3-9121-0d93ff050839	Lidoderm products are used in a intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial
product	BAO:0003067	9-16
product	BAO:0003067	87-94
833eeb4b-4921-468a-947d-bacfc7816ae6	the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR.
patient	HADO:0000008,OAE:0001817	91-98
6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6	the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events.
c317750d-6ef7-494d-8040-2c7fa3d777fb	the secondary trial and the primary trial both used MRI for their interventions.
87eca8d2-72fe-4285-9884-6d2ec7bae6df	There was exactly the same proportion of anemic patinets in both cohorts of the primary trial.
7a87c605-fc41-4d0a-9291-85e88f6eb510	the secondary trial is testing a Gel which is applied inside the vagina, and the primary trial is testing an intervention which requires daily radiation of the breast(s).
gel	BAO:0010018	33-36
vagina	UBERON:0000996	65-71
breast	UBERON:0000310	160-166
fbb853c9-bed4-4cde-a283-2d91b23d35bf	the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements.
disease	DOID:4,BAO:0002927,OGMS:0000031	97-104
patient	HADO:0000008,OAE:0001817	119-126
c3cc3621-a8ce-4f0d-a150-7e627f36e7c5	Patients with a QT interval longer than half a second are excluded from the primary trial.
qt interval	CMO:0000235	16-27
second	UO:0000010	47-53
excluded	HP:0040285	58-66
84aa97cf-efce-484e-825e-5af509e5988f	Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy, up to 160% of the starting dose.
afatinib	CHEBI:61390	84-92
a40e172a-8839-499d-896d-be71a7ca4905	Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions, however all participants taking part in these studies will need to receive stem cell transplants.
breast	UBERON:0000310	10-16
9e972e33-9ecd-4a8b-8337-7bee209f790b	The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.
f29768ba-5d79-4528-839f-933ab13faaa1	All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging.
breast	UBERON:0000310	123-129
343e0a32-aebe-4bbb-97c0-b2c597c36802	the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants. 
pain	HP:0012531	49-53
pain	HP:0012531	157-161
abdomen	UBERON:0000916	84-91
chest	UBERON:0001443	96-101
area	PATO:0001323	102-106
4d51608c-b0d8-4019-9b9a-34cf1c3d5087	All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.
lapatinib	CHEBI:49603	60-69
pazopanib	CHEBI:71219	88-97
7bb88699-1536-4fdc-9cb2-c5ef350d559b	 trastuzumab was used for the interventions in the primary trial and the secondary trial.
c86ef61b-7565-465a-82ba-25e7ac050ccc	There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial.
58dec898-e0af-41c1-96f9-7163d3e3e855	the primary trial and the secondary trial recorded three of the same types of adverse events
5cf74526-9f91-498d-a13a-6393dcd45b7b	One patient in the primary trial suffered from an inflammation of the liver.
patient	HADO:0000008,OAE:0001817	4-11
liver	UBERON:0002107	70-75
154caa20-3be1-4cee-a838-2d90b44566c4	the primary trial did not use PFS to evaluate the performance of its interventions.
c40d8532-4e66-4eef-9644-91f20a02066d	No cases of Oesophageal adenocarcinoma were recorded in the primary trial.
adenocarcinoma	DOID:299	24-38
3d450be5-4587-48e5-ae2e-745623606631	the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups.
carboplatin	CHEBI:31355	73-84
fa28753a-aa3b-4642-9fd4-a2414fd8a472	The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion.
mean	BAO:0002173	28-32
duration	PATO:0001309	33-41
day	UO:0000033	119-122
5e700303-cd26-4024-a260-62f6a1c297ed	the secondary trial is testing a Gel which is applied to the breast, whereas the primary trial is testing an intervention which requires daily radiation of the breast.
gel	BAO:0010018	33-36
breast	UBERON:0000310	61-67
breast	UBERON:0000310	160-166
4c4c191c-de68-44c8-a23c-2455acc43d46	There is no overlap between adverse events obeserved in the primary trial and the secondary trial.
e5a4cb11-2a00-4144-93ba-f5462d7efbf0	In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib.
saracatinib	CHEBI:47458	84-95
veliparib	CHEBI:62880	100-109
03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c	the primary trial participants receive more anastrozole, letrozole and exemestane than patients in the secondary trial.
anastrozole	CHEBI:2704	44-55
letrozole	CHEBI:6413	57-66
exemestane	CHEBI:4953	71-81
27a4d1a8-185b-4483-85ce-0fbb3d323b99	The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration.
group	CHEBI:24433	36-41
month	UO:0000035	74-79
duration	PATO:0001309	102-110
ff797dd4-0b4d-42fc-808d-27c439563ce2	By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.
week	UO:0000034	3-7
progressive	HP:0003676	110-121
disease	DOID:4,BAO:0002927,OGMS:0000031	122-129
9f666667-0fde-4d79-b53c-33c0ffbbed90	Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from the primary trial.
flight	GO:0060361	31-37
hip	UBERON:0001464	66-69
excluded	HP:0040285	78-86
47084742-d031-4e59-865c-d8687282c782	Paula recently had a heart attack, she is excluded from the primary trial.
heart	UBERON:0000948	21-26
excluded	HP:0040285	42-50
ae583ea3-36a5-472c-acda-825cd7d513b6	In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.
subendocardial myocardial infarction	DOID:5849	44-80
a18c447b-de08-48ef-8e65-0ecaa775c2b0	A patient in the primary trial had a vaginal fungal infection.
patient	HADO:0000008,OAE:0001817	2-9
18b900fb-b071-43df-b37d-c68a89ef78c0	 Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial.
lymph	UBERON:0002391	51-56
ebdf2841-b5e0-431a-8dc7-e100c5d27ccf	Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial.
peripheral neuropathy	HP:0009830,DOID:870	24-45
d56745c3-ba0b-4b42-b3cf-ac060f658d83	Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia .
acute coronary syndrome	HP:0033678	0-23
adverse event	OAE:0000001	47-60
thrombocytopenia	HP:0001873,DOID:1588	94-110
0ef77b5d-684a-4a87-bf61-8d4bc9975b7f	the primary trial only had a total of 6 patients in across both its cohorts.
03c7f31f-788c-4edb-a885-b6cb0fca05da	In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score. 
group	CHEBI:24433	41-46
group	CHEBI:24433	92-97
z-score	BAO:0000432	53-60
e43c01e9-20a2-4435-a32b-224d5f460d7c	The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months.
c55f34ab-b883-465e-89dc-75bbeb8afa77	One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response.
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	76-83
0ee36ceb-5790-440e-b6ad-10a0b7a23f43	Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography.
estradiol	CHEBI:23965	133-142
2535da13-e0f7-44df-aa02-89765d8d51cb	Patients with HER2 + breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial.
breast cancer	DOID:1612	21-34
94fc6e05-8a73-43d9-a48c-531d36dfbbcd	The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.
breast cancer	DOID:1612	16-29
lapatinib	CHEBI:49603	73-82
0057172f-d019-401b-a516-993a7b46a67b	Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.
bb23e8b8-c7d6-4e58-80a2-0555db5645e9	Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.
female	PATO:0000383	0-6
ductal carcinoma in situ	HP:0030075,DOID:0060074	166-190
c4588d2c-b0d4-428d-a958-29787b9d4ec5	Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy .
ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6	Patients with clinically significant grade 3 PVD are eligible for the primary trial.
00466f98-52b8-41f3-9bf1-2edaad950be9	the primary trial and the secondary trial both require the patients to activate the interventions by remote control.
50a524ae-2135-45f7-ae9b-515fd4e2e404	More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event.
adverse event	OAE:0000001	60-73
adverse event	OAE:0000001	142-155
b2062e01-0ea6-4ee8-94a1-b59dc40901d3	 Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer, with Primary tumor > 2 cm in diameter to participate in the primary trial.
breast cancer	DOID:1612	78-91
diameter	PATO:0001334	122-130
4dbce51b-1cfc-4d5f-82bb-ce9319ace3af	Cohort 1 and 2 of the primary trial receive different quantities of different drugs.
43a9cc96-4020-459c-8fa4-4bbde7173f7a	In the primary trial 11 patients had serious adverse events, no patients had serious Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events.
drug	CHEBI:23888	93-97
ff319fa6-89b6-4f1a-871d-456edb91b69b	Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial.
hip	UBERON:0001464	14-17
a321acf0-2296-4588-bf96-85b22bf1420f	There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts.
neutropenia	HP:0001875,DOID:1227	33-44
b841dfd8-4676-4d3c-a57d-6ba1055b8597	A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
patient	HADO:0000008,OAE:0001817	126-133
patient	HADO:0000008,OAE:0001817	198-205
1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4	The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg.
mtd	BAO:0001248	28-31
48d40c7e-3514-43c3-a31a-7b391727f012	Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts.
paclitaxel	CHEBI:45863	85-95
dd98fca1-27a7-41c2-ba0c-3ff90aceab54	Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being HER2-positive.
present	PATO:0000467	14-21
cancer	DOID:162	106-112
b975dc12-757e-4ef5-af33-83dfce12e6cc	the primary trial only records GI adverse events.
2c4254c9-9c40-492f-aa45-2a9ab47579b3	Female Patients with LVEF > 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial.
female	PATO:0000383	0-6
lapatinib	CHEBI:49603	103-112
excluded	HP:0040285	164-172
e140b055-b7fc-4802-a79b-9dfe7d136876	the primary trial and the secondary trial are testing completely different modalities of interventions.
0a6418c8-63a6-4900-bfc9-1659acbe1ad7	At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months.
central nervous system	UBERON:0001017	51-73
2db9e0c7-d94b-47d2-a61f-55a0896d714e	the secondary trial reported more cases of Haematemesis, but the primary trial had more cases of Sinus tachycardia.
sinus tachycardia	HP:0011703	97-114
3129e58d-0c16-42a5-90b4-f26e048dfe58	Throughout the primary trial, one patient in cohort 1 developed issues with their vision.
patient	HADO:0000008,OAE:0001817	34-41
7be7cecb-d265-4098-9969-a40555702573	1 patient in the primary trial was diangosed with Influenza.
patient	HADO:0000008,OAE:0001817	2-9
influenza	DOID:8469	50-59
5b0d3709-7879-4dea-96c3-29178cd9f162	Both cohorts of the primary trial reported the same number of patients vomiting during the trial.
vomiting	HP:0002013	71-79
af70a3a9-d2d0-4d65-81fe-15a1becb5e95	the primary trial and the secondary trial both have a control arm, and several test arms.
a378f448-eef0-465a-abc0-8b4dd1156bb5	Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial.
breast	UBERON:0000310	28-34
f30182a1-b82a-497c-885c-9bd2e805db62	All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in.
water	CHEBI:15377	57-62
water	CHEBI:15377	80-85
ae87e5a3-fdd8-4003-ae80-4b370cade158	2% of the primary trial patients had Recurrence-free Survival < 3 years.
9f3062db-16fb-41b8-ac10-f205f66070c8	Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years.
letrozole	CHEBI:6413	41-50
disease	DOID:4,BAO:0002927,OGMS:0000031	78-85
a1c5685a-8e6e-4733-aa8b-7040bac1a397	There were no patients in either cohort of the primary trial with a PFS exceeding 6 months.
d58683e2-d276-4184-a8e9-c9df6ffd8047	the primary trial participants are given saracatinib PO for a maximum of 28 days.
saracatinib	CHEBI:47458	41-52
28d8f88a-e8cb-40c0-a12b-ef555f83ff59	Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial.
0ee4c935-18bd-4807-a2af-041a3d84e125	Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial.
355fb813-cbe0-44f5-b04a-87813e060d54	Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer, aswell as not having Dysphagia.
receptor	BAO:0000281	36-44
receptor	BAO:0000281	66-74
receptor	BAO:0000281	116-124
progesterone	CHEBI:17026	53-65
growth factor	BAO:0002024	102-115
breast cancer	DOID:1612	136-149
dysphagia	HP:0002015	172-181
274d9d2b-9227-4496-a525-d5477b0003ce	More patients in cohort 1 of the secondary trial suffered from oedema in their limbs, compared to patients in cohort 2 of the primary trial.
3ab9c66c-06fc-4bc5-b504-d9193efa8701	in the primary trial participants from different ethnicities receive different interventions.
d39078d9-9bc3-4b91-a012-e95f14813c9a	Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial.
carcinoma	HP:0030731,DOID:305	69-78
02538194-97ac-4749-9301-83f108927478	Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial.
6d9113b4-9d18-4a1b-bc78-cc3ac1150876	Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients receive 1 of 2 possible drugs.
patient	HADO:0000008,OAE:0001817	5-12
patient	HADO:0000008,OAE:0001817	93-100
99599b71-85d7-4c15-8d23-4294732f87cf	All participants in the primary trial are administered with Lapatinib 1500 mg PO QD.
lapatinib	CHEBI:49603	60-69
adbc193f-ffd6-49ce-9acd-7b1675adf0c0	Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial.
triclosan	CHEBI:164200	74-83
c476f92a-a450-4e5c-9688-6557ff3d822b	Patients must have healthy kidneys, liver and ovaries to participate in the primary trial.
healthy	HP:0032322	19-26
liver	UBERON:0002107	36-41
39d685a4-b179-4687-a273-2a44e675f2c6	The two groups in the primary trial receive the same drug treatment, but group 2 gets double the dose.
drug	CHEBI:23888	53-57
group	CHEBI:24433	8-13
group	CHEBI:24433	73-78
c66963b9-19e0-4c0f-bb65-2fec15e60b8f	The most common adverse events in the primary trial where Infection and Stomatitis, affecting a total of 14 patients.
stomatitis	HP:0010280,DOID:9637	72-82
f541ce25-c43e-496b-98e6-8470fe23f840	In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial.
dafe9dce-420e-46dc-a8ed-ac2f4c84b49b	Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.
24d81b18-ce9c-4927-9386-9ebef969a159	The duration of treatment in the primary trial is half as long as in the secondary trial.
duration	PATO:0001309	4-12
0046e113-8ac5-4725-a285-e78b8c26f825	In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response.
inhibitor	CHEBI:35222	95-104
e90f7748-f4b4-4822-8768-586c3f2f9980	In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer.
female	PATO:0000383	93-99
age	PATO:0000011	110-113
breast cancer	DOID:1612	170-183
fb8f09d6-c393-4943-bc67-fa0f0a6bdd86	post-menopausal patients are excluded from the secondary trial, but eligible for the primary trial.
excluded	HP:0040285	29-37
3c3fb5e3-1994-455a-bae4-6d267c5c89d7	Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial.
peripheral neuropathy	HP:0009830,DOID:870	22-43
2ecd62df-f5ea-417d-8783-2174a6d77087	Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a fitbit.
b43c02bf-c4b0-495f-b7ba-879f409cb685	all subjects in the primary trial must commit to a regular exercise schedule.
fdff0cf1-a0a2-4516-bdf7-109ac7adb266	Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial.
female	PATO:0000383	42-48
6babfc60-5043-4f2b-9605-3e44744265e9	80% of patients in the primary trial did not suffer any adverse events.
5ca02204-6120-4b02-bf3b-fba94d6fac4f	No more than 1% of either cohorts of the primary trial felt nauseous.
625c2690-ec9e-4ecc-85c0-9b5ca8467848	Patients cannot be excluded from the primary trial on the basis of gender or ethnicity.
excluded	HP:0040285	19-27
c28ad685-4c91-492a-85ab-180f37d9cef5	There was one GU and three GI adverse events recorded in the primary trial.
52e8d676-1744-4fdb-bab4-a553874329bd	Female patients with Peripheral neuropathy >0 are excluded from the primary trial.
female	PATO:0000383	0-6
peripheral neuropathy	HP:0009830,DOID:870	21-42
excluded	HP:0040285	50-58
beff8878-9405-412d-af3a-0f2720275bf3	the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions.
96f41881-6ba5-4688-8471-9462fc727919	On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.
bone mineral density	CMO:0001226	84-104
mineral	CHEBI:46662	89-96
mineral	CHEBI:46662	137-144
9dbf55d5-6af3-4250-b5cb-97799cdf778a	There were no cases of Intracranial hemorrhage in the primary trial.
intracranial hemorrhage	HP:0002170	23-46
e8ce8686-8d5f-4d31-b442-0cb52b7b2bec	Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often.
imatinib	CHEBI:45783	50-58
letrozole	CHEBI:6413	73-82
letrozole	CHEBI:6413	105-114
d72709fd-e94e-4c27-bf56-3f028c0bbd3f	The majority of the primary trial participants achieved CR or PR.
bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b	Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.
49f44497-2382-4658-b716-38e66c5c52b7	Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study.
afatinib	CHEBI:61390	41-49
day	UO:0000033	81-84
4a6dc84a-3afd-4060-b8c5-981895f31099	Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial.
cardiomyopathy	HP:0001638,DOID:0050700	9-23
coagulation	GO:0050817	28-39
11e84dc4-6573-4ad7-b2d9-cfc66b626e1c	More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.
adverse event	OAE:0000001	80-93
f1f2e066-a016-422f-8627-d0e477933352	In the primary trial patient cohort, 3 different types of infections are observed. 
patient	HADO:0000008,OAE:0001817	21-28
efbd87d7-f8ac-42c6-ac9a-e3a35d354885	Patients with a Karnofsky status of 94% are eligible for the primary trial.
a604244f-789f-4c12-8c5a-96c86d1b976e	The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.
collagen	CHEBI:3815	104-112
week	UO:0000034	126-130
patient	HADO:0000008,OAE:0001817	169-176
group	CHEBI:24433	199-204
2b543cc7-e295-4dc6-ad04-a2e43e9b3d97	Two different types of tachycardia occurred to patients in cohort 2 of the primary trial.
tachycardia	HP:0001649	23-34
987b1da5-0276-417d-a659-8e298529ccac	In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.
b9e8a0b3-574f-4079-9191-214af99e97a8	postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for the secondary trial.
breast cancer	DOID:1612	52-65
breast cancer	DOID:1612	157-170
breast	UBERON:0000310	52-58
breast	UBERON:0000310	157-163
0151d1fa-05c8-45a0-b21e-f08478ea5110	Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.
testosterone	CHEBI:17347	14-26
cyclophosphamide	CHEBI:4026	32-48
b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de	several different mental health issues were observed in the primary trial and the secondary trial.
b838a265-99e4-42f0-bd72-b4f72d7eb16e	A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
patient	HADO:0000008,OAE:0001817	135-142
patient	HADO:0000008,OAE:0001817	211-218
month	UO:0000035	44-49
month	UO:0000035	100-105
240e9cb0-3e40-4478-9d2c-fb4ff22e1e21	Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial.
vomiting	HP:0002013	24-32
a1644573-fba8-4598-8353-a40d3ef1968c	Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial.
cancer	DOID:162	62-68
ba533122-db9d-49e1-a2d1-936c8fdfdd00	More than 15 patients in cohort 1 of the primary trial experienced adverse events.
f20cd859-7159-457a-a1cb-56bdb01d521b	There are a total of 7 cases of Gastritis in the primary trial across both cohorts.
gastritis	HP:0005263,DOID:4029	32-41
d33df923-6c12-4135-b339-5cefdd240985	Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects.
0f49a1ec-ed73-465b-be20-b70fe990b1f0	There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial.
7370c10d-f6e7-4153-9649-9d2598ce1ed7	the primary trial and the secondary trial are both evaluating imaging techniques.
3f89537a-479e-4314-b9de-4caf845850fc	The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline.
collagen	CHEBI:3815	104-112
week	UO:0000034	126-130
patient	HADO:0000008,OAE:0001817	169-176
zoledronic acid	CHEBI:46557	184-199
group	CHEBI:24433	205-210
8e9f417a-dc0f-4c20-9cf7-5f8586c23df2	Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.
brain	UBERON:0000955	180-185
8ba451be-606a-4a57-a85e-82b5e5b286fc	3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms.
breast cancer	DOID:1612	88-101
46906361-5133-4db9-b9e5-b9b7f80a8666	the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea.
nausea	HP:0002018	96-102
ab17f223-3f70-4b63-bfc5-1fca5d6ec05d	In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-3, N0 and M0 breast cancer.
anthracycline	CHEBI:48120	87-100
breast cancer	DOID:1612	164-177
3320983d-55cb-49f9-9265-ca4e77acf62a	A patient who had a Joint injection in the last month would not be eligible for the primary trial.
patient	HADO:0000008,OAE:0001817	2-9
month	UO:0000035	48-53
6c57e451-a706-4b32-ae71-254e9d0e04de	None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.
thrombocytopenia	HP:0001873,DOID:1588	46-62
pancytopenia	HP:0001876,DOID:12450	92-104
acute coronary syndrome	HP:0033678	106-129
atrial fibrillation	HP:0005110,DOID:0060224	133-152
73a5f715-6d4c-43f3-ace4-9f1217d3d0c4	the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch.
drug	CHEBI:23888	35-39
83883edd-ea16-4b20-8a97-2a545f957add	the secondary trial records only gastrointestinal adverse events, whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events.
ad0628ef-be51-4d54-a5c6-7608df258629	Orange juice is banned for patients undertaking the primary trial.
619d88fd-cef5-4f1a-83dc-3cc710c1c93d	Less than 30% of patients in the primary trial experienced at least 1 adverse event.
adverse event	OAE:0000001	70-83
42d6a15e-fa43-4ebc-b627-70f4dd0233f8	Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.
ixabepilone	CHEBI:63605	55-66
fc60c272-ceeb-47b5-b25b-dca832a2a57e	laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial.
biomarker	CHEBI:59163	11-20
dfe1236f-ac29-4c1c-a287-6f46abb7703d	Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial.
b1060434-0f7c-4c4a-bcff-53c3124bb51e	Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2.
rate	BAO:0080019	65-69
e2862bbf-562f-4c96-abf1-fc9f07655b46	Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as this would complicate the evaluation of neurologic and other adverse events.
excluded	HP:0040285	55-63
aed75656-1594-4d99-be42-7097f7926c18	At least one participant of the primary trial died in under a 100 days.
6ce5a9d7-5793-43b0-92ed-980cca3be02b	the primary trial reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1.
pericardial effusion	HP:0001698,DOID:118	58-78
asthenia	HP:0025406	80-88
gastritis	HP:0005263,DOID:4029	93-102
b2a4f905-c6b5-4977-95de-5aa6424a5bb6	To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility.
size	PATO:0000117	116-120
a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4	There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial.
4db02d9b-d96e-4ced-947c-71cebcccc933	Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial.
systemic lupus erythematosus	HP:0002725,DOID:9074	13-41
excluded	HP:0040285	46-54
cfb07772-e485-491c-8ae3-9009e3d04415	One patient in the primary trial had a WBC count far below normal.
patient	HADO:0000008,OAE:0001817	4-11
a283b69c-0f36-4773-a711-9e6088a8ee63	Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine.
naproxen	CHEBI:7476	47-55
frequency	HP:0040279	68-77
pilocarpine	CHEBI:39462	130-141
8d90d538-3b56-48dd-bd58-007d266c923c	The only cases of cardiac problems in the primary trial occurred in cohort 1.
fa0fe1a0-2b89-4b78-8fdb-04dee84b4421	Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial.
active	PATO:0002354	41-47
8502cb9e-e382-41bc-b547-02d2d7beb381	the primary trial tests two different breast imaging modalities, namely X-ray and gamma imaging.
breast	UBERON:0000310	38-44
f6c64bb3-1836-4685-8541-8856f003524b	Patients with non-measurable diseases are only eligible for phase I of the primary trial.
79272218-91b9-4331-ba44-6a3709a13f62	the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants, however they use different Units of Measure.
97e3b0d7-3320-4eb5-bc42-5031db87692e	the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients.
rate	BAO:0080019	73-77
83251670-803e-4fec-a5cf-50f052932752	All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.
disease	DOID:4,BAO:0002927,OGMS:0000031	22-29
afatinib	CHEBI:61390	105-113
letrozole	CHEBI:6413	125-134
group	CHEBI:24433	135-140
efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de	1 patient in the primary trial had an abrupt loss of heart function.
patient	HADO:0000008,OAE:0001817	2-9
heart	UBERON:0000948	53-58
function	BAO:0003117,BFO:0000034	59-67
e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a	The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).
adverse event	OAE:0000001	16-29
neutropenia	HP:0001875,DOID:1227	63-74
ejection fraction	CMO:0000180	137-154
97812fde-57f3-4299-be34-dd436757adde	Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial.
cancer	DOID:162	14-20
lymph	UBERON:0002391	30-35
f37774f4-db96-4aa6-b3a1-626953faeecf	Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial.
blood	UBERON:0000178	9-14
kidney	UBERON:0002113	16-22
function	BAO:0003117,BFO:0000034	36-44
condition	PDRO:0000129	110-119
4fef4cdf-53bf-4239-9d31-4710fd3edc6f	The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months.
ridaforolimus	CHEBI:82677	4-17
exemestane	CHEBI:4953	34-44
group	CHEBI:24433	45-50
median	BAO:0002174	78-84
331affb2-f8e9-4a55-ac4c-62d2ecc4f80b	The only difference between the interventions used in the primary trial is the patients position.
position	HP:0012830	88-96
a577e819-c928-4217-8743-f4809e852919	Patients must have a white blood cell count above 1,500/mm¬¨‚â• to participate in the primary trial.
white blood cell count	CMO:0000027	21-43
bd073d05-3ba2-4898-9d86-a51951a7ad1f	the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions.
rate	BAO:0080019	76-80
